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ABSTRACT 
The AIDS epidemic in Africa has reached dramatic proportions.  Of the 42 million people infected with 
HIV worldwide, 30 million are in Africa.  Current available therapies have begun to transform this fatal 
disease into a chronic condition but there are still major obstacles that have resulted in a great demand for 
new and better drugs.  The aim of this study was to synthesize novel and effective HIV protease 
inhibitors. 
This work describes the first account of pentacycloundecane (PCU)-peptide and peptoid based protease 
inhibitors.  These inhibitors are proposed to bind the wild type C-South African HIV protease (C-SA) 
catalytic site via the norstatine or dihydroxylethelene type functional group of the PCU.  The desired 
compounds were synthesized by the coupling of the peptides and peptoids to the PCU cage which 
resulted in a series of promising and structurally diverse HIV-1 protease inhibitors.  The inhibitors were 
characterized by Nuclear Magnetic Resonance (NMR) and evaluated against the wild type C-SA enzyme 
for its ability to inhibit 50 % of the enzyme’s activity (IC50).  Two of the compounds reported herein, 
inhibited the enzyme activity at concentrations less than 80 nM.   
NMR investigations indicated that the activity was related to the chirality of the PCU moiety and its 
ability to induce conformations of the coupled peptide side chain.  Employing the new Efficient Adiabatic 
Symmetrized Rotating Overhauser Effect Spectroscopy (EASY-ROESY) technique enabled us to obtain 
vital information about the 3D structure of these small linear peptides and peptoids in solution.  This 
technique is the first example describing the successful through space correlations of such small peptides.  
Furthermore, docking and a combined quantum mechanics/molecular mechanics (QM/MM) molecular 
dynamics MD simulation at the AM1 semi empirical level mirrored the observed NMR results and the 
experimental IC50 activity profile of the considered inhibitors.  The combination of these experimental 
and theoretical methods provided a powerful insight into the interaction mode of these cage peptide and 
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Acquired immunodeficiency syndrome (AIDS) was the first major epidemic caused by a previously 
unknown pathogen to appear during the 20th century.1  To date more than 42 million people are infected 
worldwide.2  This disease is caused by the human immunodeficiency virus (HIV), a member of the 
lentivirus subfamily of retroviruses.3  At the onset of the epidemic in the early 1980s, no existing drug 
was known to be useful against AIDS.1  The understanding of the structure and life cycle of the virus led 
to the unprecedented development of drugs targeting the retroviral enzymes-reverse transcriptase (RT), 
integrase (IN) and protease (PR).1  In the mid 1990s the success of the combination therapy (highly active 
antiretroviral therapy (HAART)) which consists of a protease inhibitor (PI), an nucleoside reverse 
transcriptase inhibitor (NRTI) and an non-nucleoside reverse transcriptase inhibitor (NNRTI) 
dramatically changed the situation for HIV/AIDS patients.4-6  
HIV protease inhibitors reduce the virus proliferation and the spread of viral infection in susceptible cells 
and this success made the HIV aspartic protease the prime target for AIDS therapies.7,8,9  In spite of recent 
progress in the development of the PIs for the treatment of AIDS, a number of problems persist.  The 
problems with most synthetic anti-retroviral peptidomimetic PIs are their low membrane permeability,10 
protease degradation to form toxic byproducts and loss of activity after enzyme mutation.9,11-13  As a 
consequence of long term use of antiretroviral therapy, a high prevalence of side effects such as 
lipodystrophy, dyslipidaemia, diarrhoea, insulin resistance, an increase in cardiovascular risks and birth 
defects has been recorded in patients.11,5,14  Numerous drug resistant strains have also been identified and 
as a result there is still a need for new antiretroviral drugs.15,16   
At present, we face a situation where HIV/AIDS has developed into one of the most devastating 
pandemics the world has ever seen as the young adults die, orphans and the elderly are left behind.17,2,18  
The lack of a healthy work force has also severely disturbed the economy in the worst-affected regions.18 
In this study we have designed HIV protease inhibitors utilizing different pentacycloundecane (PCU) 
cage moieties.  The PCU moieties have been previously reported to enhance the biological activity,19,20 
membrane permeability and retard biodegradation when incorporated into biological active molecules.21-26  
A number of antiviral active cage compounds has also been reported.27-29,22  Herein we report the 
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synthesis, biological activity, NMR, quantum mechanics/molecular mechanics (QM/MM) based 
molecular dynamics (MD) simulations and docking results of PCU derived HIV protease inhibitors.  
1.2 THE HIV VIRUS  
The HIV is an enveloped lentivirus (a member of the retrovirus family) that exists in two forms: HIV-1 
and HIV-2.30,31  The HIV-1 is the predominant form worldwide while the HIV-2 type is concentrated in 
West Africa and is rarely found elsewhere.30  The genes of the HIV virus are composed of two single 
RNA strands which are later transcribed to DNA by viral transcriptase as it enters the human cell.32  HIV 
infects primarily vital cells in the human immune system such as CD4+ T-helper cells, macrophages, and 
dendritic cells.33,34  HIV infection leads to low levels of CD4+ T cells through three main mechanisms: 
First, direct viral killing of infected cells; second, increased rates of apoptosis in infected cells;35 and 
third, killing of infected CD4+ T cells by CD8 cytotoxic lymphocytes that recognize infected cells.36  
When CD4+ T cell numbers decline below a critical level, cell-mediated immunity is lost, and the body 
becomes progressively more susceptible to opportunistic infections.37 
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1.2.1 PARTS OF THE HIV VIRUS 
A schematic drawing of the mature HIV virion is shown below in Error! Reference source not found..   
 
Figure 1: Schematic representation of the HIV virus.38 
• The viral envelope is the outer coat of the virus and it is composed of two layers of lipids with the 
proteins from the host cell embedded in the layers.  There are also about 72 copies of the 
envelope proteins, which protrudes from the envelope surface.  It consists of a cap made of three 
or four surface glycoproteins (gp120) and a stem consisting of three to four transmembrane 
protein (gp4) molecules.39   
• The p17 protein is the HIV matrix protein that lies between the envelope and the core.  The viral 
core contains 2,000 copies of the viral protein (p24).  These proteins surround two single strands 
of RNA, each containing a copy of the virus's nine genes.  Three of these genes gag, pol and env 
contain information needed to make structural proteins for new virions.39 
1.2.2 THE HIV-1 LIFE CYCLE 
The replication cycle is initiated by the binding of the virus to the cell surface, (A) Figure 2.  The virus 
then fuses with the cell membrane (B) and empties its contents into the cell (C).  The reverse transcriptase 
copies the viral genetic material from ribonucleic acid (RNA) into double-stranded deoxyribonucleic acid 
(ds-DNA) (D).  This process is subject to a vast number of errors resulting in mutations for each viral 
generation produced.  NRT and NNRT inhibitors have been developed to block the activity of the reverse 
transcriptase.  As the viral DNA enters the nucleus of the cell (E), it gets integrated with the host’s DNA 
(provirus) by the viral integrase (IN). Activity of this enzyme can be blocked by integrase inhibitors.  
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Upon activation of the infected host cell, the proviral DNA is transcribed into messenger RNA (mRNA) 
(F).  mRNA is transported to the cytoplasm of the cell where it is translated into viral polyprotein 
precursors which includes the env, gag and gag-pol polyprotein precursors (G).  The HIV protease, 
cleaves the new polyproteins (H), enabling them to join the RNA in the new viral particles that bud from 
the cell and infect others (I).  Protease inhibitors can block the catalytic activity of the protease resulting 
in the production of non-infectious virions.40 
 
Figure 2. The replication cycle and targets for therapeutic intervention in the HIV life cycle.41 
1.3 HIV INHIBITORS 
Various inhibitors have proven to be effective in inhibiting the catalytic activity of the enzymes 
responsible for the replication of the HIV virus.  This section is a brief description of these compounds.  
1.3.1 ENTRY INHIBITORS 
Entry inhibitors block cell-to-cell transmission of HIV-1 and there are three broad classes of these 
inhibitors: attachment inhibitors, co-receptor antagonists, and fusion inhibitors.42 
5 
Attachment inhibitors (AIs) represent a diverse class of compounds which disrupt the initial binding of 
the HIV-1 gp120 surface protein to the CD4 cell surface receptor by one of several possible 
mechanisms.43  Examples of clinically effective AIs are BMS-488043 and BMS-378806 (Figure 3).44  
Co-receptor Antagonists (CRAs) block the HIV entry by preventing the virus from interacting with 
either of its two principal co-receptors: CCR5 and CXCR4.43  The ability of co-receptor antagonists 
(CRAs) to inhibit HIV infection has been demonstrated in cell culture systems and animal models, and 
several compounds are advancing in clinical trials.45  Lead candidates targeting the CCR5 co-receptor 
include the monoclonal antibody, Pro140 which blocks HIV-1 infection by occupying the gp120 binding 
site on CCR5.44 
Fusion Inhibitors (FIs) inhibit the final conformational change of gp41 required for membrane fusion 
and virus entry.43  Enfuvirtide is the first and so far the only therapeutically used fusion inhibitor.46  It is a 



























Figure 3. Structures of entry inhibitors.  
1.3.2 NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND NON-
NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS 
NRTIs are analogues of the naturally occurring deoxynucleotides needed to synthesize the viral DNA and 
they compete with the natural deoxynucleotides for incorporation into the growing viral DNA chain.  
However, unlike the natural deoxynucleotides substrates, NRTIs lack a 3'-hydroxyl group on the 
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deoxyribose moiety.  As a result, following incorporation of an NRTI the next incoming deoxynucleotide 
cannot form the subsequent 5'-3' phosphodiester bond needed to extend the DNA chain.  Thus, when an 
NRTI is incorporated, viral DNA synthesis is halted, a process known as chain termination.47,48  All 
NRTIs are classified as competitive substrate inhibitors and there are currently eight drugs available on 
the market and a few examples are shown in Figure 4. 
In contrast, NNRTIs have a completely different mode of action.  NNRTIs block the reverse transcriptase 
by binding at a different site on the enzyme.  They are not incorporated into the viral DNA but instead 
inhibit the movement of protein domains of reverse transcriptase that are needed to carry out the process 
of DNA synthesis.  NNRTIs are therefore classified as non-competitive inhibitors of reverse 
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                 Nevirapine54 (1996)               Delaviridine55 (1997)                    Efavirenz56 (1998) 
Figure 5. Non Nucleotide Reverse Transcription Inhibitors (NNRTI) approved by the FDA. 
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1.3.3 HIV INTEGRASE INHIBITORS 
The HIV integrase enzyme is the last of the three essential viral enzymes to be targeted by antiretroviral 
drugs.  Development of the HIV integrase inhibitor class of drugs has lagged behind because of the 
incomplete knowledge of the enzyme structure.  To date all HIV integrase inhibitors are in the 
investigational testing phase and none have been approved by the FDA for treatment of HIV/AIDS.57 
1.3.4  HIV PROTEASE INHIBITORS 
HIV protease inhibitors, inhibits the maturation of new virions by binding to the catalytic site of the 
protease and preventing the cleavage of gag and gag-pol into functional constituents.  All commercially 
available (Figure 6, Figure 7) and some inhibitors that are currently being tested clinically have non-
hydrolyzable transition state isosteres such as the hydroxyethylene, norstatine and many others moieties 
(Figure 8) as the basic core of the molecule.  Basically, the core is a good isostere replacement at the 
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Figure 7 continuation of Figure 6. FDA approved HIV-1 protease inhibitors. 
Inhibitors derived from the non-cleavable transition state isostere (Figure 8) have been reported to bind to 
the active site of the enzyme with an affinity several orders of magnitude greater than the natural peptide 



















































































Tetrahedral intermediate of amide
hydrolysis
 
Figure 8. Non-cleavable transition state isostere developed for the synthesis of HIV PR inhibitors.8 
Although there are nine anti-HIV PR inhibitors, and many other anti-reverse transcriptase drugs that are 
commercially available, their effectiveness has been hampered by the emergence of drug-resistant and 
cross-resistant mutants, rendering AIDS with no definitive cure.16 
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1.4 HIV PROTEASE  
The HIV protease enzyme has been characterized biochemically and structurally as a member of the 
aspartyl protease family of enzymes.67  It consists of two units, each composed of 99 amino acids, which 
join together to form the C2-symmetric active homo-dimer.68  The C-termini of each dimer interdigitate to 
form a compact four-"stranded" interface.  The interfacing four terminal strands align together like 
interlocking fingers (see Figure 9).69 
 
Figure 9. Structure of HIV protease.70  
On account of high error rates of the HIV reverse transcriptase, the nucleotide sequence of HIV protease 
changes with generations.  However, residues in the catalytic triad (Asp-Thr-Gly) are well conserved both 
from the point of genetic variation and drug resistance.71 
1.4.1 DOMAINS IN THE HIV PROTEASE DIMER 
a. Terminal domain or dimerization domain 
b. The core domains 
c. The flap domains 
a. Terminal or dimerization domain consists of the termini four-stranded beta-sheet residues 1-4, and 
95-99 of each monomer, a turn encompassing residues 4-9, and the helix residues 86-94 of each 
monomer.  This domain is quite crucial in dimer formation and stabilization of an active protease.46,47 
b. The core domains are primarily composed of four beta-strand structures.  The domain sequence is 
made up of quite compact residues 10-32 and 63-85 from each monomer.  The conserved Asp25-
Thr26-Gly27 catalytic triad is situated at the interface of the core domains from the two monomers.  
This domain is quite useful in dimer stabilization, as well as the catalytic site stability. The interface 
between the core and terminal domains is composed primarily of small hydrophobic residues.  The 
helix of the terminal domain packs against several beta strands of the core domain.46,47  
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c. The flap domains: This domain includes the most solvent exposed loop residues 33-43 preceding the 
beta hairpin containing the flaps residue 44-63.  The flexible flap encloses the active site and it 
provides important ligand binding interactions.46,47  
1.4.2 DIMER STABILITY 
The dimer is stabilized by many factors such as non-covalent interactions, hydrophobic packing 
of side chains and interactions involving the catalytic residues. The catalytic residues triad 
Asp25–Thr26–Gly27 form a network of hydrogen bonds referred to as a “fireman’s grip”, Figure 
10.46,48 
 
Figure 10. The catalytic residues triad Asp25–Thr26–Gly27 forming a network of hydrogen bonds.72 
1.4.3 SUBSTRATE BINDING 
The pocket forming the active site is composed of a number of well defined sub sites which 
accommodate the side chains of the substrates.  These distinct sub sites are named as S1 to Sn and 




Figure 11. Standard nomenclature P1 _ _ _ Pn, P1'_ _ _ _ Pn'_ is used to designate amino acid residues of 
peptide substrates. The corresponding binding sites on the protease are referred to as S1_ _ _ Sn, 
S1'_ _ _ _ Sn'_ subsites.68
 
Since the protease is C2 symmetric the corresponding sub sites binding the P1' to Pn' terminal are termed 
as S1′ to Sn′.68,73 
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1.4.4 HIV PROTEASE MECHANISM 
The HIV protease catalyzes the hydrolysis of peptide bonds with high sequence selectivity (Figure 12, 
Table 1) and catalytic proficiency.  
                      1                2    3                 4 
 
                      
 
                  
                                                                     5         6                     7       8 
Figure 12. Cleavage sites within the gag and gag-pol precursor proteins.73 










The asterisk* indicates to the position of the scissile bond 
The HIV protease accomplishes the catalysis by using an activated water molecule to attack the amide 
bond carbonyl of the substrate’s scissile bond.  The activation of the water molecule is achieved by the 
two aspartyl β-carboxy groups at the active site.  The nucleophilic water molecule held between the 
catalytic aspartates, after its activation by the negative aspartate side chain, attacks the carbonyl group in 
the substrate scissile bond to generate an oxyanion tetrahedral intermediate (Figure 13).  Protonation of 
P17 P24 P1 P9 P6 




the scissile amide N atom and rearrangement results in the breakdown of the tetrahedral intermediate to 

































































(a) Substrate (b) Tetrahedral
Intermediate
(c) Intermediate(d) Product  
Figure 13. Cleavage mechanism of HIV-1 protease.8 
The knowledge accumulated through the last two decades about the structure and mechanism of HIV PR 
has paved the way towards the development of new effective drugs for this enzyme through a structure 
based activity approach.8 
1.5 POLYCYCLIC CAGE COMPOUNDS 
Polycyclic cage compounds are useful scaffolds that yield drugs with a wide scope of applications.74  
These moieties can be used to modify and improve the pharmacokinetic and pharmacodynamic properties 
of current drugs.22,79,80  Interest in the pharmacology of polycyclic cage compounds was stimulated by 
early findings that the adamantane amine and 1-amino-adamantane or amantadine, exhibited broad range 
antiviral activity.  These viruses include the influenza, hepatitis C and herpes zoster neuralgia.79,81,82  
Further studies into related polycyclic cage compounds such as pentacycloundecane, homocubane, and 
trishomocubane derivatives have led to the discovery of more pharmaceutical applications for cage 
compounds.22  Derivatives of trishomocubane exhibit promising in vivo activity against Herpes simplex II 
and the Influenza A2/Taiwan virus.22,23,24,27  The activity of these derivatives is comparable to that of 
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acyclovir and amantadine.22  Cubane and homocubane derivatives have been reported by Hasegana et al. 
to have anti-ulcer activity with cycoprotective effect and histamine (H-2) receptor antagonism activity.22 
Pentacycloundecylamines have been observed to influence the profile of KCl-induced membrane 
depolarization.75   
Furthermore, the highly rigid structure of cage molecules induces receptor site specificity for lipophillic 
regions on the receptor molecule.76  Their hydrophobic cage skeleton improved transport of drugs across 
the cell membrane thus increasing their affinity for lipophillic regions in receptor molecules.19,20,22  and 
thus enabling the drug to cross the blood-brain barrier of the central nervous system (CNS).24,82   
1.6 TECHNIQUES EMPLOYED IN STRUCTURE BASED DRUG 
DISCOVERY 
There are three common techniques that can be used to relate structre to activity (1) X-ray; (2) NMR; and 
(3) computational methods as depicted in Figure 14.77 





NMR   Computational 
Polar Solvents  Quantum Mechanics 
Nonpolar Solvents Molecular Mechanics 
Semi-empirical  
Molecular Dynamics 
Figure 14. Technique employed to assess conformational details.77 
In this section we briefly describe the NMR and computational approaches since they enabled us to 
determine conformations of the synthesized inhibitors.  X-ray diffraction could not be used because it 
requires suitable crystals which we were not able to obtain. 
1.6.1 NMR STUDIES 
The most important information needed for a 3-dimensional (3D) structure determination can be obtained 
from a Nuclear Overhauser Effect (NOE) spectroscopy (NOESY).  The NOESY shows cross peaks 
between hydrogen atoms and these peaks are observed if the two protons are separated by a distance 
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shorter than 5.0 Å.  Since the NOE depends on the through space correlation the two interacting protons 
can be as far apart as 100 residues or more.78,79 
Determination of 3D structures of small to medium sized organic and biomolecules are limited by the 
well known phenomenon that little or no NOE is observed for medium-sized compounds (MW = 1000 
gmol-1).80  This problem can be solved by using rotating-frame Nuclear Overhauser effect spectroscopy 
(ROESY).81  However, several experimental problems namely direct cross-peaks due to J coupling, 
Hartmann-Hahn matching leading to, total correlation spectroscopy (TOCSY), cross-peaks and offset 
dependence have to be avoided.  Recent design of an EASY ROESY in the year 2009 has made it 
possible to obtain ROESY spectra of medium sized peptide inhibitors without these artefacts.  This 
enables the extraction of distance information in peptide inhibitors.  These distances are then used to 
obtain valuable information about the 3D structure in solution phase.80  
1.6.2 COMPUTATIONAL STUDIES 
The 3D structure of organic molecules can be determined by the combined QM/MM/MD approach.  The 
fundamental idea behind the use of hybrid potentials is that a system is partitioned into several regions 
which are then modeled with different levels of approximation.  The atoms from the residues or 
molecules that are participating in the reaction process, or atoms that are rich in electrons, such as the 
reacting groups of the enzyme, are treated quantum mechanically.  The rest of the system is described by 
standard molecular mechanics force fields.  Finally a boundary region is defined to account for the finite 
size of the system.82,83  In the combined method the QM part corresponds to what is to be studied in detail 
such as a molecule or several molecules, a fragment of a large molecule.  Atoms in this part are explicitly 
expressed as electrons and nuclei.  The MM part is the "environment" to the QM part.  It is "non reactive" 
meaning there is no charge transfer or other chemical exchange between the QM and MM part.84  In our 
case the environment was either water as a solvent, or the protease enzyme inside a cubic box of water.  
From the QM/MM calculations, information about position of and forces on the atoms can be obtained.  
This information is needed for the MD simulations.  MD is a form of computer simulation in which atoms 
and molecules are allowed to interact for a period of time by approximations of known physics, giving a 
view of the motion of the particles due to a simulated temperature.84  The hybrid calculations 
(QM/MM/MD) then afford low energy conformation structures of the inhibitors in solution.85-87   
To obtain good starting structures for the inhibitors inside the protease enzyme, docking calculations can 
also be performed.88  Molecular docking gives an approximation of the host-guest interaction.  It is a 
method which predicts the preferred orientation of one molecule to a second when bound to each other to 
form a stable complex.89  To perform a docking screen, the first requirement is a structure of the protein 
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of interest.  Usually the structure has been determined using a biophysical technique such as x-ray 
crystallography, or less often, NMR spectroscopy.  This protein structure and a database of potential 
ligands serve as inputs to a docking program. The success of a docking program depends on two 
components: the search algorithm (The search space in theory consists of all possible orientations and 
conformations of the protein paired with the ligand) and the scoring function (The scoring function takes 
a pose as input and returns a number indicating the likelihood that the pose represents a favorable binding 
interaction).83  To obtain a better understanding of the interaction of the inhibitor inside the active pocket 
of the docked structure it can be subjected to a QM/MM/MD calculations. 
1.7 AIMS OF THE PRESENT STUDY  
This study is part of a research project aimed at the discovery of novel cage HIV-1 protease inhibitors, 
with the ultimate objective of developing new non hydrolysable transition state isosteres to be used in the 
simple synthesis of potent and bioavailable inhibitors.   The specific objectives of this study have been: 
• To design and synthesize PCU-peptide and peptoid derived HIV protease inhibitors. 
• To determine the concentrations of the synthesized inhibitors that are needed to inhibit 50 % of 
the protease catalytic activity. 
• To explore the PIs structural conformations via NMR and QM/MM/MD simulations. 
• To understand the interactive mode of the inhibitor with the enzyme using docking. 
18 
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PENTACYCLOUNDECANE-BASED INHIBITORS OF WILD 
TYPE C-SOUTH AFRICAN HIV-PROTEASE  
INTRODUCTION  
In this chapter, the first account of pentacycloundecane (PCU) lactam-peptide based HIV protease 
inhibitors is presented.   
The PCU lactam was selected for this study because it contains a hydroxyl carbonyl functional group, 
resembling a norstatine transition-state isostere (Figure 13, Chapter 1).1  Furthermore, it consists of a very 
stable amide bond situated at the axial position of a rigid cyclohexane boat structure (see the figure with 
Table 1) which can potentially interact with the catalytic residues in the active site.2  Various peptide 
sequences were coupled to the racemic PCU-cage (see Table 1).  The first sequence was selected from a 
natural HIV-protease substrate, FEAIS,3 where F is replaced with the cage lactam, to potentially ensure 
high specificity of the proposed inhibitor to the active site.  This peptide sequence was then systematically 
varied.  
Although the PCU lactam has a non-conventional bulky structure,4 it has been reported that the S1 and S1’ 
sub-binding site of the HIV-PR accommodates bulky hydrophobic substituents.1  We therefore proposed 
that the PCU group of the inhibitor could potentially occupy these sub-sites.  Even though the S2 and S2’ 
pockets are of a hydrophobic nature too, both hydrophilic and hydrophobic side chains from the gag and 
gag-pol polyproteins can occupy these sites.5  Based on literature and the HIV substrate sequence, we 
envisaged that either glutamic acid or alanine, in the peptide chain, would be a preferred binder to the S2 
and S2’ sub-sites.  
Presented herein is the first report of the synthesis, biological activity, NMR and computational 
investigation of seven PCU derived HIV-protease inhibitors.  We introduce the PCU-lactam as a potent 
and accessible moiety for protease inhibition. 
22 
MATERIALS AND METHODS 
PCU-Peptide Synthesis: Peptides were synthesized on a CEM automated microwave assisted peptide 
synthesizer on 2-chlorotrityl-chloride resin via the Fmoc strategy.  The desired crude peptides, all (S)-
amino acids, were cleaved from the resin and coupled to the PCU lactam in solution.  Purification of the 
peptides was achieved via semi-preparative HPLC.  Only one of the diastereomeric cage peptides could 
be separated (see Table 1).  Detailed methods for the synthesis and purification are described in the 
Appendix 1. 
Optical Rotation (OR) and Circular Dichroism (CD): Measurements were recorded on a Perkin-Elmer 
Polarimeter (Model 341) and Jasco J-810 CD spectrometer instruments, respectively, and all compounds 
were dissolved in MeOH.  Optical rotation was measured at 589 nm and the CD spectra were recorded 
from 190 to 260 nm.   
NMR: Samples were dissolved in 450 µl of deuterated DMSO-d6 and measured at 25 °C.  All 1H,13C, 
COSY, HMBC and HSQC NMR spectra, required for assignment were recorded on a Bruker AVANCE 
III 400 MHz spectrometer, BBO probe with z-gradient with standard parameters.  The EASY-ROESY 
measurements required for structural analysis were recorded on a Bruker AVANCE III 600 MHz 
spectrometer using a BBO probe with z-gradient at a transmitter frequency of 600.1 MHz (spectral width, 
8223.7 Hz; acquisition time, 0.1704436 s; 90° pulse width, 11.02 µs; scans, 8; relaxation delay, 2.0 s, 
mixing time 0.12s).6  Processing and assignments were carried out using the Topspin 2.3 software from 
Bruker Karlsruhe.  In order to determine if the same 3D structural conformation observed for the 
inhibitors in DMSO-d6 are also valid for the HIV-PR activity studies, the NMR spectra for PCU-EAIS 
were recorded in a buffered D2O solution.  All spectra mentioned in the text are available in Appendix1. 
In vitro HIV-1 protease inhibition assay: Synthesis and purification of the HIV protease type C were 
performed as described in Appendix 1.7-9  The catalytic activity of the protease was monitored following 
the hydrolysis of a chromogenic peptide substrate, Ala-Arg-Val-Nle-p-nitro-Phe-Glu-Ala-Nle-NH2 at 300 
nm using an Fpecord 210 spectrophotometer.  Activity was standardized using commercially available 
drugs Atazanavir and Lopinavir.  All cage peptides were soluble in the aqueous buffer solution.   
Computational methods: The structures of the selected cage diastereomeric compounds [PCU-AISa/b 
and PCU-EAISa/b] were constructed using the Avogadro software.10  A β-sheet conformation was used as 
starting structure for both the conformational and docking studies.  
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3D structure of the inhibitors in aqueous solution 
A computational method, in which molecular dynamics using a hybrid quantum mechanics/molecular 
mechanics (QM/MM ) molecular dynamics MD, was employed to determine the low energy 
conformations of the inhibitors in aqueous solution.  Gas phase AM1 optimized structures of the 
inhibitors were enveloped in a cubic box of TIP3P water of side-length 31.4 Å.11  The energy of the 
inhibitor in solution was minimized to a residual gradient of less than 0.001 kJ mol-1 Å-1 with a QM/MM 
method using the DYNAMO package.12  The QM region (PCU-AIS, 70 atoms and PCU-EAIS, 86 atoms) 
was described by AM1 semi-empirical Hamiltonian.13  The whole system was then equilibrated without 
any constraints by MD for 50 ps at 300 K, using the NVT ensemble prior to 1 ns of separate production 
MD runs at 300 K, 400 K, 500 K and 600 K (1 fs time step, switched cut off radius of 16 Å applied to all 
interactions).14-16 
Docking of the inhibitors with the C-SA PR 
A model system for C-SA HIV-PR was constructed by substituting T12S, I15V, L19I, M36I, R41K, 
H69K, L89M and I93L in the crystal structure of the subtype B HIV-PR (PDB accession code 1HXW).7,17  
Docking studies were performed using the Autodock software18 under physiological pH conditions, 
ensuring the correct protonation state of all ionizable groups.19  Both aspartates 25 (D25) were fully 
protonated and as a control one of the D25 acid groups was deprotonated in an independent run.  The 
suitability of the constructed C-SA PR for docking experiments was tested by a control experiment in 
which Ritonavir was docked into active site of the enzyme.  The cage-peptide inhibitors were docked into 
the active site pocket of the modeled C-SA.  
QM/MM/MD simulation of the HIV-PR and cage peptide inhibitor complexes 
The docked complexes with the lowest binding energy were energy minimized as described previously 
and were used as an input for the MD simulations of the inhibitor-enzyme complex.20  The QM region 
comprised of the inhibitors and the two catalytic residues, ASP25 and ASP25’, was described by AM1 
semi-empirical Hamiltonian.  The MM region contained the rest of the enzyme and was described by the 
OPLSAA potential.21  The inhibitor-enzyme complex was enveloped in a cubic box of TIP3P water of 
side-length 79.5 Å.  QM link atoms were placed along the Cβ(QM)–Cα(MM) bonds of Asp25 and 
Asp25`.  A no-constraint-MD run for 300 ps at 300 K was performed, where hydrogen bond interaction 
analysis and inhibitor-enzyme interaction energies were monitored along the MD simulations.   
All inhibitor-enzyme complex structures mentioned in the text are available in PDB format in Appendix 
1. 
24 
RESULTS AND DISCUSSION 
The PCU-peptides were obtained as diastereomers from the coupling of the enantiopure short peptide to 
the racemic PCU-lactam.22,23  The sequences of the different inhibitor PCU-peptides are presented in 
Table 1.  All inhibitors were characterized by high-resolution mass spectrometry and NMR.  The peptides 






























Table 1. IC50 values for the inhibition of wild type C-SA HIV-1 protease by PCU lactam peptides and 
control compounds.  Structural information from EASY-ROESY NMR and binding energies from 














/kcal mol-1  
IC50 /µM 
PCU-EAISa H 47 Yes - -10.23 0.078 ± 0.0035 
Phenol-EAISb  87 - - - 10.0 ± 3.53 
PCU-EAISa Ac 27 - - -7.06 >10 
PCU-EAIa H 23 Yes - - 0.5 ± 0.035 
PCU-EVISa H 33 Yes - - 2.0 ± 0.18 
PCU-QAISa H 20 - - - 5.0 ± 0.71 
PCU-AISac H 18 Yes - -9.41 0.5 ± 0.035 
PCU-AISbc H 17 - Yes -9.27 10.0 ± 1.06 
Atazanavir      0.004 ± 0.00071
Lopinavir      0.025 ± 0.0014 
a. Diastereomeric mixtures. 
b. Enantiopure.  
c. Diastereomer was separated with semi-preparative HPLC. 
d. CP: ROE interaction of the Cage protons with a Peptide NH in solution was observed.  
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e. PP: ROE interaction of the same Peptide NH with the Peptide side chain in solution was observed. 
Interestingly, the first cage peptide sequence (PCU-EAIS) that was chosen from the natural HIV-protease 
substrate (FEAIS3 where F is replaced with the cage lactam) gave the best inhibition activity (IC50 = 78 
nM).  To confirm the significance of the role of the cage in the inhibition of the HIV-PR active center it 
was replaced with hydroxyphenylamine to produce the control peptide (Phenol-EAIS), which had an IC50 
= 10.0 µM, a 120 fold decrease when compared to PCU-EAIS.  Furthermore the hydroxyl-group at 
position C8 of the PCU-cage is essential, because after acetylation thereof, activity was completely lost 
(Ac-PCU-EAIS with IC50 > 10.0 µM). 
Systematic removal or substitution of the peptide amino acid residues resulted in a decrease in inhibitory 
activity.  Removal of the serine segment resulted in a six fold decrease (PCU-EAI with IC50 = 0.5 µM), 
the substitution of alanine with valine to PCU-EVIS caused a 25 fold decrease, substitution of the 
glutamic acid in PCU-EAIS with glutamine resulted in PCU-QAIS with a 64 fold decrease.  Removal of 
the glutamic acid yielded diastereoisomers PCU-AISa (IC50 = 0.5 µM) and PCU-AISb (IC50 = 10.0 µM), 
which were separated by preparative HPLC.  These diastereomers exhibited a 20-fold difference in 
activity and a 6 fold and 120 fold reduction in respective activities, compared to PCU-EAIS.   
These results clearly confirm the significant bioactive contribution of the cage, with a non-cleavable 
norstatine-type bond and the importance of the appropriate peptide sequence for enhanced and specific 
binding to the active side.  
NMR and computational chemistry techniques were employed to determine a potential correlation 
between the IC50 results and the 3D structure of the corresponding inhibitors in solution.  We measured 
1H and 13C spectra, 2D 1H,1H correlation and 1H,13C correlation spectra to validate the chemical structure 
of all compounds (NMR assignments are presented within the Appendix 1).   
The NMR elucidation of the mixture of PCU-EAIS diastereomers were extremely challenging.  Firstly, 
the diastereomers could not be separated and secondly, it was clear from the data that each of the two 
diastereomers also exhibited different conformational preferences.  It therefore made sense to assign the 
signals for the separated diastereomers PCU-AISa and b first.  In addition, these diastereomers exhibited a 
20-fold difference in IC50, which may enable us to investigate the influence of the cage-chirality on the 
HIV PR inhibition by means of applied high-resolution heteronuclear NMR techniques.  The 1H and 13C 





































































PCU-AISa PCU-AISb  
Figure 1. EASY-ROESY long-range correlations observed for the two cage peptide diastereomers. 
The 1H,13C-HSQC spectrum of PCU-AISa showed that carbons C-1 and C-10 of the cage were split, 
which was not observed in the spectrum of PCU-AISb.  Upon heating, the splitting was reduced and 
disappeared completely at 333 K (60 °C) indicating that different inter-convertible conformations exist.  
The EASY-ROESY spectra enabled us to detect 1H,1H through space ROESY interactions of the various 
inhibitors.6  PCU-AISa showed long-range correlations between the NHc amide protons of alanine with 
the PCU protons H-1, H-3 and H-10 and the side chain methyl protons of alanine (H-3’) also showed a 
correlation with H-3 of the cage.  This first conformation was named CP (long-range cage-peptide 
interaction).  Therefore the splitting of the cage carbon signals C-10 and C-1 of PCU-AISa was attributed 
to the existence of at least two low energy conformations of the peptide side chain.  In the dominant 
conformation (CP), a through space shielding of C-1 and C-10 existed as result of the interaction between 
one of the split alanine amide proton signals (NHc, 8.03 ppm) and the cage protons H-1 and H-10.  We 
observed a second peptide conformation for PCU-AISa, in which the alanine NHc signal is at 8.07 ppm.  
These conformations are most certainly induced by the chiral cage structure and are remarkably stable in 
the light of the relatively high temperatures (~ 60 °C) required to obtain interconversion.  
PCU-AISb showed only one set of C-1 and C-10 resonances in the 1H,13C-HSQC, coinciding with the 
second conformation of PCU-AISa.  It was clear from the EASY-ROESY spectra that CP interactions for 
PCU-AISb were absent.  Interestingly, a ROESY interaction of the alanine-NHc (8.10 ppm) with the 
serine side chain (H-8’ – see Figure 1) was observed for PCU-AISb; which was not observed for PCU-
AISa.   
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This other long-range peptide-peptide interaction was named PP.  We therefore concluded, that the 
chirality* of the cage induces different secondary structures on the peptide chains, either interacting with 
he cage (CP) or with the peptide itself (PP).  The difference in HIV-PR inhibition activities of these two 
inhibitors (PCU-AISa is 20 times more active that PCU-AISb) seem to suggest that the peptide 
conformations induced by the cage enantiomers play an important role in the activity.  
Applying the knowledge obtained from elucidating the NMR spectra of PCU-AIS, enabled us to solve the 
intriguing NMR spectra of the PCU-EAIS mixture.  The EASY-ROESY spectrum of the most potent 
inhibitor, the diastereomeric mixture of PCU-EAIS, displayed the same dominant CP conformation, as 
present for PCU-AISa.  We could not detect the PP conformation as present in PCU-AISb, but a second, 
most likely elongated, side chain conformation is present, indicated by the splitting of C-1and C-10.  To 
prove that the CP conformation is biologically relevant and present in the conditions of binding to the 
HIV-PR, NMR spectra of PCU-EAIS were also recorded in an aqueous buffer (D2O) used for the HIV-PR 
inhibition assay; similar EASY-ROESY correlations and HSQC spectra were observed as with DMSO-d6 
(see Table 11 in Appendix 1).  
The ROESY spectra of compounds PCU-EAI and PCU-EVIS also only revealed the CP conformation, 
but not the PP conformation.  The ROESY spectra of PCU-QAIS and PCU-AISb showed no sign of CP 
interactions and these peptides were found to be the weakest inhibitors in the group.  This chirality 
induced conformation of the cage with the peptide chain is crucial for better recognition and/or binding.   
It was anticipated that a computational chemistry investigation could explain why the change of the 
peptide sequence reduced the inhibitory activity.  We therefore embarked on a computational chemistry 
investigation involving three different approaches.  First, a hybrid method of quantum mechanics, 
molecular mechanics and molecular dynamics (QM/MM/MD) was used to determine the prominent low 
energy conformations for selected cage peptide systems in aqueous solution.  Second, the PCU-peptides 
were subjected to docking studies, and last QM/MM/MD simulations of the docked structures inside the 
HIV-PR enzyme were performed.  
We have previously reported that cage peptides required much higher MD simulation temperatures than 
room temperature (298 K) for a reasonable exploration of the conformational profile.24,25  Our NMR 
results indicated that the two different conformations for PCU-AISa required heating to 333 K (60 °C) to 
overcome the energy barrier between them.  The MD simulations for all peptides (PCU-EAISa/b and 
                                                     
* The chirality of the cage diastereomers were deduced from the computational work.  The stereochemistry for the 
cage peptides are 8-(R)-11-(R)-PCU–AISa, 8-(S)-11-(S)-PCU–AISb. 
28 
PCU-AISa/b) were therefore executed at 300 K, 400 K, 500 K and 600 K.  The QM/MM/MD results 
showed that the whole conformational space of each peptide could only be explored at 500 K.  The 
Ramachandran plots and the 10 lowest energy structures for each of the diastereomeric peptides were 
analyzed (see Appendix 1).  The Ramachandran plots at 500 K for PCU-EAISa revealed that only the first 
amino segment (Glu) favored a α-helical character (CP interaction is possible) while the other segments 
(Ala and Ile) both exhibited β-sheet conformations (CP interaction is not possible).  The alanine segment 
of PCU-AISa adopted a α-helical conformation, while that of PCU-AISb exhibited a β-sheet 
conformation.  The same trend holds for the isoleucine segment.   
Analysis of the l0 lowest conformations of each of the cage peptides from the MD simulation (500 K) 
also confirmed the NMR observations.  Nine out of the ten lowest energy structures from PCU-EAISa 
demonstrated cage peptide (CP) interactions (distances less than 5.0 Å) while none of the PCU-EAISb 
lowest energy structures showed CP interaction.  Similar observations were made for PCU-AISa and b.   
These MD results therefore confirmed the existence of the conformations observed with the EASY-
ROESY experiments.  It also suggests that the active conformation for the most active inhibitor (PCU-
EAISa) is most likely twice as active as the mixture of diastereomers, since PCU-EAISb does not exhibit 
the same CP conformation as all the active inhibitors.   
The PCU-peptide inhibitors were next subjected to a docking experiment with the C-SA PR (see Figure 2 
and Appendix 1).  To test the validity of the technique with the newly generated C-SA enzyme, a control 
docking experiment with Ritonavir was performed.  The docked complex orientation gave a reasonable 
RMSD of 0.559 Å with the crystal structure of Ritonavir17 with HIV-PR type B.  Upon docking it was 
found that for the most potent inhibitor PCU-EAISa, the hydroxyl-group of the PCU-lactam (the proposed 
norstatine moiety) was forming a hydrogen bond with Asp25 of the dimeric catalytic triad residues 
Asp25-Thr26-Gly27 (A/B chains), most noticeable Asp25and Asp25’ (see Figure 3).  The docked 
structures of Ac-PCU-EAISa and PCU-EAISb failed to reveal any interaction between the cage lactam 
and the two Asp25 segments of the PR.  The binding energies of the docked inhibitor enzyme complexes 
are reported in Table 1.    
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Figure 2. Lowest energy docked structure for PCU-AISa (CP) with C-SA HIV-PR. The two PR 
monomers are colored in yellow and green ribbon and the inhibitor and the two Asp25 residues are 
presented in ball and stick form.  The 3D presentations for all docking results are available as PDB files in 
the Appendix 1. 
The second lowest docked binding energy was obtained for PCU-AISa, which also exhibited the second 
best HIV-PR inhibition activity.  Interestingly, the low energy docked cage peptide structures (PCU-
EAISa and PCU-AISa) did not exhibit the same cage-peptide (CP) interaction observed with the NMR 
studies and the QM/MM/MD solution structures.  This observation could suggest that the specific low 
energy CP conformation is not the active conformation. 
The crude docked binding energies are largely in accordance with the in vitro HIV-PR inhibition results.  
Docking of the same inhibitors with C-SA PR where only one of the Asp25 residues was protonated, gave 
similar docking behavior to the unprotonated Asp25 residues.     
The lowest energy docked complexes of the inhibitors (PCU-EAISa/b and PCU-AISa/b) with the C-SA 
PR were then subjected to unconstrained QM/MM/MD unconstrained simulations (300 ps) to obtain a 
better simulated picture where full flexibility of the inhibitor and the enzyme is taken into account.  The 
RMSD values for each complex relative to the initial minimized structures were calculated.  These values 
were < 1.2 Å from the mean value, indicating that the stabilities of the dynamic equilibrium of all 
complexes were reliable.  Very little movement of the cage lactam inside the enzyme pocket is observed 
during the course of the MD run, however significant degrees of movement for the peptide side chains 
were observed.  
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The success of an inhibitor is also dependant on the effectivity of hydrogen bonds that are formed with 
the enzyme pocket.  Post-dynamic electrostatic and hydrogen bond interactions were plotted for the four 
complexes (Figure 3). Analysis of the hydrogen bond interactions along the MD trajectories clearly 
showed that PCU-EAISa and PCU-AISa were forming hydrogen bonds between the cage hydroxyl group 
and at least one of the two Asp25 groups.  This interaction for the PCU-EAISb and PCU-AISb structures 
did not develop during the MD simulation as the low energy docked complexes gave a starting structure 
where the cage hydroxyl group was rotated away from the two Asp25 residues.  Based on X-ray 
structures of inhibitor/HIV-PR (subtype B) complexes,17,26,27 it is clear that hydrogen bond interactions 
between the inhibitor and the ASP25 groups of the enzyme are crucial for effective for binding and hence 
effective inhibitory activity. 
 
Figure 3. Selected electrostatic and hydrogen bond interactions for the CSA HIV-PR complexes with 
PCU-EAISa and PCU-AISa from the MD simulation.  These plots were created with the Ligplot 
software.28  (The plots for the electrostatic and hydrogen bond interactions of PCU-AISa and b and the 
corresponding 3D structures are provided in Appendix 1). 
Unfortunately the QM/MM/MD results do not provide easily interpretable binding energy values for the 
enzyme-inhibitor interaction.  MD results show that all inhibitors easily fit into the active enzyme pocket, 
31 
but do not provide an explanation why the cage with the natural peptide sequence (PCU-EAIS) is more 
active than the shorter version (PCU-AIS).  The MD results confirm that the CP conformation, observed 
for the free inhibitor in solution, is not restored through movement of the side chain inside the enzyme 
pocket during the MD simulation.  It therefore appears that the CP conformation is perhaps required as 
starting structure for an induced fit model. 
CONCLUSION 
The combination of the PCU-cage with HIV-PR substrate-peptides yields a potential lead compound for 
HIV-PR inhibition.  A promising IC50 of 78 nM was obtained from a series of seven cage peptides.  
Variation of the amino acid sequence and protection of the cage hydroxyl group enabled us to determine a 
structure-activity relationship for this family of cage peptide inhibitors, showing that the cage with the 
natural HIV-PR substrate (PCU-EAIS) exhibits the best activity.  These results indicate the importance of 
the cage for bioactivity: removal of the cage destroys activity, while activity is observed for cage-peptides 
where the natural peptide sequence is markedly varied.  The EASY-ROESY technique has proven to be 
an extremely powerful method to provide vital information about the 3D solution structure of small 
peptides.  All active inhibitors exhibited the same ROESY interaction between the cage protons and the 
peptide side chain.  NMR and QM/MM/MD simulations were instrumental to show for the first time that 
the chirality of the PCU-cage induces different peptide conformations which are stable at temperatures up 
to 60 °C.  The different cage enantiomers were shown to exhibit a 20-fold difference in their in vitro IC50 
PR inhibition results.  Protection of the cage hydroxyl group, which is proposed to be a norstatine type 
isosteric bond, resulted in a complete loss of inhibitory activity.  This result was confirmed with a 
docking experiment where the acetyl protected cage peptide appeared to have lost the required interaction 
between the norstatine bond and the two enzymatic Asp25 residues.  The docking results also confirmed 
that most active cage inhibitor (PCU-EAIS), gives the best binding energy.  A MD simulation revealed 
that the most potent compounds exhibited interaction between the cage hydroxyl-group and one of the PR 
Asp25 groups.  The computational results also suggest that the low energy CP conformation is most likely 
not the active conformation, as this conformation was not observed for the inhibitor/enzyme complexes.  
This interaction is likely to play a role in early host-guest recognition in a type of induced fit model.   The 
combination of drug design with in-vitro assays, NMR and computational techniques has enabled us to 
rationalize the observed HIV-PR inhibition for the different cage peptides.  Employment of these 
techniques, combined with a systematic variation of alternative cage analogues and peptide sequences 
should lead to the design of more active cage peptide inhibitors in future.  The possibility of cage peptides 
to inhibit some of the many alternative disease related protease families will also be investigated.  
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Supporting Information Available in Appendix 1: Detailed procedures for the synthesis of inhibitors; 
over-expression, extraction, purification and in-vitro activity screening of the C-SA HIV-PR, Tables with 
NMR, mass, CLogP and microwave peptide synthesis conditions data; NMR, CD and HRMS spectra; 
PDB files of the enzyme-inhibitor complexes and Ramachandran plots 
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PENTACYCLO-UNDECANE LACTAM PEPTIDES AND 
PEPTOIDS AS POTENTIAL HIV-1 WILD TYPE C-SA 
PROTEASE INHIBITORS 
INTRODUCTION 
Biodegradation is one of the major limiting factors of peptide drugs (Chapter 1).  Considerable 
effort has gone into improving the pharmacological properties of peptides, mainly by increasing 
their enzymatic stability while preserving the chemical moieties required for functionality.1,2  
Peptoids represent a class of oligomeric compounds that closely mimic the natural structure of 
peptides and possess increased enzymatic stability as compared with homologous peptides.  
Peptoids are polymeric compounds composed of N-substituted glycine (NSG) residues.  The 
advances in the synthetic strategies used to prepare peptoid oligomers make them an attractive class 
of peptidomimetics.3-5 
In this chapter, peptoid chains mimicking the peptide sequence phenylalanine-valine-alanine- 
carbobenzyloxy (FVACbz) were coupled to the PCU-lactam and tested against the wild type C-SA 
HIV protease enzyme.  The FVACbz amino acid sequence have been proven to bind efficiently to 
the S1-S4 subsites of the HIV protease.6  The cage hydroxyl has been clearly shown in chapter 2 to 
form hydrogen bonds with at least one of the two Asp25 groups.  This proved the PCU-lactam 
moiety’s tendency to bind to the protease active site.   
Herein, the synthesis, biological testing and NMR studies using the new Efficient Adiabatic 
SYmmetrized Rotating Overhauser Effect Spectroscopy (EASY-ROESY) technique for eight PCU-
peptide and peptoid inhibitors are presented.  
RESULTS AND DISCUSSION 
The peptides were synthesized via solid phase peptide synthesis (SPPS) on a 2-chlorotrityl chloride 
resin.  Upon activation of the resin, the first amino acid was loaded onto the resin in the presence of 
N,N-diisopropylethylamine (DIPEA).  The remaining amino acids were coupled to the loaded resin 
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via microwave assistance on an automated peptide synthesizer.  The completed peptides were 
cleaved from the resin with 5 % trifluoroacetic acid/dichloromethane (TFA/DCM) mixture.  In most 
cases, the peptides/peptoids were of sufficient purity to be coupled to the lactam after lyophilisation.  
The peptoid oligomers were synthesized via solid phase synthesis on activated 2-chlorotrityl 
chloride resin 2 by attaching bromoacetic acid in the presence of DIPEA in dry DCM affording 
compound 3.  Upon filtration, the amine solution in DMF was added and mixed under a stream of 
nitrogen bubbles to give compound 4.  The chain was elongated by coupling bromoacetic acid in the 
presence of N,N'-diisopropylcarbodiimide (DIC).  Similarly the corresponding amine groups were 
coupled to the extended chain followed by bromoacetic acid to give compounds 5-9.  The 





























































Scheme 1. General procedure for the synthesis of peptoids.  i = bromoacetic acid, DIPEA, dry 
DCM ii = amine, DMF iii = bromoacetic acid, DIC, DMF iv = 5 % TFA/DCM. 
The pentacylcloundecane (PCU) lactam 14 was synthesized from pentacycloundecane-8, 11-dione 
13 which can be easily obtained from photocyclisation of the Diels-Alder adduct 12 of 
cyclopentadiene 10 and p-benzoquinone 11.7  When the dione 13 is treated with ammonia, 
ammonium chloride and a mixture of aqueous sodium cyanide it produces racemic amino-
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hydroxylactam 14.  The peptides and peptoids were coupled to the amino lactam with 2-(7-aza-1H-
benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) and DIPEA in 
dimethylformamide (DMF) at ambient temperature as shown in Scheme 2.  The compounds were 
purified via semi-preparative HPLC and obtained as non-separable diastereomeric mixtures.    
+
i




















Scheme 2. Synthesis of the PCU-lactam peptide and peptoid analogues. i = NaCN, NH4Cl, NH3, 0 
ºC ii = HATU, DIPEA, DMF, RT R = peptides or peptoids. 
The catalytic activities of the HIV-1 proteases were determined by monitoring the hydrolysis of the 
chromogenic peptide substrate His-Lys-Ala-Arg-Val-Leu-Phe(p-NO2)-Glu-Ala-Nle-Ser.  This 
substrate mimics the conserved KARVL/AEAM cleavage site between the capsid protein and 
nucleocapsid (CA-p2) in the gag polyprotein precursor and its use for the determination of the HIV-
1 protease inhibitors efficacy has been established.8,9 
According to Table 1, it can be inferred that compound 16a in which the phenylalanine was 
removed as the first amino acid from the peptide sequence showed a slightly higher activity than 15.  
This could be attributed to the phenylalanine occupying the S2 subsite instead of the S1 subsite since 
the cage would already occupy this space.  As mentioned before, the S2 subsite prefers less bulky 
molecules such as valine thus phenylalanine would not have maximum interaction with this 
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subsite.10  It was therefore postulated that for 16a, the cage norstatine moiety interacted with the 
active site while the cage occupied the S1 subsite which can accommodate bulky groups.  The valine 
and alanine would then fit into the S2 and S3 subsite respectively.  The carbobenzyloxy (Cbz) group 
was removed from 16a to increase aqueous solubility but this led to a decrease in activity (16b with 
an IC50 = 0.75 µM).  In an attempt to increase the aqueous solubility, the Cbz group was replaced 
with 2-pyrimidinyl-ethane-thioic acid and this led to an increased inhibitory activity (16c with an 
IC50 = 0.5 µM).11  
The peptoid 17 consisting of an aromatic moiety showed the best inhibitory activity when compared 
to the other PCU-lactam peptoid analogs 18a-c.  This observation was attributed to the 
conformational difference reported by Fowler et al.12 between peptoids consisting of an aromatic 
and/or negatively charged side chain and those with only alkyl chains.  According to Fowler et al.12 
aromatic groups on the side chains cause charge-charge repulsion with backbone carbonyls that 
assist in peptoid folding.  This folding can be advantageous since it gives the peptoid a well-defined 
secondary structure which can be lacking in most peptoids.  Peptoids are highly flexible because of 
the lack of hydrogen bonding and the tertiary nature of the amide bonds that allows them to 
isomerize between trans and cis conformations far more readily than secondary amides in 
peptides.12  The decrease in activity could be attributed to the lack of a defined structure for 
peptoids 18a-c.   
According to the NMR observations of 18a, more than two conformations were observed for this 
inhibitor suggesting that the compound do not exhibit a well defined structure.  Compound 18a was 
designed to mimic the peptide inhibitor 16a but the inhibitory activity of 18a was observed to be 






























































Table 1. Inhibition of wild type C-SA HIV-1 protease by PCU lactam peptide derivatives 15-16c 
and peptoid derivatives 17-18c. 
IC50  =  inhibitor concentration that inhibits 50 % of the protease activity, CBz = Benzyloxy carbonyl. 
Compounds R1 R2 R3 R4 IC50 (µM) Yield (%) 
15 benzyl isopropyl methyl Cbz 0.75±0.035 52.5  
16a isopropyl methyl Cbz - 0.6±0.071 76.2 
16b isopropyl methyl H - 0.75±0.071 78.3 
16c isopropyl methyl 2-pyrimidinyl-
h hi i
- 0.5±0.035 43.2 
17 benzyl isopropyl methyl Cbz 0.5±0.035 46.2 
18a isopropyl methyl Cbz - 10.0±0.71 65.3 
18b isopropyl methyl H - 10.0±0.71 68.3 
18c isopropyl methyl 2-pyrimidinyl-
h hi i
- 5.0±1.06 38.3 
 Atazanavir 0.004±0.0007  
 Lopinavir 0.025± 0.0014  
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The EASY-ROESY measurements required for structural analysis were recorded on a Bruker 
AVANCE III 600 MHz spectrometer using a BBO probe with z-gradient at a transmitter frequency 
of 600.1 MHz (spectral width, 8223.7 Hz; acquisition time, 0.1704436 s; 90° pulse width, 11.02 µs; 
scans, 8; relaxation delay, 2.0 s, mixing time 0.12s).13  Processing and assignments were carried out 
using the Topspin 2.3 software from Bruker Karlsruhe.  In order to investigate the effect of using 
DMSO-d6 as a solvent had on the conformations, one of the compounds ROESY spectrum in D2O 
was compared.  These two spectra did not show any significant  differences in the correlations and 
it was therefore decided to use DMSO-d6 to dissolve all other NMR samples. 
The ROESY spectra of compounds 16a and 18a confirmed the presence of more than one 
conformation.  Based on the 2D spectra, it was suggested that 16a had fewer conformations as 
compared to 18a, see Appendix 2 Tables 1 and 2.  The HSQC spectrum of compound 18a revealed 
three different chemical shifts for each of the methylene protons (H-2’ and H-6’) of the peptoid 
chain.  According to the ROESY spectra, the most prevalent conformations in both inhibitors are 
those with the valine methyl group’s H-4’ interacting with the cage atoms H-1 and H-3 (Figure 1).  
In the other conformation the H-4’ atoms interacted with the cage amine NHa (Figure 1).  The 
weaker activity observed for 18a was then attributed to the lack of a stable conformation that can 








































































































Figure 1. Inhibitor 16a, 16b and 18a with arrows showing the EASY-ROESY correlations. 
40 
The ROESY spectrum of compound 16b showed the interaction between the alanine amine NHd 
with the cage atoms H-1 and H-3 and the valine amine NHc with the H-3 (Figure 1).  This suggests 
a cyclised conformation which allows only the cage and the valine to interact with the catalytic site 
and S1 substite of the enzyme respectively, leaving the S2 pocket unoccupied.  Most of the clinically 
available inhibitors extend to either the S2 or S3 pocket of the enzyme for maximum binding.10,14  It 
was therefore concluded that for the PCU-lactam derived inhibitors, the P3 substituent was 
necessary for efficient binding to the enzyme. 
CONCLUSION 
The coupling of the PCU-lactam to a series of peptides and peptoid chains resulted in compounds 
that inhibit 50 % of the HIV protease activity at good concentrations.  The proper selection of 
residues for the peptoid was proven to be essential since the stability or formation of the well 
defined structure depends on the charge-charge repulsion caused by the residue.  PCU-
peptides/peptoid inhibitors that do not extend to either the P2/P3 subsite bind less efficiently to the 
enzyme.  The EASY-ROESY technique enabled the determination of 3D structures of the inhibitors 
and correlate it to activity.  Hence proper modifications of the residue in the inhibitors will be done 
in the future to obtain inhibitors with better activity.  This is currently the only example of the use 
of a polycyclic cage framework to be employed as a transition state analogue and shows excellent 
promise to target other disease related proteases.  
Supporting Information Available in Appendix 2: Detailed procedures for the synthesis of 
inhibitors; over-expression, extraction, purification and in-vitro activity screening of the C-SA HIV 
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DESIGN, SYNTHESIS AND SCREENING OF 
PENTACYCLOUNDECANE-DIOL INHIBITORS TARGETING 
THE HIV PROTEASE ENZYME 
INTRODUCTION 
A strategy for inhibiting the HIV protease has been to prepare C2-symmetric inhibitors in the form of 
peptidomimetics.  One family of active compounds are symmetric 1,2-diols flanked by short peptide units 
eg. A-75925 and DMP 450 (Figure 1).1,2  This family of inhibitors were designed after the 
hydroxyethylene isosteres provided the first highly potent inhibitors toward the HIV in a cell based 
assay.3-6  It was found that the contribution from the second hydroxyl group could be significant, as 
suggested by similar or better binding affinities of hydroxyethylene and dihydroxyethylene based 
transition state analogues.7  To date it has been proven using crystallography that diols form hydrogen 














































A-74704 (IC50 = 0.003 µM)7 
Figure 1. C2-symmetric 1,2-diol inhibitors.  
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In this study, the cage moiety was employed as a core molecule because of its 1,2-diol functional group 
(see Figure 2).  Another advantage of using the PCU cage diol moiety would be to allow for the 
synthesis of symmetric inhibitors which are expected to exhibit higher specificity for the HIV protease 
over other aspartic proteases with less symmetric binding sites.  
Rational for the design of these inhibitors 
This study involved the reformulation of the ritonavir precursor A-75925 (Figure 1) by introducing well 
defined and systematic changes.  These changes were introduced in view of first, substituting the core 
diols with cage diol moieties to increase stereospecificity and lipophilicity.  The replacement of the P3 
position with groups that maintains the activity of the inhibitor after the protease had mutated.  The 
binding affinity of the inhibitors to the mutated HIV protease enzyme have been reported to be affected 
by the inability of the P3 group of the inhibitors to bind the enzyme S3/S3’ subsite.11  This was caused by 
a reduction in the size of the S3 pocket in the mutated protease enzyme.11  It was therefore crucial to 
design inhibitors with the appropriate P3 groups.  Taekyu Lee et al.11 have reported alanine as an 
appropriate amino acid to use in the P3 position.  With this in mind all the inhibitors synthesized in this 
study have alanine in the P3 position.  Since the cage diol protease inhibitors were synthesized for the first 
time, the EASY ROESY was employed to elucidate the structural conformations and to get through space 
1H,1H distances/contacts.  




O O NH2OH HO
NH2
O
1 2 3  
Figure 2. The structures of pentacycloundecane diol moieties.  
Seven, inhibitors were designed namely 1a-1c, 2a-2c and 3a.  Inhibitors 1a-1c consist of the cage diacid 
112 and inhibitors 2a-2c and 3a of the cage diamine 2 and cage amine 3 moeities, respectively.  Cages 2 
and 3 were synthesized for the first time in this study.  All inhibitors except 1c were designed such that 
the diol cage would potentially fit into the catalytic site of the enzyme while phenylalanine, valine, 
alanine, alanine/carbobenzyloxy parts occupy the S1,S2,S3 and S4 pockets, respectively (see Figure 3).   
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Figure 3. Schematic representation of how the cage diol inhibitor may bind to the HIV protease enzyme. 
[Standard nomenclature P1 _ _ _ Pn, P1'_ _ _ _ Pn'_ is used to designate amino acid residues of peptide 
substrates. The corresponding binding sites on the protease are referred to as S1 _ _ _ Sn, S1'_ _ _ _ Sn'_ 
subsites].13 
Compound 1c was designed to investigate the ability of the cage to fit into the S1 pocket of the enzyme.  
The S1 pocket has been observed to prefer binding to bulky groups.2  In the absence of the phenylalanine 
compound 1c will allow the investigation of the ability of the cage to bind to this site.  
Cage 2 was synthesized to enable the coupling of the exact sequence (Phe-Val-Ala-Cbz) used by Lee et 
al.11 and to investigate the effect of introducing the cage to this sequence.  Inhibitor 2a derived from cage 
2 was designed to also allow the investigation of the effect that the positioning of the carbonyl next to the 
scissile bond would have on binding.  On cage 1 the carbonyl is three bonds away from the diols while on 
cage 2 the carbonyl is four bonds away.  The proposed mechanism for the binding of HIV protease to the 
inhibitors illustrated the significance of the efficient binding of the carbonyl after scissile bond to the 
flaps.  
Pearl et al. have suggested that upon binding of the inhibitor to the catalytic site, the scissile bond is 
distorted. This reduces the double bond character in the C–N bond and polarizes the carbonyl, rendering it 
more electrophilic towards the incoming nucleophilic water molecule.  The distortion of the amide bond 
is stabilized by interactions of the substrate with the extended binding cleft, mostly by hydrogen bond 
interactions between the interior side of the flap and the substrate carbonyls on either side of the scissile 
bond as shown in Figure 4.2   
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Figure 4. Schematic representation of two flaps of HIV PR and their hydrogen bonds with the water 
molecule.2   
Inhibitor 3a was designed for better exposure of the core diols for efficient binding to the catalytic site.  
An X-ray crystallography of the diacid coupled to one amino acid showed that one arm of the cage is 
positioned over the diols which can potentially cause steric hinderance and prevent efficient binding of 
the diols to the catalytic site.14 
RESULTS AND DISCUSSION 
The cage diacid 1 was the precursor in the synthesis of the novel cage moieties 2 and 3.  The cage acid 
was synthesized as illustrated in Appendix 3.  Cage 2 and 3 were obtained from the Hofmann 
rearrangement of the diamide (Scheme 1) which was obtained by reacting the diacid with ammonium 
chloride (NH4Cl), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), 1-hydroxybenzotriazole 





















63 2  
Scheme 1. Synthesis of cage diol from the cage dione.12 
The peptides to fit into the S1/S1’-S4/S4’ pockets were synthesized on an automated peptide synthesizer on 
2-chlorotrityl chloride resin (see Appendix 3).   
The peptides to be coupled to the cage 1 moiety were cleaved form the resin and the acid terminal 
converted to a methyl ester before coupling the amine to the cage diacid.  Different coupling reagents 
were evaluated for the formation of the amide bond between the cage acid and the peptide amines.  
Firstly, the diacid was converted to an acid chloride and coupled with the amine terminal of the peptide in 
presence of a base.  Secondly, the cage diacid and peptide were coupled in the presence of either O-
benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate/N,N-diisopropylethylamine 
(HBTU/DIPEA) or 2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
(HATU)/DIPEA or EDC/NMM/HOBT.  The acid chloride route afforded the product in low yield with 
too many impurities.  The HBTU/DIPEA coupling reagents afforded the product with only one side 
coupled.  The HATU/DIPEA afforded the product in low yield with impurities.  The EDC/NMM/HOBT 
resulted in good yields of 1a – 1c with few impurities.  
Coupling of the peptides to the cage diamine 2 and cage amine 3 to the peptide acid group were evaluated 
with three different coupling conditions that included HBTU/DIPEA, HATU/DIPEA and 
EDC/NMM/HOBT.  The latter set gave good yields with fewer impurities.  All the synthesized 
compounds were purified using semi-preparative HPLC carried out on a Shimadzu Instrument (Ace C18 
150 mm x 21.2 mm x 5 microns) with a UV/VIS detector (215 nm).  The peptides were characterized 
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using NMR Bruker AVANCE III 400 MHz and 600 MHz spectrometer and High Resolution Mass 
Spectroscopic analysis performed on a Bruker MicroTOF QII. 
In vitro HIV-1 protease activity 
Synthesis and purification of the HIV protease type C were performed as described in the Appendix 3.  
The catalytic activity of the protease was monitored following the hydrolysis of a chromogenic peptide 
substrate, Ala-Arg-Val-Nle-p-nitro-Phe-Glu-Ala-Nle-NH2 at 300 nm using an Fpecord 210 
spectrophotometer.15-17  Activity was standardized using commercially available drugs Atazanavir and 




















































































































Figure 6 continuation of Figure 5. Structures of synthesized inhibitors. 
50 
HN NHOH HOOH HO
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Table 1. Inhibition of wild type C-SA HIV protease by the PCU peptide derivatives. 
Compound  R1 IC 50 (μM) Yield (%) Log P 
1a Phe-Ile-Ala-Ala 5 38 2.59 ± 0.92 
1b Phe-Val-Ala-Ala 5 59 3.65+/- 0.92 
1c Val-Ala-Ala ND (> 10) 48 -0.56+/- 0.85 
 R2    




0.5 22 3.80+/- 0.93 
2c Phe-Val-Ala-NH2 0.5 17 1.68 ± 0.89 
 R3    
3a Phe-Val-Ala-Cbz 0.6 44 1.67+/- 0.85 
 
All of the designed inhibitors were synthesized and evaluated for their activity against the wild type C-SA 
protease enzyme.  According to the results in table 1, inhibitors 1a-1c did not show considerable activity.  
Inhibitor 1c showed the least activity and this was initially attributed to the absence of the phenylalanine 
ring which must interact with the S1/S1’ subsites for efficient binding.  Further investigations of the 
structural conformations of 1c and 1b using NMR enabled us to explain the activity observed.  From the 
ROESY spectrum of 1c it was noted that one of the valine methyl H-6’ or H7’ interacted with cage 















































































































































Figure 7. Numbered structures of inhibitor 1b, 1c and 3a with arrows indicating the long range 
correlations observed in the EASY-ROESY spectra. 
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This arrangement of the cage to the peptide obstructs the diols, shielding them from the protease catalytic 
site.  The ROESY spectrum of 1b showed the presence of two conformations.  In one conformation the 
phenyl ring (H-p4-H-p8) interacted with cage protons H-1/7 which are situated at the back of the cage.  
This conformation therefore allowed for the diols to be exposed to interact with the catalytic site.  In the 
second conformation the phenyl ring (H-p4-H-p8) interacted with H-9/10 thus the peptide chain extended 
to the front and obstructed the diols.  It was then concluded that the phenyl ring was important because it 
allowed the inhibitor to exist in a conformation that exposes the diols.  All other inhibitors were then 
designed with the phenyalanine in the S1 subsite.   
The diamine inhibitor 2a did not have good solubility in the pH 5 sodium acetate buffer that was used for 
the protease assay and thus the high IC50 observed was attributed to low solubility.  The benzyl group was 
then substituted with a (2-pyrimidinylthio) acetic acid moiety (2b).  The IC50 improved from 7.5 µM to 
0.5 µM.  It was then decided to remove the benzyl group completely to reduce the size and use the free 
amine group on the alanine to increase solubility.  The IC50 obtained for 2c was the same as the one of 2b.  
The diamine derivatives exhibited better activity when compared to the diacid inhibitors.  Although 
inhibitor 3a was synthesized with the benzyl group furthest away from the cage, like in 2a, it showed 
good activity because of the free amide which increased its solubility.  The EASY-ROESY spectrum of 
inhibitor 3a showed a long range correlation between the methylene protons of phenylalanine H-5’ and 
the cage protons H-5 (Figure 7).  This arrangement of the PCU-peptide allowed the chain to extend away 
from the diols thereby exposing them for binding to the enzyme catalytic site. 
CONCLUSION 
Peptides derived from the cage diol moieties can inhibit the catalytic activity of the wild type C-SA HIV 
protease enzyme.  The PCU-diol diacid derived inhibitors exhibited less activity when compared to the 
inhibitors derived from the PCU-diol diamine and PCU-diol amino amide moieties.  The phenylalanine 
was observed to be an appropriate residue for the P1 position of the inhibitors.  Inhibitors with less bulky 
amino acid groups at the P1 position were proven to be less active.  Large inhibitors that were insoluble in 
the buffer exhibited low inhibitory activity when compared to more soluble compounds.  The EASY-
ROESY NMR technique enabled the determination of the 3D structures of the inhibitors.  Using the 
predicted structural arrangement it was possible to explain the activity observed since it depended on the 
exposure of the diols which are crucial for binding to the catalytic site of the enzyme.  The combination of 
drug design with in-vitro assays and NMR techniques has enabled the rationalization of the observed 
HIV-PR inhibition for the different cage peptides.  Computational studies are currently being conducted 
to understand the interaction modes of these inhibitor with the enzyme.   
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Supporting Information Available in Appendix 3: Detailed procedures for the synthesis of inhibitors; 
over-expression, extraction, purification and in-vitro activity screening of the C-SA HIV protease, Tables 
with NMR, mass, and microwave peptide synthesis conditions data; NMR and HRMS spectra. 
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SYNTHESIS AND SCREENING OF PENTACYCLOUNDECANE-
PEPTOIDS AS POTENT HIV PROTEASE INHIBITORS 
INTRODUCTION 
In the previous chapters we have reported PCU-peptide/peptoid derived HIV protease inhibitors.  The 
activities of these inhibitors were related to their structural conformations with the aid of NMR and 
computational studies (Chapters 2, 3 and 4).  The activity was also noted to be dependent on the chirality 
of the cage moiety (Chapter 2).  For this study the cage diol moieties were coupled to peptoids.  The 
peptoid side chains were selected to mimic the peptide, phenylalanine-valine-alanine-Cbz (FVA-Cbz), as 
in Chapter 3.  This peptide sequence has been reported to have a high binding affinity for the HIV-
protease subsites.1,2   
Herein, five novel pentacycloundecane-peptoid inhibitors that consist of the cage diol moieties coupled to 
a peptoid chain are presented. 
Rational for the design of these inhibitors 
Five inhibitors were designed, namely 1a, 2a, 2b, 3a and 3b (Figure 1 and Figure 2).  Inhibitor 1a 
consists of the cage diacid 13 and inhibitors 2a, 2b and 3a, 3b of the cage diamine 2 and cage amine 3 
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Figure 2 continuation of Figure 1. Structures of synthesized inhibitors. 
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Inhibitor 1a was designed such that the diol cage groups would potentially fit into the catalytic site of the 
enzyme while the benzyl, isopropyl, methyl and methyl/ carbobenzyloxy groups occupied the S1,S2,S3 and 
S4 pockets, respectively (see Figure 3).   
 
Figure 3. Schematic representation of the proposed interaction between the cage diol and the HIV 
protease enzyme. [Standard nomenclature P1 _ _ _ Pn, P1'_ _ _ _ Pn'_ is used to designate amino acid 
residues of peptide substrates. The corresponding binding sites on the protease are referred to as S1 _ _ _ 
Sn, S1'_ _ _ _ Sn'_ subsites according to literature].4 
Cage 2 was synthesized to enable the coupling of the peptoid version of the sequence (FVA-Cbz) reported 
by Lee et al.1 and to investigate the effect of introducing the cage to this sequence.  Inhibitor 2a derived 
from cage 2 enabled the investigation of the effect that the positioning of the carbonyl next to the scissile 
bond would have on binding.  On cage 1 the carbonyl is three bonds away from the diols while on cage 2 
the carbonyl is four bonds away.  The proposed mechanism for the binding of HIV protease to inhibitors 
illustrated the importance of the positioning of the carbonyl after scissile for efficient binding with the 
enzyme flaps.5 
The cage inhibitor 3a was designed for better exposure of the core diols for efficient binding to the 
catalytic site.  An X-ray crystallography of the diacid coupled to one amino acid showed that one arm of 
the cage is positioned over the diols and can cause steric hinderance and prevent efficient binding of the 
diols to the catalytic site, Figure 4.6 
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Figure 4. Crystal structure of the PCU diol diacid 1 coupled to phenylalanine.6 
RESULTS AND DISCUSSION 
All cage moieties were synthesized according to previously reported procedures (Chapter 4, Scheme 1, 
Appendix 4). 
The peptoids to be coupled to the cage diacid 1 were synthesized according to procedures described in 
Chapter 3, cleaved from the resin and the acid terminal converted to a methyl ester before coupling the 
amine terminal to the cage.  The peptoids synthesized from cages 2 and 3 were coupled directly after 
cleavage without any further modification using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), 
1-hydroxybenzotriazole (HOBT) and N-methlymorpholine (NMM) (see Appendix 4 and chapter 4). 
All of the designed inhibitors (Figure 1 and Figure 2) were successfully synthesized and tested against the 
wild type C-SA protease enzyme, see Table 1. 
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Table 1. Inhibition of wild type C-SA HIV protease by the PCU diol peptoid derivatives, yields for the 
coupling of peptoids to the cage diols and the size as confirmed by high-resolution mass spectroscopy. 
Compound IC 50 (μM) Yield (%) Mass calculated 
 
Mass found 
1a 6.5 ±0.35 19 1121.5530 C57H78N8NaO14 1121.5530 
2a 0.075±0.0035 30 1139.5812 C63H79N8O12 1139.5780 
2b 1.0±0.17 39 1175.5165 C59H75N12O10S2 1175.5159 
3a 0.5±0.18 22 716.3654 C39H50N5O8 716.3654 
3b 0.75±0.071 33 591.2789 C30H40N4NaO7 591.2787 
 
According to the results in Table 1 inhibitor 1a did not show good activity (IC50 = 6.5 µM) when 
compared to the cage 2 and cage 3 peptoid derivatives.  Thus other cage 1 derivatives were not 
synthesized.  Inhibitor 2a showed very good activity (IC50 = 0.075 µM) and was derivatised by 
substituting the carbobenzyloxy group with the (2-pyrimidinylthio)acetic acid group in order to produce 
compound 2b with an improved solubility.  Inhibitor 2b exhibited significantly less binding affinity to the 
enzyme (IC50 = 1.0 µM).  The same peptoid sequence used in 2a was then coupled to cage 3 (3a) to 
investigate if the activity would increase when the diols were less sterically hindered.  Inhibitor 3a 
exhibited less activity than 2a.  This decrease was attributed to the presence of the free amide which could 
be binding to the catalytic site or form a hydrogen bond with one of the diols.  If the primary amide was 
to interact with the catalytic site, the cage moiety would bind to the S1 substite which can accommodate 
bulky hydrophobic groups.  The next substituent on the peptoid (benzyl group) will now have to fit into 
the S2 subsite.  This subsite does not accommodate bulky hydrophobic moieties therefore the benzyl 
group was removed to synthesize 3b in order to investigate the assumption.  Inhibitor 3b showed a 
decrease in activity when compared to 3a, prompting the full analysis of 2a via NMR while further 
computational studies are being conducted to investigate the effect of hydrogen bonding between the 
amide and the diols and to also understand the interaction modes of the PCU-diol peptoids with the HIV 
protease.  With this set of compounds it was not possible to suggest a structure activity relationship like in 
previous chapters.  Peptoids have been reported to be highly flexible compounds (chapter 3) that can exist 
in many conformations.7  Thus relating their structure to activity would not be straight forward.  It 
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requires assistance from computational studies.  The good activity observed for inhibitor 2a can be 
attributed to the presence of four benzyl groups.  In peptoid aromatic groups on the side chains cause 
charge-charge repulsion with backbone carbonyls that assist in peptoid folding.  This folding can be 
advantageous since it gives the peptoid a well-defined secondary structure.  It was therefore suggested 









































Figure 5. Numbered structure of inhibitor 2a with arrows indicating the long range correlations observed 
in the EASY-ROESY spectrum. 
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Table 2. 1H chemical shift and EASY-ROESY correlations of inhibitor 2a.  The chemical shift was 
referenced to 2.50 ppm and the long-range interactions through space, measured by ROESY, are marked 
in red. 
Atom δ1Ha,b ROESY (δ1Ha,b) 
1/7   
2/6 2.09-2.63 4a, 4s 
3/5   
9/10   
8/11 -  
4a 1.44 3/5, 4s 
4s 1.78 3/5, 4a 
1’ 3.41 NH, 3’ 
NH 8.29 1’, 3’ 
2’ - - 
3’ 4.03 1’, 4’, 6’-10’, 12’, 14’, 15’, NH 
4’ 4.46 3’, 6’-10’ 
5’ - - 
6’-10’ 7.23-7.38 3’, 4’ 
11’ - - 
12’ 4.22 3’, 13’,14’, 15’, 18’ 
13’ 4.66 12’, 14’, 15’ 
14’ 0.85 3’, 12’, 13’ 
15’ 0.99 3’, 12’, 13’ 
16’ - - 
17’ 4.66  
18’ 2.83 12’ 
19’ - - 
20’ 5.02, 5.08 22’-26’ 
21’ - - 
22’-26’ 7.23-7.38 20’ 
a. Solvent (CD3)2SO. 
b. 600 MHz for 1H. 
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According to the EASY-ROESY correlations in Table 2, the peptoid chain did not exist in an extended 
conformation.  The H-3’ proton showed correlations with many groups including those at the end of the 
chain.  Another interesting observation was noted in the HSQC spectrum, the C-4 signals of the cage diol 
are deshielded compared to the reported chemical shift of these carbons.3  The reported chemical shift 
ranged from 33.5 to 34.8 ppm and the observed chemical shift is 43.1 ppm.  This downfield shift could be 
attributed to through space desheilding caused by electron rich atoms close to the C-4 as reported 
previously.3,8  The presence of electron rich groups around C-4 could not be proven using the ROESY 
spectra since the correlations observed were only between the peptoid side chain atoms and not between 
the cage and the peptoid.  The HSQC spectrum of cage 2 coupled to t-BOC anhydride was recorded.  The 
C-4 signal was observed at 33.8 ppm which proved that it was the presence of the peptoid chain that 
caused the deshielding.  The other interesting point to note in Table 2 is that the cage and the peptoid 
protons did not show splitting which was observed from the PCU-lactam peptoids in chapter 3.  This 
confirms that the four benzyl groups stabilized the secondary structure to a single conformation.  
Currently the hybrid method (quantum mechanics/molecular mechanics (QM/MM) molecular dynamics 
(MD) is being conducted to obtain the lowest energy conformations.  This will enable us to fully predict 
the 3D structure of compound 2a.   
CONCLUSION 
PCU-Peptoid derivatives can inhibit the catalytic activity of the wild type C-SA HIV protease enzyme.  
The best candidate inhibited 50 % of the enzyme activity at a concentration of 75 nM.  Structural 
modification of this inhibitor with the best activity resulted in a decrease in activity.  The EASY-ROESY 
technique provided vital information about the 3D structure of the inhibitor which was related to the 
biological activity.  Aromatic residues in a peptoid chain stabilize the secondary structure of the inhibitor.  
Further studies involving computational are currently being conducted to determine the correct structural 
changes to be made to improve the activity. 
Supporting Information Available in Appendix 4: Detailed procedures for the synthesis of inhibitors; 
over-expression, extraction, purification and in-vitro activity screening of the C-SA HIV protease, Tables 
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SUMMARY AND CONCLUSION 
To date there is an urgent demand for new drugs that can inhibit the catalytic activity of the HIV protease 
enzyme.  Currently available HIV protease inhibitors suffer from low oral bioavailability, rapid 
metabolism, unspecific protein binding and increased drug-resistant as a result of mutations.  Thus, in this 
study inhibitors that incorporate the cage moieties which can improve the pharmacokinetic and 
pharmacodynamic properties of molecules were designed.  Polycyclic cage compounds are useful 
scaffolds that yield drugs with a wide scope of applications.  Although cages have non-conventional 
structures their highly rigid nature induces receptor site specificity, especially for lipophilic regions.  The 
hydrophobic cage skeleton improves transport of drugs across the cell membrane thus increasing their 
affinity for lipophillic regions in the receptor molecules and enabling the drug to cross the blood-brain 
barrier of the central nervous system (CNS).  Four different cage molecules namely the PCU-lactam, 
PCU-diol diacid PCU-diol diamine and PCU-diol amino amide were chosen for this study.  The cage 
moieties were coupled to peptide and peptoid chain sequences that fit the protease subsites and this 
resulted in a series of novel HIV inhibitors. 
PCU-LACTAM INHIBITORS 
The PCU-lactam was coupled to three different classes of sequences.  The first class was made up of the 
EAIS amino acids, the second of the FVA-Cbz and the third of the peptoid chain that mimics the FVA-
Cbz amino acids sequence.  The EAIS sequence yielded the best inhibitor in this family with an IC50 
value of 0.078 µM.  Substitution or removal of amino acids from this sequence resulted in a decrease in 
activity.  The FVA-Cbz derived inhibitors exhibited moderate inhibition (IC50 ≤ 0.75µM).  The peptoid 
compounds exhibited poor activity (IC50 ≥ 10µM) and this was attributed to a lack of stable 
conformations which was deduced from NMR (Figure 1).   
Protection of the cage hydroxyl group, which is proposed to be a norstatine type isosteric bond and the 
results obtained from computational studies confirmed that these inhibitors bind to the catalytic site via 
this group.  The inhibitory activity and structural conformations were proven to be dependent on the cage 
chilarity.  All of the active inhibitors from the EAIS class exhibited a correlation between the peptide 
chain alanine residue and the H-3, H-10 and H-1 cage protons (Figure 1).  The combination of drug 
design with in-vitro assays, NMR and computational techniques enabled us to rationalize the observed 












































































































































































Figure 1. Inhibitor PCU-AISa, PCU-AISb, 16a, 16b and 18a with arrows showing the EASY-ROESY 
correlations. 
PCU-DIOL INHIBITORS 
These inhibitors were synthesized by coupling the cage-diol moieties (PCU-diol diacid PCU-diol diamine 
and PCU-diol amino amide) to peptides (FVA-Cbz) and peptoids (FVA-Cbz mimics) chain sequences 















































































































































Figure 2. Numbered structures of inhibitor 1b, 1c and 3a with arrows indicating the long range 
correlations observed in the EASY-ROESY spectra. 
67 
The different cage diol moieties were coupled to the peptide/peptoid sequences and yielded compounds 
with moderate to good activity.  The peptoid coupled to the diamne resulted into the best inhibitor in this 








































Figure 3. Numbered structure of inhibitor 2a with arrows indicating the long range correlations observed 
in the EASY-ROESY spectrum. 
The PCU-diol diacid derived inhibitors exhibited less activity when compared to the inhibitors derived 
from the PCU-diol diamine and PCU-diol amino amide moieties.  Using the EASY-ROESY technique it 
was proven that the benzyl group is the appropriate P1 substituent for this family of compounds.  Large 
inhibitors that were insoluble in the buffer exhibited low inhibition activity when compared to large 
soluble compounds.  The EASY-ROESY NMR technique enabled the determination of the 3D structures 




The combination of the different cage moieties with peptides and peptoids yielded potential lead 
compounds for HIV-PR inhibition.  Promising IC50 values of 75 nM and 78 nM were obtained from the 
peptoid and peptide series, respectively.  Variation of the amino acid sequence, peptoid residues and 
protection of the cage hydroxyl (PCU-lactam) group enabled the determination of a structure-activity 
relationship for the cage peptide/peptoid inhibitors.  Substitution of the cage moiety of the inhibitor PCU-
EAIS (IC50 = 78 nM) with a phenol group destroyed the activity and this indicated the importance of the 
cage for bioactivity.  The EASY-ROESY technique has proven to be an extremely powerful method to 
provide vital information about the 3D solution structure of small peptides and peptoid.  NMR and 
computational techniques has enabled the rationalization of the observed HIV protease inhibition for the 
different cage peptides.   
Employment of these techniques, combined with a systematic variation of alternative cage analogues and 
peptide/peptoids sequences lead to the design of active cage inhibitors. In the future the possibility of 
cage peptides/peptoids to inhibit some of the many alternative disease related protease families will also 
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MATERIALS AND METHODS 
Analytical analysis was performed on an Agilent 1100 HPLC with a flowrate of 1 mL/min on a Waters 
Xbridge C18 (150 mm x 4.6 mm x 5 microns) coupled to a UV detector (215 nm) and an Agilent VL ion 
trap mass spectrophotometer in the positive mode.  Semi-preparative HPLC was carried out on a 
Shimadzu semi-preparative instrument with a flowrate of 17 mL/min on a Ace C18 (150 mm x 21.2 mm x 
5 microns) with a UV/VIS detector (215 nm) and an automated fraction collector.  A two-buffer system 
was employed, utilizing formic acid as the ion-pairing agent.  Buffer A consisted of 0.1 % formic 
acid/H2O (v/v) and buffer B consisted of 0.1 % formic acid/acetonitrile (v/v).  High resolution mass 
spectroscopic analysis was performed on a Bruker MicroTOF QII mass spectrometer in positive mode 
with an internal calibration.  Peptides were synthesized on an automated CEM Liberty microwave peptide 
synthesizer (see Table 1 for conditions, not same as supplier).  All 1H, 13C, HSQC, COSY and HMBC 
NMR data were recorded on a Bruker AVANCE III 400 MHz spectrometer.  The ROESY data was 
recorded on a Bruker AVANCE III 600 MHz spectrometer. 








Single coupling    
30 minute coupling 
0 25 900 
35 73 900 
Deprotection 40 73 180 
72 
SYNTHESIS OF AMINO LACTAM (6)  
To an ice cold solution of 25 % ammonia (15 mL) the dione (1.00 g, 5.7 mmol) was added, followed by 
NH4Cl (0.42 g, 9.1 mmol, 2.2 eq) and NaCN (0.45 g, 7.9 mmol, 2.3 eq), respectively.  The mixture was 
stirred in the ice-bath for 2 hours resulting in a white thick solution that was filtered using a sintered glass 
funnel.  The precipitate was washed with acetone (2 x 15 mL) and the product was recrystallized from 
methanol to yield 14 as white crystals (73 % yield).   
GENERAL PROCEDURE FOR THE SYNTHESIS OF PEPTIDES USING 
MICROWAVE POWER 
Stock solutions of all amino acids (0.2 mM), DIPEA (1 mM) and HBTU (2 mM) were prepared in DMF 
and peptides were synthesized on a 0.5 mmol scale.  The modified coupling method described in Table 1 
above was used for coupling the subsequent amino acids to the 2-chlorotrityl chloride resin (1 g) 
preloaded with the first amino acid. 
Final cleavage :  The resin bound peptide was removed from the peptide synthesizer and transferred to a 
manual peptide synthesis reaction vessel for the final cleavage.  It was washed with DCM (3 x 10 mL) 
and a cleavage mixture of 5:95 % (v/v) TFA:DCM was added to the resin while nitrogen was bubbled 
through the solution for 10 minutes.  The resin was washed three times with the cleavage mixture and the 
cleaved peptide was removed by filtration and collected in a flask containing water (100 mL).  The filtrate 
was extracted several times with DCM so as to remove the peptide from the water layer.  DCM was 
removed under reduced vacuum with at 40°C and the peptide remained as a white powder. 
GENERAL PROCEDURE FOR COUPLING OF PEPTIDES TO THE PCU-LACTAM 
The cleaved peptide (1.2 eq.) was dissolved in DCM (3 mL) followed by addition of PCU lactam 14 (1 
eq), HATU (2.5 eq) in DMF (7 mL) and DIPEA (3 eq).  The mixture was stirred at room temperature for 
24 hours and thereafter the DMF was removed under reduced pressure using a Teflon pump at 40°C.  The 
crude product was dissolved with EtOAc (200 mL) and the resulting solution was washed with 1M HCl, 
NaHCO3 (saturated solution) and NaCl (saturated solution), dried over MgSO4, filtered and concentrated 
in vacuo.  A cleavage mixture (10 mL) of 95:5 (v/v) TFA:DCM was added to the crude product and 
stirred for 24 hours at room temperature.  Cold ether was then added and the product was obtained as 
yellow precipitate which was purified by reverse phase semi-preparative HPLC. 
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OVER-EXPRESSION, EXTRACTION AND PURIFICATION OF THE C-SA 
PROTEASE 
Plasmid encoding HIV-1 subtype C protease (containing the mutation Q7K designed to reduce the 
hypersensitive autolytic site) is expressed as inclusion bodies (2) in Escherichia coli BL21 (DE3) pLysS 
cells. Briefly, Escherichia coli cells harboring the plasmid DNA were grown at 37 °C in LB medium 
supplemented with 100 μg/mL of ampicillin and 35 μg/mL of chloramphenicol. The overnight culture 
was diluted 100-fold into fresh 2 × YT medium supplemented with ampicillin (100 μg/mL) and 
chloramphenicol (35 μg/mL) and grown at 37 °C.  When the optical density (OD600) of the culture 
reached 0.4 to 0.5, over-expression of the HIV-1 C-SA protease was induced by adding IPTG.  IPTG was 
added to final concentrations of 0.4 mM.  Over-expression of the protease was allowed to continue for 
four hours.  
The cells were pelleted after growth and resuspended in ice-cold extraction buffer [10 mM Tris, 1 mM 
EDTA, and 1 mM PMSF (added only fresh before use), pH 8] and disrupted using an ultra-sonicator.  
Following the addition of MgCl2 and DNase I to final concentrations of 10 mM and 10 μg/mL, 
respectively, the culture medium was stirred on ice until the viscosity of the mixture decreased.  The cells 
were then ruptured by sonication and centrifuged at 15 000 × g for 30 minutes at 4 °C. The pellet was 
resuspended in ice-cold extraction buffer containing 1 % (v/v) of Triton X-100.  Cell debris and protease-
containing inclusion bodies were pelleted by centrifugation at 15 000 × g for 30 minutes at 4 °C.  The 
pellet was then resuspended in a freshly prepared solubilization buffer containing 10 mM Tris, 2 mM 
DTT, 8 M urea, pH 8.0, at room temperature, and centrifuged at 15 000 × g for 30 minutes at 20 °C.  
The protease, in the supernatant, was purified by passing it through an anion exchange (DEAE) column 
previously equilibrated with solubilization buffer.  Upon elution from the column, the protease was 
acidified by adding formic acid to a final concentration of 25 mM.  Precipitation of significant amount of 
contaminating proteins occurred upon acidification.  Following an overnight incubation, the precipitated 
contaminants were removed by centrifugation at 15 000 × g for 30 minutes at 4 °C.  
HIV-1 protease was refolded by dialysis into 10 mM formic acid at 4 °C.  Subsequently, the protease was 
dialyzed into storage buffer containing 10 mM sodium acetate, 1 mM NaCl and 1 mM DTT, pH 5.0.  The 




IN VITRO HIV-1 PROTEASE ACTIVITY 
The catalytic activity of the HIV-1 protease was monitored following the hydrolysis of the chromogenic 
peptide substrate Lys-Ala-Arg-Val-Nle-p-nitro-Phe-Glu-Ala-Nle-NH2.  This substrate mimics the 
conserved KARVL/AEAM cleavage site between the capsid protein and nucleocapsid (CA-p2) in the Gag 
polyprotein precursor.  
For this study the chromogenic substrate was synthesized using the Discovery CEM Liberty microwave 
peptide synthesizer on Rink amide resin.  The substrate was cleaved from the resin and deprotected using 
95 %:5 % (v/v) TFA:TIS for 3 hours.  It was then precipitated using cold ether and purified via reverse 
phase semi-preparative HPLC on a Shimadzu instrument and characterized using the Bruker microTOF-Q 
II instrument (Table 2).   
To determine the concentration of the inhibitors that resulted in 50 % inhibition (IC50) of HIV-1 protease 
enzyme activity, the protein (100 nM) and chromogenic substrate (50 μM) were added into a 120 µL 
microcuvette containing increasing concentrations of inhibitor in a pH 5.0 buffer (50 mM sodium acetate 
and 0.1 M NaCl).  Protease hydrolytic activity was measured by monitoring the relative decrease in 








Supplementary Table 3. The inhibition of wild type C-SA HIV-1 protease by PCU lactam peptide 
derivatives compared with the commercial available drugs, the optical rotation, the membrane 
permeability, ClogP values and stability 
Compound R1 R2 IC50 (µM) CLogP 
PCU-EAIS -Glu-Ala-Ile-Ser H 0.078 ± 0.0035 -3.45 ± 0.92 
PCU-EAI -Glu-Ala-Ile H 0.5 ± 0.035 -2.53 ± 0.90 
PCU-EVIS -Glu-Val-Ile-Ser H 2.0 ± 0.18    -2.57 ± 0.89 
PCU-QAIS -Gln-Ala-Ile-Ser H 5.0 ± 0.71 -3.84 ± 0.84 
PCU-AISa -Ala-Ile-Ser H 0.5 ± 0.035    -2.65 ± 0.75 
PCU-AISa -Ala-Ile-Ser H 10.0 ± 1.06    -2.65 ± 0.75 
Ac-PCU-EAIS -Glu-Ala-Ile-Ser Ac >10 -2.55 ± 0.92 
Phenol-EAIS   10.0 ± 3.53 -0.06 ± 0.92 
Atazanavir   0.004 ± 0.00071  









Supplementary Table 3. Yields for coupling of peptides to the lactam and the size as confirmed by high-
resolution mass spectroscopy 







PCU-EAIS -Glu-Ala-Ile-Ser H 47 619.2880 
C29H43N6O9 
619.2878 (M+H+) 
PCU-EAI -Glu-Ala-Ile H 23 532.2766 
C26H38N5O7 
532.2776 (M+H+) 
PCU-EVIS -Glu-Val-Ile-Ser H 33 647.3399 
C31H47N6O9 
647.3389 (M+H+) 
PCU-QAIS -Gln-Ala-Ile-Ser H 20 618.3255 
C29H44N7O8 
618.3253 (M+H+) 
PCU-AISa -Ala-Ile-Ser H 18 490.2460 
C24H36N5O6 
490.2464 (M+H+) 
PCU-AISb -Ala-Ile-Ser H 17 490.2660 
C24H36N5O6 
490.2665 (M+H+) 





































Supplementary Table 4. 1H and 13C chemical shift of the PCU-AISa as measured by HSQC, COSY, 
HMBC, ROESY, 1H and 13C spectra.  The chemical shift was referenced to 2.50 ppm for COSY and 
ROESY the correlation that aided in assignment are marked in black (sequential correlations) and the 
long-range interactions through space, measured by ROESY, are marked in red 
Atom δ1Ha,b δ13Ca,d COSY (δ1Ha,b) HMBC ROESY (δ1Ha,c) 
1x 2.82 43.4 1y, 2, 7  3, 2, 7, 9, NHaa, NHbb 
1y 2.97 42.9 1x, 2, 7  3, 7, NHa, NHc, NHcc 
2 2.46 39.6 1x, 1y, 6, 7 3 1x, 4a, NHaa, NHbb 
3 2.42 43.1 4a, 4s, 10x, 10y 2, 10x 1x, 1y, 3’, 6, 4a, 4s, 10y, 
NHc, NHcc 
4a 1.35 (d. J = 10.2 
Hz) 
36.9 3, 4s, 5 9 2, 3, 4s, 5, 6, 10x 
4s 1.68 (d. J = 10.5 36.9 3, 4a, 5 2, 6  3, 5, 4a, 6, 9, 10x 
Phenol-EAIS   87 510.2572 
C23H35N5O8 
510.2573 (M+H+) 
Atazanavir    -   
Lopinavir    -   
78 
Hz) 
5 2.66 45.2 4a, 4s, 9 2, 9 4a, 4s, 7, 9 
6 2.75 41.6 2, 7 9 3, 4a, 4s 7, 9 
7 2.34 44.3 1x, 1y, 2, 6 8, 9, 11 1x, 1y, 5, 6, 10x 
8  79.7    
9 2.17 51.9 5, 10x, 10y 5, 8 1x, 4s, 5, 6,  
10x 2.72 50.8 3, 9, 10y 3, 9 4a, 4s, 7, NHa, NHc, 
NHcc 
10y 2.88 50.2 3, 9, 10x 3 3, NHa, NHaa 
11  72.9    
12  173.6    
1’  172.4    
2’ 4.21 48.5 * 1’, 3’ 3’, NHbb, NHc, NHcc 
3’ 1.18 18.0 * 1’, 2’  2’, 3 
4’  170.1    
5’ 4.25 56.9 9’ 4’, 6’, 9’, 11’ 9’, 10’, 11a’, 11s’, 12’ 
6’  167.4    
7’ 3.88 54.3  6’, 8a’, 8s’ 8a’, 8s’, NHd 
8a’ 3.61 60.9  6’, 7’, 8s’ 7’, 8s, NHd 
8s’ 3.72 60.9  6’, 7’, 8a 7’, 8a 
9’ 1.74 37.0 5’, 10’, 11a, 11s 10’ 5’, 10’, 11a’, 11s’, 12’ 
NHd 
10’ 0.85 15.3 9’, 11a, 11s 5’, 11a’, 11s’ 5’, 9’, 11a’, 11s’, NHd 
79 
11a’ 1.08 24.2 9’, 11s’, 12’  5’, 9’, 10’, 11s’, 12’, NHd 
11s’ 1.43 24.2 9’ 11a’, 12’  5’, 9’, 10, 11a’, 12’ 
12’ 0.82 11.3 11a’, 11s’ 9’, 11’ 5’, 9’, 11a’, 11s’ 
NHa 7.94  * 1, 8, 10, 11, 12 1y, 10x, 10y 
NHaa 7.99  *  8, 10, 11, 12 1x, 2, 10y 
NHb 8.09  * 1’, 1x, 10a, 10s, 
11  
 
NHbb 8.11  * 1’, 1x, 10a, 10s 
11 
1x, 2, 2’ 
NHc 8.03  * 2’, 3’, 4’ 1y, 2’, 3, 10x 
NHcc 8.07  * 2’, 3’, 4’ 1s, 2’, 3, 10x 
NHd 8.42  * 5, 6’  7’, 8a’, 9’, 10’, 11a 
a Solvent (CD3)2SO. 
b 400 MHz for 1H. 
c 600 MHz for 1H. 
d 100 MHz for 13C. 
* Overlapping signals 
80 

































Supplementary Table 5. 1H and 13C chemical shift of PCU-AISb as measured by HSQC, COSY, 
HMBC, ROESY, 1H and 13C spectra.  The chemical shift was referenced to 2.50 ppm for COSY and 
ROESY the correlation aided in assignment are marked in black (sequential correlations) and the long-
range interactions through space, measured by ROESY, are marked in red.  The carbon spectrum was also 





δ13Ca,d (PCU-AISa) ROESY (δ1Ha,c) (PCU-AISb) 
1x   43.4  
1y 2.92 42.9 42.9 2, 7, NHa, NHb 
2 2.47 39.3 39.6 1x, 1y, 5, 6 NHa, NHb 
3 2.42 43.1 43.1 4a, 4s, 10x, 10y, NHa, NHb 
4a 1.35 (d. J = 10.1 
Hz) 
36.9 36.9 3, 4s, 5, 6 
4s 1.68 (d. J = 10.4 
Hz) 
36.9 36.9 3, 4a, 5, 6, 9, 10x 
5 2.66 45.2 45.2 2, 4a, 4s, 7, 6, 9 
6 2.75 41.6 41.6 2, 4a, 4s, 5, 7, 9, 10s 
7 2.34 44.3 44.3 1x, 1y, 6, 5, NHa, NHaa 
8  79.7 79.7  
81 
9 2.17 51.9 51.9 4s, 5, 6, 10x, 10y, NHa, NHaa 
10x 2.83 50.6 50.8 3, 4s, 9, NHa, NHb 
10y   50.2  
11  72.9 72.9  
12  173.7 173.6  
1’  172.3 172.4  
2’ 4.29 48.5 48.5 3’, NHb, NHc 
3’ 1.18 18.0 18.0 2’, NHa, NHb, NHc, NHcc 
4’  170.1 170.1  
5’ 4.26 57.1 56.9 9’, 10’, NHd 
6’  166.9 167.4  
7’ 3.95 54.1 54.3 8a’, 8s’, NHcc, NHd 
8a’ 3.62 60.6 60.9 7’, 8s’, NHcc, NHd 
8s’ 3.72 60.6 60.9 7’,8a’, NHcc, NHd 
9’ 1.74 37.0 37.0 5’, 10’, 11a’, 11s’, 12’ NHc, 
NHd 
10’ 0.85 15.3 15.3 5’, 9, 11s’ 
11a’ 1.09 24.2 24.2 9’, 11s’, NHd 
11s’ 1.43 24.2 24.2 9’, 10’, 11a’, 12’ NHd, NHc 
12’ 0.81 11.3 11.3 9’, 11s’,  NHc, NHcc, NHd 
NHa 7.99   1s, 2, 3, 3’, 7, 9, 10x 
NHaa 8.01   1a, 7, 9, 10y 
82 
NHb 8.15   1s, 2, 2’/5’, 3, 3’, 10x, 10y 
NHbb     
NHc 8.09   2’/5’, 3’, 9’, 11s’, 12’  
NHcc 8.10   3’, 7’, 8a’, 8s’, 9’, 12’ 
NHd 8.44   2’/5’, 7’, 8a’, 8s’, 9’, 11a’, 
11s’, 12’  
a Solvent (CD3)2SO. 
b 400 MHz for 1H. 
c 600 MHz for 1H. 
d 100 MHz for 13C. 
83 










































Supplementary Table 6. 1H and 13C chemical shift of PCU-EAIS as measured by HSQC, COSY, 
HMBC, ROESY, 1H and 13C spectra.  The chemical shift was referenced to 2.50 ppm for COSY and 
ROESY the correlation aided in assignment are marked in black (sequential correlations) and the long-
range interactions through space, measured by ROESY, are marked in red. The carbon spectrum was also 






1x 2.89 43.2 43.4 2, 3,6, 7, NHc 
1y 2.97 42.9 42.9 2, 3, 6, 7, 10, NHa, NHg 
2 2.45 39.6 39.6 1x, 1y, NHa, NHb 
3 2.41 43.1 43.1 1x, 1y, 3’, 4a, 4s, 6, 10, 10’, 
NHa, NHb, NHc, NHg 
4a 1.35 (d. J = 10.6 
Hz) 
36.9 36.9 3, 4s, 5, 6 
4s 1.68 36.9 36.9 3, 4a, 5, 6, 9, 10 
5 2.66 45.2 45.2 4a, 4s, 6, 9 
6 2.75 41.6 41.6 1x, 1y, 2, 3, 4a, 4s, 5, 7, 9 
7 2.34 44.4 44.3 1x, 1y, 6 
8  79.6 79.7  
84 
9 2.17 51.9 51.9 4s, 5, 6, 10 
10x   50.8  
10y 2.77 50.5 50.2 1y, 3, 4s, 9, 10, NHa, NHb, 
NHc 
11  72.9 72.9  
12  171.8 173.6  
g1’  171.2   
g2’ 4.22 51.9  g3a’, g3s, g4, NHa 
g3a’ 1.72 27.4  g2’, g3s, g4, NHa, NHg 
g3s’ 1.89 27.4  g2’, g3a, g4, NHa, NHg 
g4’ 2.21 29.8  3’, g2’, g3a’, g3s’, 10’, NHa 
g5’  174.0   
1’  172.1 172.4  
2’ 4.27 48.6 48.5 3’, NHb, NHc, NHcc 
3’ 1.19 17.9 18.0 2’, 3, g4’, NHb, NHc, NHcc, 
NHg 
4’  170.3 170.1  
5’ 4.25 56.9 56.9 9’, 10’, 11a, 11s, NHd 
6’  166.7 167.4  
7’ 3.93 54.1 54.3 8a’, 8s’, 10’, 12’, NHd 
8a’ 3.62 60.5 60.9 7’, 8s’, NHd 
8s’ 3.72 60.5 60.9 7’,8a’, NHd 
9’ 1.73 37.0 37.0 5’, 10’, 11a’, 11s’, 12’, NHc, 
85 
NHcc NHd 
10’ 0.86 15.3 15.3 3, g4’, 5’, 7, 9’, 11a’, NHc, 
NHcc 
11a’ 1.05 24.2 24.2 5’, 9’, 10, 11s’, 12’, NHd 
11s’ 1.43 24.2 24.2 5’, 7, 9’, 11a’, 12’ NHd, NHc 
12’ 0.82 11.2 11.3 5’, 9’, 11a’, 11s’, NHcc, NHd 
NHa 8.08   1x, 1y, 2,  3, 10, g2’, g3a’, 
g3s, g4’ 
NHaa     
NHg 8.10   1y, 3, 3’, g3a’, g3s 
NHb 7.80   2’, 2, 3, 3’, g2’, g3a’, g3s, g4’ 
NHbb 7.94   2’, 2, 3, 3’, g2’, g3a’, g3s, g4’ 
NHc 8.16   1x, 2’, 3’, 3, 6, 9’, 10’, 11s’ 
NHcc 8.20   2’, 3’, 9’, 10’, 12’ 
NHd 8.40   2’/5’, 7’, 8a’, 8s’, 9’, 11a’, 
11s’, 12’  
a Solvent (CD3)2SO. 
b 400 MHz for 1H. 
c 600 MHz for 1H. 
d 100 MHz for 13C 
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Supplementary Table 7. 1H and 13C chemical shift of PCU-EAI as measured by HSQC, COSY, HMBC, 
ROESY, 1H and 13C spectra.  The chemical shift was referenced to 2.50 ppm for COSY and ROESY the 
correlation aided in assignment are marked in black (sequential correlations) and the long-range 
interactions through space, measured by ROESY, are marked in red.  The carbon spectrum was also 






1x 2.93 43.6 43.2 2, 5, 6, 7, NHa, NHb, NHg, 
NHgg 
1y 3.01 42.9 42.9 2, 5, 6, 7 NHa, NHbb 
2 2.47 39.6 39.6 1x, 1y, 4a, 4s, 6, 10y, NHa, 
NHb, NHg, NHgg 
3 2.44 43.0 43.1 3’, 10x 
4a 1.35 (d. J = 10.1 
Hz) 
36.9 36.9 2, 4s, 5, 6 
4s 1.68 36.9 36.9 2, 4a, 5, 9, 10x 
5 2.66 45.1 45.2 1x, 1y, 4a, 4s, 6, 7, 9 
6 2.75 41.5 41.6 1x, 1y, 2, 4a, 4s, 5, 7, 10y 
7 2.34 44.3 44.4 1x, 1y, 5, 6, NHa, NHb 
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8  79.6 79.6  
9 2.17 52.0 51.9 4s, 5, 10x, 10y, NHa 
10x 2.79 50.7  3, 4s, 9, 10y, NHa, NHbb, 
NHg, NHgg 
10y 2.87 50.5 50.5 2, 6, 9, 10x, NHb 
11  72.9 72.9  
12  173.6 171.8  
g1’  171.5 171.2  
g2’ 4.14 53.0 51.9 g3a’, g3s, g4, NHa, NHb, 
NHg, NHgg 
g3a’ 1.78 27.2 27.4 g2’, g3s, NHb, NHbb, NHc, 
NHcc 
g3s’ 1.88 27.2 27.4 g2’, g3a, NHb, NHbb, NHc, 
NHcc 
g4’ 2.18 31.0 29.8 3’, g2’, NHb, NHbb, NHc, 
NHcc 
g5’  175.5 174.0  
1’  171.6 172.1  
2’x 4.18 48.6 48.6 3’, 10’, NHb, NHbb, NHc 
2’y 4.25 48.4  3’, 10’, NHcc 
3’ 1.25 17.9 17.9 3, 2’x, 2’y, g4’, NHc, NHcc, 
NHb 
4’  170.8 170.3  
5’ 3.37 57.8 56.9 9’, 10’ 
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6’   166.7  
7’   54.1  
8a’   60.5  
8s’   60.5  
9’ 1.74 37.1 37.0 5’, 10’, 11a’, 11s’, 12’ 
10’ 0.86 15.1 15.3 2’x, 2’y, g4’, 5’, 7, 9’, 11a’ 
11a’ 1.12 24.0 24.2 9’, 10’, 11s’, 12’ 
11s’ 1.46 24.0 24.2 9’, 11a’, 12’ 
12’ 0.82 11.3 11.2 9’, 11a’, 11s’ 
NHa 7.96   1x, 1y, 2, g2’, 7, 9, 10x  
NHg 8.12   1x, 2, g2’, 10x 
NHgg 8.19   1x, 2, g2, 10x 
NHb 7.95   1x, 2’x, 3’, g2’, g3a’, g3s g4’, 
7, 10y 
NHbb 8.06   2’x, 1y, 10x, g3a’, g3s, g4’,  
NHc 8.14   2’x, 2’y, 3’, g3a’, g3s, g4’ 
NHcc 8.31   2’y, 3’, 5’, g3a’, g3s, g4’ 
a Solvent (CD3)2SO. 
b 400 MHz for 1H. 
c 600 MHz for 1H. 
d 100 MHz for 13C 
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Supplementary Table 8. 1H and 13C chemical shift of PCU-EVIS as measured by HSQC, COSY, 
HMBC, ROESY, 1H and 13C spectra.  The chemical shift was referenced to 2.50 ppm for COSY and 
ROESY the correlation aided in assignment are marked in black (sequential correlations) and the long-
range interactions through space, measured by ROESY, are marked in red.  The carbon spectrum was also 
compared with the carbon spectrum of PCU-EAIS 
Atom δ1Ha,b(PCU-EVIS) δ13Ca,d(PCU-
EVIS) 
δ13Ca,d (PCU-EAIS) ROESY(δ1Ha,c) (PCU-EVIS) 
1x 2.84 43.1 43.2 3, 4s, 7, 9, 10’, NHg, NHgg 
1y 2.95 42.9 42.9 2, 4a, 7, 10’, NHa, NHg 
2 2.46 39.6 39.6 1y, 4a, 5, 10x, NHbb 
3 2.43 43.1 43.1 1x, 4a, 4s, 6, 10’, 10x, 10y, 
NHb, NHg, NHgg 
4a 1.35 (d. J = 10.1 
Hz) 
36.9 36.9 1y, 2, 3, 4s, 5, 10x 
4s 1.67 (d. J = 10.8 
Hz) 
36.9 36.9 1x, 3, 4a, 5, 9 
5 2.66 45.1 45.2 2, 4a, 4s, 6, 7, 9, 10x 
6 2.75 41.6 41.6 3, 5, g4’  
7 2.34 44.4 44.4 1x, 1y, 5, 10x, 10y, 12’ 
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8  79.6 79.6  
9 2.17 51.9 51.9 1x, 4s, 5 
10x 2.73 50.7  2, 3, 4a, 5, 6, 7 
10y 2.81 50.5 50.5 3, 7, g4’ 
11  72.9 72.9  
12  173.6 171.8  
g1’  171.4 171.2  
g2’ 4.21 52.1 51.9 g3a’, g3s, g4, NHb, NHbb, NHg, 
NHgg 
g3a’ 1.73 27.4 27.4 g2’, g3s 
g3s’ 1.93 27.4 27.4 g2’, g3a,  
g4’ 2.20 30.2 29.8 g2’, 6, V4’, 10y 
g5’  174.3 174.0  
1’  170.8 172.1  
2’ 4.09 58.5 48.6 3’, v4’, NHb, NHc, NHbb 
3’ 1.94 30.2 17.9 2’, V4’, NHb, NHc, NHbb 
v4’ 0.84 19.1  2’, 3’, g4’, V4’, NHb, NHc, 
NHbb 
v4’ 0.84 19.1  2’, 3’, g4’, NHb, NHc, NHbb 
4’  171.2 170.3  
5’ 4.27 57.0 56.9 9’, 10’, 11a, 11s 
6’  173.2 166.7  
7’ 3.54 55.6 54.1 - 
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8a’ 3.51 62.9 60.5 - 
8s’ 3.59 62.9 60.5 - 
9’ 1.74 37.0 37.0 5’, 10’, 11a’, 11s’, NHb, NHc,  
10’ 0.82 15.3 15.3 1x, 1y, 5’, 9’ 
11a’ 1.06 24.2 24.2 5’, 9’, 11s’, 12’ 
11s’ 1.41 24.2 24.2 5’, 9’, 11a’, 12’ 
12’ 0.79 11.2 11.2 11a’, 11s’, 
NHa 8.04   1y 
NHaa     
NHg 8.15   1x, 1y, 2, 3, g2’ 
NHgg 8.21   1x, 3, g2’ 
NHb 7.93   2’, 3’, g2’, g3’a, g3’s, V4’ 
NHbb    1y, 2’, 2, 3’, 3, g2’, V4’ 
NHc 8.02   2’, 3’, 5’, 9’, V4’ 
NHcc     
NHd 8.24   - 
a Solvent (CD3)2SO. 
b 400 MHz for 1H. 
c 600 MHz for 1H. 
d 100 MHz for 13C 
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Aromatic protons 1-6 were observed at 6.94 ppm -7.23 ppm. The HSQC spectrum showed the same 
pattern for the EAIS side chain as the one observed for PCU-EAIS.  The ROESY spectrum did not show 
long range correlations. 
Supplementary Table 9. 1H and 13C chemical shift of Phenol-EAIS as measured by HSQC, COSY, 
HMBC, ROESY, 1H and 13C spectra.  The chemical shift was referenced to 2.50 ppm for COSY and 
ROESY the correlation aided in assignment are marked in black (sequential correlations) and the long-
range interactions through space, measured by ROESY, are marked in red.  The carbon spectrum was also 







1-6 6.94-7.23 106.5-157.6   
g1’   171.2  
g2’ 4.35 52.6 51.9 g2’, g3a’, g3s’, NHg 
g3a’ 1.85 27.4 27.4 g2’, g3s’, NHg 
g3s’ 2.02 27.4 27.4 g2’, g3a’, NHg 
g4’ 2.33 29.1 29.8 g2’, NHg 
g5’  173.0 174.0  
1’  172.2 172.1  
2’ 4.26 48.7 48.6 3’, NHb, NHg 
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3’ 1.23 17.6 17.9 2’, NHb, NHc, NHd 
4’   170.3  
5’ 4.23 56.5 56.9 9’, 12’, NHd 
6’  169.6 166.7  
7’ 3.52 55.7 54.1 -
8a’ 3.51 62.8 60.5 -
8s’ 3.59 62.8 60.5 -
9’ 1.75 37.2 37.0 5’, 10’, 11a’, 11s’, 12’, 
NHc, NHd 
10’ 0.83 15.2 15.3 9’, NHc 
11a’ 1.08 24.1 24.2 9’, 11s’, 12’ 
11s’ 1.43 24.1 24.2 9’, 11a’, 12’ 
12’ 0.80 11.1 11.2 5’, 9’, 11a’, 11s’ 
NHg 8.20   2’, g2’, g3a’, g3s’, g4’ 
NHb 8.00   2’, 3’ 
NHc 8.16   3’, 5’, 9’, 10’ 
NHd 8.31   3’, 5’, 9’, 12’ 
a Solvent (CD3)2SO. 
b 400 MHz for 1H. 
c 600 MHz for 1H. 
d 100 MHz for 13C 
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Supplementary Table 10. 1H and 13C chemical shift of PCU-QAIS as measured by HSQC, COSY, 
HMBC, ROESY, 1H and 13C spectra.  The chemical shift was referenced to 2.50 ppm for COSY and 
ROESY the correlation aided in assignment are marked in black (sequential correlations) and the long-
range interactions through space, measured by ROESY, are marked in red.  The carbon spectrum was also 






1x 2.91 43.1 43.2 7, NHaa 
1y 2.98 42.7 42.9 3, NHg,  
2 2.45 39.6 39.6 4a, 4s, 10, NHaa, NHb, NHbb, 
NHg, NHgg 
3 2.41 43.0 43.1 1y 
4a 1.35 (d. J = 10.5 
Hz) 
36.9 36.9 2, 4s, 5, 6 
4s 1.68 36.9 36.9 2, 4a, 5, 9, 10 
5 2.66 45.1 45.2 4a, 4s, 6, 9 
6 2.75 41.6 41.6 4a, 5, 7 
7 2.34 44.4 44.4 1x, 6 
8  79.6 79.6  
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9 2.17 51.9 51.9 4s, 5, 10 
10x     
10y 2.78 50.7 50.5 2, 4s, 9, NHa, NHaa, NHg, 
NHgg 
11  72.9 72.9  
12  173.6 171.8  
g1’  171.4 171.2  
g2’ 4.18 52.3 51.9 g3a’, g3s, g4, NHb, NHbb, 
NHg, NHgg 
g3a’ 1.66 27.6 27.4 g2’, g3s, g4, NHb, NHbb, 
NHg, NHgg 
g3s’ 1.88 27.6 27.4 g2’, g3a, g4’, NHb, NHbb, 
NHg, NHgg 
g4’ 2.05 31.1 29.8 g2’, g3s’, NHb, NHbb 
g5’  173.7 174.0  
1’  172.0 172.1  
2’ 4.22 56.3 48.6 3’, NHb, NHbb, NHc, NHcc 
3’ 1.17 17.9 17.9 2’, NHb, NHbb, NHc, NHcc, 
NHd 
4’  170.7 170.3  
5’ 4.23 48.6 56.9 9’, 10’, 11a, 11s, 12’, NHc 
6’  - 166.7  
7’ 3.37 56.3 54.1 -
8a’ 3.46 - 60.5 -
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8s’ 3.53 - 60.5 -
9’ 1.70 37.2 37.0 5’, 10’, 11a’, 11s’, 12’, NHcc 
10’ 0.82 15.2 15.3 5’, 9’, 11s’ 
11a’ 1.03 24.1 24.2 5’, 9’,11s’, 12’ 
11s’ 1.40 24.1 24.2 5’, 9’, 10’, 11a’, 12’ 
12’ 0.79 11.2 11.2 5’, 9’, 11a’, 11s’ 
NHa 8.00   10 
NHaa 8.14   1x, 2, 10y 
NHg 8.05   1y, 2, g2’, g3a’ g3s’, 10 
NHgg 8.08   2, g2’, g3a’ g3s’, 10 
NHb 7.93   2’, 2, 3’, g2’, g3a’, g3s’, g4’ 
NHbb 7.95   2’, 2, 3’, g2’, g3a’, g3s’, g4’ 
NHc 8.16   2’, 3’, 5’ 
NHcc 8.23   2’, 3’, 9’ 
NHd 8.30   3’ 
a Solvent (CD3)2SO. 
b 400 MHz for 1H. 
c 600 MHz for 1H. 












































Supplementary Table 11. EASY ROESY correlations observed in the spectra of PCU-EAIS recorded in 
DMSO-d6 and the D2O as the solvent.  The chemical shift was referenced to 2.50 ppm 
Atom 1H PCU-EAIS ROESY(δ1Hc)(PCU-EAIS) 
(DMSO-d6) 
ROESY(δ1Hc)(PCU-EAIS (D2O) 
1x 2.89 2, 3,6, 7, NHc 2, 3, 7,NHa, NHc, NHcc 
1y 2.97 2, 3, 6, 7, 10, NHa, NHg 2, 3, 7, NHa 
2 2.45 1a, 1s, NHa, NHb 1a, 1s 
3 2.41 1a, 1s, 3’, 4a, 4s, 6, 10, 10’, NHa, 
NHb, NHc, NHg 
1a, 1s, 4a, 4s, 10, NHa, NHc, NHcc 
4a 1.35 (d. J = 10.6 
Hz) 
3, 4s, 5, 6 3, 4s, 5, 6 
4s 1.68 3, 4a, 5, 6, 9, 10 3, 4a, 5, 6, 9, 10 
5 2.66 4a, 4s, 6, 9 4a, 4s, 6 
6 2.75 1a, 1s, 2, 3, 4a, 4s, 5, 7, 9 4a, 4s, 5, 7, 9 
7 2.34 1a, 1s, 6 1a, 1s, 6 
8    
9 2.17 4s, 5, 6, 10 4s, 6, 10 
10 2.77 1s, 3, 4s, 9, 10, NHa, NHb, NHc 3, 4s, 9, NHa, NHc 
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11    
12    
g1’    
g2’ 4.22 g3a’, g3s, g4, NHa g3a’, g3s, g4, NHa, NHg 
g3a’ 1.72 g2’, g3s, g4, NHa, NHg g2’, g3s, g4, NHg, NHbb, 
g3s’ 1.89 g2’, g3a, g4, NHa, NHg g2’, g3a, g4, NHg 
g4’ 2.21 3’, g2’, g3a’, g3s’, 10’, NHa g2’, g3a’, g3s’, NHg 
g5’    
1’    
2’ 4.27 3’, NHb, NHc, NHcc 3’, NHbb, NHc, NHcc 
3’ 1.19 2’, 3, g4’, NHb, NHc, NHcc, 
NHg 
2’, NHbb, NHc, NHcc 
4’    
5’ 4.25 9’, 10’, 11a, 11s, NHd 9’, 11a’, 11s’, 12’ 
6’    
7’ 3.93 8a’, 8s’, 10’, 12’, NHd 8a’, 8s’, NHd 
8a’ 3.62 7’, 8s’, NHd 7’, 8s’, NHd 
8s’ 3.72 7’,8a’, NHd 7’,8a’, NHd 
9’ 1.73 5’, 10’, 11a’, 11s’, 12’, NHc, 
NHcc NHd 
5’, 10’, 11a’, 11s’, 12’, NHc, NHcc, 
NHd 
10’ 0.86 3, g4’, 5’, 7, 9’, 11a’, NHc, NHcc 9’, 11a’, NHcc 
11a’ 1.05 5’, 9’, 10, 11s’, 12’, NHd 5’, 9’, 10, 11s’, NHd 
11s’ 1.43 5’, 7, 9’, 11a’, 12’ NHd, NHc 5’, 9’, 11a’, 12’  
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12’ 0.82 5’, 9’, 11a’, 11s’, NHcc, NHd 5’, 9’, 11a’, 11s’ 
NHa 8.08 1a, 1s, 2,  3, 10, g2’, g3a’, g3s, 
g4’ 
1a, 1s, 2,  3, 10, g2’ 
NHaa    
NHg 8.10 1s, 3, 3’, g3a’, g3s g2’, g3a’, g3s, g4’ 
NHb 7.80 2’, 2, 3, 3’, g2’, g3a’, g3s, g4’  
NHbb 7.94 2’, 2, 3, 3’, g2’, g3a’, g3s, g4’ 2’, 3’, g3a’ 
NHc 8.16 1a, 2’, 3’, 3, 6, 9’, 10’, 11s’ 1a, 2’, 3’, 3, 9’, 10’ 
NHcc 8.20 2’, 3’, 9’, 10’, 12’ 1a, 2’, 3, 3’, 3, 9’, 10’ 
NHd 8.40 2’/5’, 7’, 8a’, 8s’, 9’, 11a’, 11s’, 
12’  
7’, 8a’, 8s’, 9’, 11a’ 
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MD Minimization PCU-EAISb 400k.f90 
ROGRAM QMMM_RELAX_SYSTEM 
 
 USE DYNAMO 
 IMPLICIT NONE 
 
        integer                :: i, cnt, A1, A2, A3, A4, A5 
       real( kind=dp )                    :: d1, d2, d3, d4 
       REAL ( KIND=DP ), DIMENSION (1:2)  :: COEFF 
       CHARACTER ( LEN = 10 )             :: si 
 
        character ( len = 10 ) :: scnt 
        logical, dimension(:), allocatable ::  quant, flg 
 
        call dynamo_header 
 
 call random_initialize ( 314159 ) 
 
 CALL MM_SYSTEM_READ ( 'inh_ext_box.sys_bin' ) 
 CALL COORDINATES_READ ( 'inh_ext_box.crd' ) 
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!A1 = ATOM_NUMBER ( ATOM_NAME = 'H41', RESIDUE_NUMBER = 1 , SUBSYSTEM = 
'LAALSA' ) 
!A2 = ATOM_NUMBER ( ATOM_NAME = 'H7', RESIDUE_NUMBER = 1 , SUBSYSTEM = 
'LAALSA' ) 
!A3 = ATOM_NUMBER ( ATOM_NAME = 'H37', RESIDUE_NUMBER = 1 , SUBSYSTEM = 
'LAALSA' ) 





        allocate (quant(1:natoms)) 
 
        quant = atom_selection( & 
                subsystem      = (/ "INH_EXT" /) ) 
!        quant = quant .or. atom_selection( & 
!                atom_name      = (/ "CB", "HB1", "HB2", "HG2", "HG1", "CG", "CD", "OE1", "OE2" /), & 
!                residue_number = (/ 78 /), & 
!                subsystem      = (/ "PROTEIN" /) ) 
!        quant = quant .or. atom_selection( &  
!                atom_name      = (/ "CB", "HB1", "HB2", "HG2", "HG1", "CG", "CD", "OE1", "OE2"/), & 
!                residue_number = (/ 172 /), & 
!                subsystem      = (/ "PROTEIN" /) ) 
!         quant = quant .or. atom_selection( & 
102 
!                residue_number = (/ 2275 /), & 
!                subsystem      = (/ "WAT" /) ) 
 
 
! keep the following atom fixed 
!        call atoms_fix ( atom_selection ( subsystem = (/ 'ACS' /) ) ) 
!        call atoms_fix ( atom_selection ( subsystem = (/ 'PROTEIN' /) ) ) 
!       call atoms_fix ( atom_selection ( subsystem = (/ 'WAT' /) ) ) 
 
 
        call mopac_setup ( & 
                method              =  'AM1', & 
                charge              =  0, & 
                selection           =  quant ) 





        CALL ENERGY_NON_BONDING_OPTIONS ( & 
                LIST_CUTOFF   = 15.5_dp, & 
                OUTER_CUTOFF  = 13.5_dp, & 
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                INNER_CUTOFF  = 11.5_dp, & 
                MINIMUM_IMAGE = .true. ) 
        CALL ENERGY_INITIALIZE 
        CALL GRADIENT 
 
!call constraint_initialize 
!                call constraint_point_define( & 
!                       atom_selection( atom_number = (/ A1  /) ) ) 
!                call constraint_point_define( & 
!                       atom_selection( atom_number = (/ A2  /) ) ) 
!                d1 = 3.400_dp 
!                call constraint_define( & 
!                        type = 'DISTANCE', & 
!                        fc   = 10000._dp, & 
!                        eq   = d1 ) 
! 
!              call constraint_point_define( & 
!                       atom_selection( atom_number = (/ A3  /) ) ) 
!                call constraint_point_define( & 
!                       atom_selection( atom_number = (/ A4  /) ) ) 
!                d2 = 3.400_dp 
!                call constraint_define( & 
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!                        type = 'DISTANCE', & 
!                        fc   = 10000._dp, & 
!                        eq   = d2 ) 
 
 CALL OPTIMIZE_CONJUGATE_GRADIENT ( & 
  STEP_SIZE       = 0.001_dp, & 
  PRINT_FREQUENCY = 100, & 
  STEP_NUMBER     = 30000 ) 
        CALL COORDINATES_WRITE ('opt_LaEAISb_from_ext.crd') 
        CALL PDB_WRITE         ('opt_LaEAISb_from_ext.pdb') 
 
 
 call velocity_assign ( tneeded = 400._dp, remove_translation = .false. ) 
 
  call dynamics_options ( & 
   time_step       = 0.001_dp, & 
   steps           = 1000000, & 
                        save_frequency = 100 , & 
                        coordinate_file = '400K_LaEAISb_ext.trj.dcd', & 
                        print_frequency = 100 ) 
 
        call constraint_writing_start 
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        call langevin_verlet_dynamics ( tbath = 400._dp, gamma = 100._dp ) 




        deallocate( quant ) 
 
 CALL COORDINATES_WRITE ('400K_rel_LaEAISb_from_ext.crd') 
        CALL PDB_WRITE         ('400K_rel_LaEASIb_from_ext.pdb')   
END  




TYPE (DCD_TYPE) :: TRJ 
logical, dimension(:), allocatable :: flg, quant 
INTEGER         :: NF, I 
OPEN (UNIT=70, FILE="qm.energy", STATUS="UNKNOWN") 
call dynamo_header 
 
CALL MM_SYSTEM_READ ( "inh_ext_box.sys_bin" ) 
allocate (quant(1:natoms)) 
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                quant = atom_selection( & 
                subsystem      = (/ "INH_EXT" /) ) 
 
        call mopac_setup ( & 
                method              =  'AM1', & 
                charge              =  0, & 
                selection           =  quant ) 





        CALL ENERGY_NON_BONDING_OPTIONS ( & 
                LIST_CUTOFF   = 15.5_dp, & 
                OUTER_CUTOFF  = 13.5_dp, & 
                INNER_CUTOFF  = 11.5_dp, & 
                MINIMUM_IMAGE = .true. ) 
 
 
CALL DCD_INITIALIZE ( TRJ ) 
! Put the trayectory file 
CALL DCD_ACTIVATE_READ ( "400K_LaEAISb_ext.trj.dcd", TRJ ) 
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NF = TRJ%NFRAMES 
CALL SYMMETRY_CUBIC_BOX ( 34.5_DP ) 
DO I = 1, NF 
 CALL DCD_READ (DCD = TRJ, BOXDAT = BOXL, ATMDAT = ATMCRD ) 
        CALL ENERGY 
        write(70,*) eqm 
END DO 
END 
Dihedral PCU-EAISb 400k.f90 
Last login: Fri Mar 11 17:04:18 on ttys000 
/Volumes/SABELO/Maye\ refree/dihedral-PCU-EAISb-400k-f90 ; exit; 
Administrators-Mac-mini:~ Mac$ /Volumes/SABELO/Maye\ refree/dihedral-PCU-EAISb-400k-f90 ; 
exit; 
/Volumes/SABELO/Maye refree/dihedral-PCU-EAISb-400k-f90: line 1: PROGRAM: command not 
found 
/Volumes/SABELO/Maye refree/dihedral-PCU-EAISb-400k-f90: line 2: USE: command not found 
/Volumes/SABELO/Maye refree/dihedral-PCU-EAISb-400k-f90: line 3: IMPLICIT: command not found 
/Volumes/SABELO/Maye refree/dihedral-PCU-EAISb-400k-f90: line 4: syntax error near unexpected 
token `DCD_TYPE' 





PDB FILES OF THE PCU-PEPTIDE ENZYME COMPLEXES 
See the attached folder 
ELECTROSTATIC AND HYDROGEN BOND INTERACTIONS OF HIV-
PR COMPLEXES FROM THE MD SIMULATION. 
 
Figure 2. Electrostatic and hydrogen bond interactions for the PCU-AISa (CP) and PCU-AISa (PP) CSA 





Figure 3. Electrostatic and hydrogen bond interactions for the PCU-AISb (CP) and PCU-AISb (PP) CSA 
HIV-PR complexes from the MD simulation.  These plots were created with the Ligplot software.  
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RAMACHANDRAN PLOTS 
   
   
Figure 4.  Ramachandran plots for PCU-AISa (left) and PCU-AISb (right) at 500 K.  The 100 lowest 
energy structures were plotted.   
   
111 
   
   
Figure 5.  Ramachandran plots for PCU-EAISa (left) and PCU-EAISb (right) at 500 K.  The 100 lowest 
energy structures were plotted. 
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HRMS spectrum of Ac-PCU-EAIS 
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1. White WCCaPD (2004) Fmoc solid phase peptide synthesis: A practical approach (Oxford 
University Press, New York). 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































MATERIALS AND METHODS 
Analytical analysis was performed on an Agilent 1100 HPLC with a flow rate of 1 mL/min on a Waters 
Xbridge C18 (150 mm x 4.6 mm x 5 microns) coupled to a UV detector (215 nm) and an Agilent VL ion 
trap mass spectrophotometer in the positive mode.  Semi-preparative HPLC was carried out on a 
Shimadzu semi-preparative instrument with a flow rate of 17 mL/min on a Ace C18 (150 mm x 21.2 mm 
x 5 microns) with a UV/VIS detector (215 nm) and an automated fraction collector.  A two-buffer system 
was employed, utilizing formic acid as the ion-pairing agent.  Buffer A consisted of 0.1 % formic 
acid/H2O (v/v) and buffer B consisted of 0.1 % formic acid/acetonitrile (v/v).  High resolution mass 
spectroscopic analysis was performed on a Bruker MicroTOF QII mass spectrometer in positive mode 
with an internal calibration.  Peptides were synthesized on an automated CEM Liberty microwave peptide 
synthesizer (see Table 1 for conditions, not same as supplier).  All 1H, 13C, HSQC, COSY and HMBC 
NMR data were recorded on a Bruker AVANCE III 400 MHz spectrometer.  The ROESY data was 
recorded on a Bruker AVANCE III 600 MHz spectrometer. 








Single coupling    
30 minute coupling 
0 25 900 
35 73 900 
Deprotection 40 73 180 
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SYNTHESIS OF AMINO LACTAM  
To an ice cold solution of 25 % ammonia (15 mL) the dione (1.00 g, 5.7 mmol) was added, followed by 
NH4Cl (0.42 g, 9.1 mmol, 2.2 eq) and NaCN (0.45 g, 7.9 mmol, 2.3 eq), respectively.  The mixture was 
stirred in the ice-bath for 2 hours resulting in a white thick solution that was filtered using a sintered glass 
funnel.  The precipitate was washed with acetone (2 x 15 mL) and the product was recrystallized from 
methanol to yield 14 as white crystals (73 % yield).   
GENERAL PROCEDURE FOR LOADING OF FIRST AMINO ACID TO THE 2-
CHLOROTRITYL CHLORIDE RESIN 
Activated 2-chlorotrityl chloride resin (1 g, 1.33 mmol) was swelled in dry DCM (10 mL) for 10 minutes 
in a sintered glass reaction vessel.  Fmoc-amino acid-OH (3.99 mmol) was dissolved in DCM (10 mL) 
and DIPEA (6.65 mmol) and then added to the reaction vessel.  The mixture was bubbled for 2 hours 
using nitrogen.  The solvent was removed by filtration and the resin was washed with DCM (3 x 10 mL).  
A few resin beads (~5 mg) were removed from the reaction vessel and left to dry in the vacuum oven for 
an hour.  A solution of 20 % piperidine in DMF was added to the dried resin beads (1 mg) and left to 
stand for 20 min.  General washing procedure for manual SPPS: after each step, the resin was washed 
with DCM (3 x 10 mL), DMF (3 x 10 mL) then DCM (3 x 10 mL). 
GENERAL PROCEDURE FOR THE SYNTHESIS OF PEPTIDES USING 
MICROWAVE POWER 
Stock solutions of all amino acids (0.2 mM), DIPEA (1 mM) and HBTU (2 mM) were prepared in DMF 
and peptides were synthesized on a 0.5 mmol scale.  The modified coupling method described in Table 1 
above was used for coupling the subsequent amino acids to the 2-chlorotrityl chloride resin (1 g) 
preloaded with the first amino acid. 
Final cleavage :  The resin bound peptide was removed from the peptide synthesizer and transferred to a 
manual peptide synthesis reaction vessel for the final cleavage.  It was washed with DCM (3 x 10 mL) 
and a cleavage mixture of 5:95 % (v/v) TFA:DCM was added to the resin while nitrogen was bubbled 
through the solution for 10 minutes.  The resin was washed three times with the cleavage mixture and the 
cleaved peptide was removed by filtration and collected in a flask containing water (100 mL).  The filtrate 
was extracted several times with DCM so as to remove the peptide from the water layer.  DCM was 
removed under reduced vacuum with at 40°C and the peptide remained as a white powder. 
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GENERAL PROCEDURE FOR THE SYNTHESIS OF THE PEPTOIDS. 
Activated 2-chlorotrityl chloride resin (1 g, 1.33 mmol) was swelled in dry DCM (10 mL) for 10 
minutes in a sintered glass reaction vessel.  Bromoacetic acid (1.6 g) in DMF (final concentration 
of 1.2 M) and DIPEA (2 mL) was added to the reaction vessel and the mixture was bubbled for 2 
hours with nitrogen.  The solvent was removed by filtration and the resin washed with DCM (3 x 
10 mL) and DMF (3 x 10 mL).  A solution of the amine (1 M) in DMF was added to the reaction 
vessel and bubbled for 1 hr using nitrogen.  The solvent was removed by filtration and the resin 
was washed with DCM (3 x 10 mL) and DMF (3 x 10 mL).  Bromoacetic acid (1.6 g) in DMF 
(final concentration of 1.2 M) and DIC (2 mL) was added to the reaction vessel and bubbled for 
2 hours using nitrogen.  These steps were repeated for the desired sequences.  Final cleavage of 
the peptoid from the resin was carried out similarly as that of peptides described above. 
GENERAL PROCEDURE FOR COUPLING OF PEPTIDES AND PEPTOIDS TO PCU-
LACTAM 
The cleaved peptide (1.2 eq.) was dissolved in DCM (3 mL) followed by addition of PCU lactam 
14 (1 eq), HATU (2.5 eq) in DMF (7 mL) and DIPEA (3 eq).  The mixture was stirred at room 
temperature for 24 hours and thereafter evaporated to dryness under reduced pressure using a 
Teflon pump at 40°C.  A cleavage mixture (10 mL) of 95:5 (v/v) TFA:DCM was added to the 
crude product and stirred for 24 hours at room temperature.  The TFA was removed from the 
mixture by bubbling air through the solution and the remaining DCM was removed under 
reduced pressure at 30°C.  The product was obtained as yellow oil which was purified by reverse 
phase semi-preparative HPLC. 
OVER-EXPRESSION, EXTRACTION AND PURIFICATION OF THE C-SA 
PROTEASE 
Plasmid encoding HIV-1 subtype C protease (containing the mutation Q7K designed to reduce the 
hypersensitive autolytic site) is expressed as inclusion bodies (2) in Escherichia coli BL21 (DE3) pLysS 
cells. Briefly, Escherichia coli cells harboring the plasmid DNA were grown at 37 °C in LB medium 
supplemented with 100 μg/mL of ampicillin and 35 μg/mL of chloramphenicol. The overnight culture 
was diluted 100-fold into fresh 2 × YT medium supplemented with ampicillin (100 μg/mL) and 
chloramphenicol (35 μg/mL) and grown at 37 °C.  When the optical density (OD600) of the culture 
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reached 0.4 to 0.5, over-expression of the HIV-1 C-SA protease was induced by adding IPTG. IPTG was 
added to final concentrations of 0.4 mM.  Over-expression of the protease was allowed to continue for 
four hours.  
The cells were pelleted after growth and resuspended in ice-cold extraction buffer [10 mM Tris, 1 mM 
EDTA, and 1 mM PMSF (added only fresh before use), pH 8] and disrupted using an ultra-sonicator.  
Following the addition of MgCl2 and DNase I to final concentrations of 10 mM and 10 μg/mL, 
respectively, the culture medium was stirred on ice until the viscosity of the mixture decreased.  The cells 
were then ruptured by sonication and centrifuged at 15 000 × g for 30 minutes at 4 °C. The pellet was 
resuspended in ice-cold extraction buffer containing 1 % (v/v) of Triton X-100.  Cell debris and protease-
containing inclusion bodies were pelleted by centrifugation at 15 000 × g for 30 minutes at 4 °C.  The 
pellet was then resuspended in a freshly prepared solubilization buffer containing 10 mM Tris, 2 mM 
DTT, 8 M urea, pH 8.0, at room temperature, and centrifuged at 15 000 × g for 30 minutes at 20 °C.  
The protease, in the supernatant, was purified by passing it through an anion exchange (DEAE) column 
previously equilibrated with solubilization buffer.  Upon elution from the column, the protease was 
acidified by adding formic acid to a final concentration of 25 mM.  Precipitation of significant amount of 
contaminating proteins occurred upon acidification.  Following an overnight incubation, the precipitated 
contaminants were removed by centrifugation at 15 000 × g for 30 minutes at 4 °C.  
HIV-1 protease was refolded by dialysis into 10 mM formic acid at 4 °C.  Subsequently, the protease was 
dialyzed into storage buffer containing 10 mM sodium acetate, 1 mM NaCl and 1 mM DTT, pH 5.0.  The 
folded protease was concentrated to a final volume of ~5 mL and stored at -20 °C.  
IN VITRO HIV-1 PROTEASE ACTIVITY 
The catalytic activity of the HIV-1 protease was monitored following the hydrolysis of the chromogenic 
peptide substrate Lys-Ala-Arg-Val-Nle-p-nitro-Phe-Glu-Ala-Nle-NH2.  This substrate mimics the 
conserved KARVL/AEAM cleavage site between the capsid protein and nucleocapsid (CA-p2) in the Gag 
polyprotein precursor.  
For this study the chromogenic substrate was synthesized using the Discovery CEM Liberty microwave 
peptide synthesizer on Rink amide resin.  The substrate was cleaved from the resin and deprotected using 
95 %:5 % (v/v) TFA:TIS for 3 hours.  It was then precipitated using cold ether and purified via reverse 
phase semi-preparative HPLC on a Shimadzu instrument and characterized using the Bruker microTOF-Q 
II instrument. 
173 
To determine the concentration of the inhibitors that resulted in 50 % inhibition (IC50) of HIV-1 protease 
enzyme activity, the protein (100 nM) and chromogenic substrate (50 μM) were added into a 120 µL 
microcuvette containing increasing concentrations of inhibitor in a pH 5.0 buffer (50 mM sodium acetate 
and 0.1 M NaCl).  Protease hydrolytic activity was measured by monitoring the relative decrease in 
absorbance at 300 nm using Fpecord 210 spectrophotometer. 









IC50 (µM) % Yield  
15 C37H43N5O7 670.3228 670.3235 (M+H+) 0.75± 0.035 52.5  
16a C28H34N4O6 523.2554 523.2551 (M+H+) 0.6±0.071 76.2 
16b C20H28N4O4 389.2186 389.2183 (M+H+) 0.75±0.071 78.3 
16c C26H32N6O4S 546.2943 546.2928 (M+Na+) 0.5±0.035 43.2 
17 C37H43N5O7 670.3255 670.3249 (M+H+) 0.5±0.035 46.2 
18a C28H34N4O6 545.2375 545.2371 (M+Na+) 10.0±0.71 65.3 
18b C20H28N4O4 389.2185 389.2183 (M+H+) 10.0±0.71 68.3 
18c C26H32N6O4S 546.2947 546.2948 (M+Na+) 5.0±1.06 38.3 
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Supplementary Table 1. 1H and 13C chemical shift of PCU-VAZ as measured by HSQC, COSY, HMBC, 
ROESY and 1H and 13C spectra. The chemical shift was referenced to 2.50 ppm for COSY and ROESY 
the correlation aided in assignment are marked in black (sequential correlations) and the long-range 
interactions through space, measured by ROESY, are marked in red 
Atom δ1Ha,b δ13Ca,d COSY(δ1Ha,b) HMBC ROESY (δ1Ha,c) 
1x 2.79 43.5 7  7, NHa, NHb, NHbb 
1y 3.11 41.9 2, 7  2, 7, v4’, NHaa, NHaaa, 
NHbb, NHbbb 
2 2.46 39.6 1y, 6 3, 5, 7 1y, 4a 
3x 2.38 43.1 4a, 4s, 10y  4a, 4s, v4’, 10y, NHb, NHbb 
3y 2.45 43.1 4a, 4s  4a, 4s, v4’, NHbb, NHbbb 
4a 1.34 (d. J 
= 10.3 
Hz) 
36.9 3x, 3y, 4s, 5 10x 2, 3x, 3y, 4s, 5, 6 
4s 1.68 (d. J 
= 10.5 
Hz) 
36.9 3x, 3y, 4a, 5  3x, 3y, 4a, 5, 9, 10x, 10y 
5 2.66 45.2 4a, 4s, 9  4a, 4s, 9 
6 2.74 41.7 2, 7  4a, 7 
7 2.34 44.4 1x, 1y, 6, 2 1x, 1y, 6 
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8  79.9    
9 2.17 (d. J 
= 10.8 
Hz) 
51.9 4s, 5, 10x, 10y  4s, 5, 10x, 10y 
10x 2.58 51.4 9  4s, 9, NHaa, NHaaa, NHbb, 
NHbbb 
10y 2.91 50.1 3x, 9  3x, 4s, 9, NHa, NHb, NHbb 
11  72.9    
12  173.5    
1’  171.1    
2’x 4.19 57.3 3’ 1’, 3’, v4’ 3’, v4’, NHbb, NHbbb 
2’y 4.25 57.0 3’ 1’, 3’, v4’ 3’, v4’, NHb, NHbb 
3’ 1.95 30.9 2’x, 2’y, v4’  2’x, 2’y, v4’, NHb, NHbb, 
NHbbb, NHc, NHcc, NHccc  
v4’ 0.78 17.5 3’ 2’, 3’ 1y, 2’x, 2’y, 3’, 3x, 3y, NHa, 
NHaa, NHb, NHbb, NHbbb, 
NHc, NHcc, NHccc 
v4’ 0.82 19.4 3’ 2’, 3’ 1y, 2’x, 2’y, 3’, 3x, 3y, NHa, 
NHaa, NHb, NHbb, NHbbb, 
NHc, NHcc, NHccc 
5’  172.2    
6’x 4.11 50.2 7’  7’, NHc, NHccc  
6’y 4.16 50.1 7’  7’, NHcc, NHd 
7’ 1.20 18.5 6’x, 6’y 5’, 6’ 6’, 11’-15’, NHc, NHcc, 
NHccc, NHd 
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8’  155.6   11’-15’ 
9’ 5.06 65.4  11’-15’ 11’-15’ 
10’  137.0    
11’-15’ 7.30-7.36 127.6-128.3  9’ 7’, 9’ 
NHa 8.04    1x, v4’, 10y 
NHaa 8.06   8 v4’, 10x, 1y 
NHaaa 8.09   8 1y, 10x 
NHb 8.17    1, 2’y, 3’, 3, v4’, 10y 
NHbb 8.24   1’, 11 1x, 1y, 2’x, 2’y, 3’, 3x, 3y, 
v4’, 10x, 10y 
NHbbb 8.32   1’, 11 1y, 2’x, 3’, 3y, v4’, 10x,  
NHc 7.60    3’, v4’, 6’x, 7’ 
NHcc 7.79  2’x, 2’y  3’, v4’, 6’y, 7’ 
NHccc 7.94  2’y  3’, v4’, 6’x, 7’ 
NHd 7.47  6’  6’y, 7’ 
a Solvent (CD3)2SO. 
b 400 MHz for 1H. 
c 600 MHz for 1H. 
d 100 MHz for 13C. 
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Supplementary Table 2: 1H and 13C chemical shift of PCU-VAZ peptoid as measured by HSQC, COSY, 
HMBC, ROESY and 1H and 13C spectra. The chemical shift was referenced to 2.50 ppm for COSY and 
ROESY the correlation aided in assignment are marked in black (sequential correlations) and the long-
range interactions through space, measured by ROESY, are marked in red 
Atom δ1Ha,b δ13Ca,d COSY (δ1Ha,b) HMBC ROESY (δ1Ha,c) 
1 2.89 43.1 2, 7  2, v4’x, 7, NHa, NHb, 
NHbb, NHbbb, NHbbbb 
2 2.49 39.6 1, 6  1, 4a, v4’x, NHbbbb 
3 2.43 43.1 4a, 4s  4a, 4s, v4’x, 10, NHb, 
NHbb, NHbbbb 
4a(d. J = 
10.6 Hz) 
1.35 36.9 3, 4s, 5  2, 3, 4s, 5, 6 
4s 1.68 36.9 3, 4a, 5  3, 4a, 5, 9, 10 
5 2.66 45.1 4a, 4s, 9  4a, 4s, 9 
6 2.74 41.7 2, 7  4a, 7 
7 2.34 44.4 1, 6, 2, 5 1, 6, NHbbb 
8  79.5    
9 2.17 51.9 5, 10  4s, 5, 10, NHbbb 
10 2.79 50.6 9  3, 4s, v4’x, 9, NHa, NHb, 
NHbb, NHbbb, NHbbbb 
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11  72.9    
12  173.4    
1’  169.2    
2’x 3.74 43.8 v4’ 1’, 3’ 3’, v4’x, v4’y, v4’z, NHb, 
NHbb, NHbbbb 
2’y 3.79 44.2 v4’ 1’, 3’ 3’, v4’x, v4’y, v4’z, NHb, 
NHbb, NHbbbb 
2’z 3.82 44.2 v4’ 1’, 3’ 3’, v4’x, v4’y, v4’z, NHb, 
NHbb, NHbbb, NHbbbb 
3’ 4.61 44.5   2’x, 2’y, 2’z , v4’ 
v4’x 0.96 19.5 3’ 3’ 1, 2, 2’x, 2’y, 2’z, 3’, 3, 10, 
NHa, NHb, NHbb, NHbbb, 
NHbbbb 
v4’y 1.05 20.6 3’ 3’ 2’x, 2’y, 2’z, 3’ 
v4’z 1.13 20.6 3’ 3’ 2’x, 2’y, 2’z, 3’ 
5’  168.3    
6’x 4.05 50.5  5’, 8’ 7’x, 7’y 
6’y 4.09 50.2  5’, 8’ 7’x, 7’y 
6’z 4.18 50.2  5’, 8’ 7’x, 7’y 
7’x 2.82 35.8  8’ 6’x, 6’y, 6’z, 11’-15’ 
7’y 2.86 35.1  8’ 6’x, 6’y, 6’z, 11’-15’ 
8’  156.1    
9’x 4.99 66.1  8, 11’-15’ 11’-15’ 
9’y 5.04 65.8  8, 11’-15’ 11’-15’ 
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9’z 5.06 66.1  8, 11’-15’ 11’-15’ 
10’  137.1    
11’-15’ 7.25-7.32 126.8-128.3  9’ 7’, 9’ 
NHa 8.16   8, 12 1, v4’, 10 
NHb 7.95    1, 2’x, 2’y, 2’z, 3, v4’, 10 
NHbb 8.02    1, 2’x, 2’y, 2’z, 3, v4’, 10 
NHbbb 8.23    1, 2’z, 7, 9, v4’, 10 
NHbbbb 8.36   1’, 1, 10, 11 1, 2, 2’x, 2’y, 2’z, 3, v4’, 10 
a Solvent (CD3)2SO. 
b 400 MHz for 1H. 
c 600 MHz for 1H. 
d 100 MHz for 13C. 
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Supplementary Table 3. 1H and 13C chemical shift of PCU-VANH2 as measured by HSQC, COSY, 
HMBC, ROESY and 1H and 13C spectra. The chemical shift was referenced to 2.50 ppm for COSY and 
ROESY the correlation aided in assignment are marked in black (sequential correlations) and the long-
range interactions through space, measured by ROESY, are marked in red 








1x 2.77 43.5 43.5 7, NHa, NHc 
1y 3.10 41.6 41.9 2, 7, NHb, NHd 
2 2.49 39.7 39.6 1y 
3x 2.39 43.5 43.1 4a, 4s, v4’, 10y, NHc, NHd 
3y 2.45 43.2 43.1 4a, 4s, v4’ 




1.70 36.9 36.9 3x, 3y, 4a, 5, 9, 10y 
5 2.67 45.2 45.2 4a, 4s, 6, 9 
6 2.75 41.6 41.7 4a, 5, 7 
7 2.36 44.3 44.4 1x, 1y, 6 
8  79.5 79.9  
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9 2.18 51.9 51.9 4s, 5, 10x, 10y 
10x 2.58 51.3 51.4 9, NHb 
10y 2.92 50.0 50.1 3x, 4s, 9, NHa, NHc 
11  72.9 72.9  
12  173.6 173.5  
1’  170.8 171.1  
2’x 4.23 57.8 57.3 3’, v4’, NHb, NHc 
2’y 4.34 57.7 57.0 3’, v4’, NHbb, NHcc 
3’ 1.95 30.9 30.9 2’x, 2’y, v4’, NHb, NHbb, 
NHc, NHcc  
v4’ 0.85 18.0 17.5 2’x, 2’y, 3’, 3x, 3y, NHb, 
NHbb, NHc, NHcc  
v4’ 0.87 19.4 19.4 2’x, 2’y, 3’, 3x, 3y, NHb, 
NHbb, NHc, NHcc 
5’  169.3 172.2  
6’ 3.94 50.0 50.2 7’x, 7’y, NHc, NHcc, NHd 
7’x 1.33 17.6 18.5 6’, NHc, NHd 
7’y 1.36 18.0  6’, NHcc 
8’   155.6  
9’   65.4  
10’   137.0  
11’-15’   127.6-128.3  
NHa 8.04   1x, 10y 
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NHaa     
NHaaa     
NHb 8.41   1y, 2’x, 3’ , v4’, 10x 
NHbb 8.44   1x, 1y, 2’y, 3’, v4’, 10x, 
10y 
NHbbb     
NHc 8.36   1x, 2’x, 3’, 3x, v4’, 6’, 7’x, 
10y,  
NHcc 8.47   2’y, 3’, v4’, 6’, 7’y 
NHccc     
NHd 8.07   1y, 3x, 6’, 7’x 
a Solvent (CD3)2SO. 
b 400 MHz for 1H. 
c 600 MHz for 1H. 
d 100 MHz for 13C. 
183 
Supplementary Table 4. 1H chemical shifts of 15, 16c, 17, 18b and 18c.  The chemical shift was 
referenced to 2.50 ppm 










1 3.03 2.80 2.91 2.91 2.69 
2 2.55 2.55 2.50 2.49 2.50 
3 2.40 2.45 2.41 2.43 2.61 
4a 1.34  1.47 (d. J = 
10.5 Hz) 
1.36 (d. J = 
10.3 Hz) 
1.36 (d. J = 
10.3 Hz) 
1.40 (d. J = 10.3 
Hz) 
4s 1.70 1.77 (d. J = 
10.6 Hz) 
1.70 (d. J = 
10.3 Hz) 
1.69 (d. J = 
10.3 Hz) 
1.74 (d. J = 10.3 
Hz) 
5 2.69 2.66 2.67 2.67 2.70 
6 2.78 2.75 2.75 2.75 2.62 
7 2.37 2.33 2.34 2.35 2.43 
8 -  - - - 
9 2.21 2.18 2.18 2.18 2.28 
10 2.89 2.89 2.77 2.82 2.40 
11 - - - - - 
12, 1’, 5’, 8’ - - - - - 
P1’ - - - - - 
P2’ 4.64 - 4.01-4.47 - - 
P3’a 3.11 - 3.89 - - 
P3’s 3.14 - 3.91 - - 
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P4’-P9’ 7.16-7.45 - 7.21-7.41 - - 
2’ 4.47-4.90 4.12-4.41 4.01-4.47 3.69-3.82 3.00-3.81 
3’ 2.07 1.98 4.61 4.60 3.54 
v4’ 0.85 (d. J = 
6.8 Hz) 
1.14 0.99 0.96 0.99 
v4’ 0.90 (d. J = 
6.8 Hz) 
1.16 1.01 1.08 0.99 
6’x 4.11 4.12-4.41 4.01-4.47 3.44-3.59 3.00-3.81 
6’y 4.16     
7’ 1.20 1.20 2.76-2.86 2.35 2.54 
9’ 5.08 3.90 5.04 - 2.70 
10’ - - - - - 
11’-15’ 7.16-7.45 7.21-7.23  
8.60-8.63 
7.21-7.49 - 7.40-7.97 
NHa- NHd 8.01-8.89     
NHa- NHb  8.04-8.63 8.14-8.71 8.16-8.47 8.61-8.67 
a Solvent (CD3)2SO. 












































Supplementary Table 5. EASY ROESY correlations observed in the spectra of PCU-EAIS recorded in 
DMSO-d6 and the D2O as the solvent.  The chemical shift was referenced to 2.50 ppm 
Atom 1H PCU-EAIS ROESY(δ1Hc)(PCU-EAIS) 
(DMSO-d6) 
ROESY(δ1Hc)(PCU-EAIS (D2O) 
1x 2.89 2, 3,6, 7, NHc 2, 3, 7,NHa, NHc, NHcc 
1y 2.97 2, 3, 6, 7, 10, NHa, NHg 2, 3, 7, NHa 
2 2.45 1a, 1s, NHa, NHb 1a, 1s 
3 2.41 1a, 1s, 3’, 4a, 4s, 6, 10, 10’, NHa, 
NHb, NHc, NHg 
1a, 1s, 4a, 4s, 10, NHa, NHc, NHcc 
4a 1.35 (d. J = 10.6 
Hz) 
3, 4s, 5, 6 3, 4s, 5, 6 
4s 1.68 3, 4a, 5, 6, 9, 10 3, 4a, 5, 6, 9, 10 
5 2.66 4a, 4s, 6, 9 4a, 4s, 6 
6 2.75 1a, 1s, 2, 3, 4a, 4s, 5, 7, 9 4a, 4s, 5, 7, 9 
7 2.34 1a, 1s, 6 1a, 1s, 6 
8    
9 2.17 4s, 5, 6, 10 4s, 6, 10 
10 2.77 1s, 3, 4s, 9, 10, NHa, NHb, NHc 3, 4s, 9, NHa, NHc 
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11    
12    
g1’    
g2’ 4.22 g3a’, g3s, g4, NHa g3a’, g3s, g4, NHa, NHg 
g3a’ 1.72 g2’, g3s, g4, NHa, NHg g2’, g3s, g4, NHg, NHbb, 
g3s’ 1.89 g2’, g3a, g4, NHa, NHg g2’, g3a, g4, NHg 
g4’ 2.21 3’, g2’, g3a’, g3s’, 10’, NHa g2’, g3a’, g3s’, NHg 
g5’    
1’    
2’ 4.27 3’, NHb, NHc, NHcc 3’, NHbb, NHc, NHcc 
3’ 1.19 2’, 3, g4’, NHb, NHc, NHcc, 
NHg 
2’, NHbb, NHc, NHcc 
4’    
5’ 4.25 9’, 10’, 11a, 11s, NHd 9’, 11a’, 11s’, 12’ 
6’    
7’ 3.93 8a’, 8s’, 10’, 12’, NHd 8a’, 8s’, NHd 
8a’ 3.62 7’, 8s’, NHd 7’, 8s’, NHd 
8s’ 3.72 7’,8a’, NHd 7’,8a’, NHd 
9’ 1.73 5’, 10’, 11a’, 11s’, 12’, NHc, 
NHcc NHd 
5’, 10’, 11a’, 11s’, 12’, NHc, NHcc, 
NHd 
10’ 0.86 3, g4’, 5’, 7, 9’, 11a’, NHc, NHcc 9’, 11a’, NHcc 
11a’ 1.05 5’, 9’, 10, 11s’, 12’, NHd 5’, 9’, 10, 11s’, NHd 
11s’ 1.43 5’, 7, 9’, 11a’, 12’ NHd, NHc 5’, 9’, 11a’, 12’  
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12’ 0.82 5’, 9’, 11a’, 11s’, NHcc, NHd 5’, 9’, 11a’, 11s’ 
NHa 8.08 1a, 1s, 2,  3, 10, g2’, g3a’, g3s, 
g4’ 
1a, 1s, 2,  3, 10, g2’ 
NHaa    
NHg 8.10 1s, 3, 3’, g3a’, g3s g2’, g3a’, g3s, g4’ 
NHb 7.80 2’, 2, 3, 3’, g2’, g3a’, g3s, g4’  
NHbb 7.94 2’, 2, 3, 3’, g2’, g3a’, g3s, g4’ 2’, 3’, g3a’ 
NHc 8.16 1a, 2’, 3’, 3, 6, 9’, 10’, 11s’ 1a, 2’, 3’, 3, 9’, 10’ 
NHcc 8.20 2’, 3’, 9’, 10’, 12’ 1a, 2’, 3, 3’, 3, 9’, 10’ 
NHd 8.40 2’/5’, 7’, 8a’, 8s’, 9’, 11a’, 11s’, 
12’  
7’, 8a’, 8s’, 9’, 11a’ 
c 600 MHz for 1H. 
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MATERIALS AND METHODS 
Analytical analysis was performed on an Agilent 1100 HPLC with a flowrate of 1 mL/min on a Waters 
Xbridge C18 (150 mm x 4.6 mm x 5 microns) coupled to a UV detector (215 nm) and an Agilent VL ion 
trap mass spectrophotometer in the positive mode.  Semi-preparative HPLC was carried out on a 
Shimadzu semi-preparative instrument with a flowrate of 17 mL/min on a Ace C18 (150 mm x 21.2 mm x 
5 microns) with a UV/VIS detector (215 nm) and an automated fraction collector.  A two-buffer system 
was employed, utilizing formic acid as the ion-pairing agent.  Buffer A consisted of 0.1 % formic 
acid/H2O (v/v) and buffer B consisted of 0.1 % formic acid/acetonitrile (v/v).  High resolution mass 
spectroscopic analysis was performed on a Bruker MicroTOF QII mass spectrometer in positive mode 
with an internal calibration.  Peptides were synthesized on an automated CEM Liberty microwave peptide 
synthesizer (see Table 1 for conditions, not same as supplier).  All 1H, 13C, HSQC, COSY and HMBC 
NMR data were recorded on a Bruker AVANCE III 400 MHz spectrometer.  The ROESY data was 
recorded on a Bruker AVANCE III 600 MHz spectrometer. 








Single coupling    
30 minute coupling 0 25 900 
35 73 900 
Deprotection 40 73 180 
 
NMR 
Samples were dissolved in 450 µl of deuterated DMSO-d6 and measured at 25 °C.  All 1H,13C, COSY, 
HMBC and HSQC NMR spectra, required for assignment were recorded on a Bruker AVANCE III 400 
MHz spectrometer, BBO probe with z-gradient with standard parameters.  The EASY-ROESY(28) 
measurements required for structural analysis were recorded on a Bruker AVANCE III 600 MHz 
spectrometer using a BBO probe with z-gradient at a transmitter frequency of 600.1 MHz (spectral width, 
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10.0143 Hz; acquisition time, 0.1704436 s; 90° pulse width, 11.02 µs; scans, 8; relaxation delay, 2.0 s, 
mixing time 0.12s, 2048 points in F2 dimensions).  Processing and assignments were carried out using the 
Topspin 2.3 software from Bruker Karlsruhe.  In order to determine if the same 3D structural 
conformation observed for the inhibitors in DMSO-d6 are also valid for the HIV-PR activity studies, the 
NMR spectra for PCU-EAIS were recorded in a buffered D2O solution (see chapter 1). 
SYNTHESIS OF PCU DIACID 1 
A solution of the diene 5 (31) (15.0 g, 58.0 mmol) in dry methanol (100 mL) was purged with nitrogen 
for 6 h while cooling in a dry ice–isopropanol bath (−78 °C).  Ozone was bubbled into the reaction 
mixture until a blue–purple color persisted indicating the presence of excess ozone in the system and 
hence the completion of the reaction. The excess ozone gas was purge with nitrogen and the solvent 
(MeOH) removed in vacuo.  Formic acid (100 mL) was added to the ozonide and the mixture was cooled 
in an ice bath with stirring.  Hydrogen peroxide (150 mL, 30 %) was then added drop-wise to the stirring 
cooled reaction mixture.  The reaction was left to attain ambient temperature for 1 h and refluxed gently 
for 12 h, the resulting mixture was concentrated in vacuo to yield the diol diacid 1 (15.6 g, 92 % yield) as 
a white solid. mp: 153–157°C, 1H NMR [(CD3)2SO, 400 MHz]: δH 1.03 (AB, JAB = 10.4 Hz, 1H), 1.51 
(AB, JAB = 10.4 Hz, 1H), 2.23 (s, 3H), 2.26 (s, 2H), 2.37 (s, 2H), 2.48–2.50 (m, 3H), 2.57–2.59 (m, 2H). 
13C NMR [(CD3)2SO, 100 MHz]: δC 33.6 (CH2), 38.9 (CH), 42.3 (CH), 43.9 (CH), 44.2 (CH2), 50.0 (CH), 
76.6 (C), 172.5 (C). 
SYNTHESIS OF PCU DIAMIDE 6 
The PCU diol diacid 1 (5.0 g, 17.0 mmol),NH4Cl (2.4 g, 44.2 mmol), HOBt (5.7 g, 37.4 mmol), EDC (7.1 
g, 37.4 mmol), and NMM (4.9 mL, 44.2 mmol) was dissolved in dimethylformamide (DMF) (30 mL) and 
stirred at room temperature for 36 h. The reaction mixture was concentrated in vacuo.  The crude product 
was dissolved in ethylacetate and washed successively with 1 M HCl (50 mL), 10 % NaHCO3 (50 mL), 
and brine (50 mL).  The organic solution was dried over Na2SO4 and concentrated in vacuo.  The crude 
product was purified via column chromatography on silica gel using CHCl3:MeOH:25 % NH4OH (88 : 10 
: 2, Rf = 0.3,72 %yield) to obtain a white solid. mp; 207–209 °C, IR vmax: 3172, 2961, 1656, 1408, 1287, 
728, 634, and 436 cm−1. Mass spectrometry (time of flight) [MS (TOF)] calculated for C15H21N2O4 (M + 
H+) 293.1496, found 293.1484.  1H NMR [(CD3)2SO, 400 MHz]: δH 1.03 (AB, JAB = 10.5 Hz, 1H), 1.48 
(AB, JAB = 10.5 Hz, 1H), 2.09 (AB, JAB = 14.4 Hz, 1H), 2.19 (AB, JAB = 14.4.5 Hz, 1H) 2.19 (s, 2H), 2.40 
(s, 2H), 2.41 (s, 2H), 2.48 (s, 2H). 13C NMR [(CD3)2SO, 100 MHz]: δC 33.5 (CH2), 38.9 (CH), 42.5 (CH), 
43.8 (CH), 43.9 (CH2), 49.3 (CH), 76.6 (C), 173.8 (C). 
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SYNTHESIS OF PCU DIAMINE 2 
Sodium hypochlorite (90 mL) and 4 M NaOH (48 mL) were added to 7 g of the diamide.  The reaction 
was stirred for an hour at 80°C and then left to stir at room temperature for 24 hours.  HCl (1M) was then 
added to adjust the pH to 7 before the reaction was concentrated in vacou.  The crude product was then 
purified using column chromatography CHCl3:MeOH:25 % NH4OH (88 : 10 : 2) (2.9 g, 53 % yield).  The 
diamine (2.5g, 10.6 mmol) was dissolved in 15 mL of water and 3 equivalence (eq) of NaHCO3 was 
added while stirring.  The resulting solution was cooled to 5°C and t-BOC anhydride (2.4 eq) was added 
slowly as a solution in cooled THF (15 mL).  The mixture was stirred at 0°C for 1 hour and allowed to 
warm to room temperature overnight.  Water was then added and extracted twice with DCM.  The organic 
layer was back extracted with saturated NaHCO3.  The aqueous layer was acidified to pH1 and then 
extracted with DCM twice.  All organic layers were combined, dried over MgSO4 and concentrated under 
reduced pressure.  The crude t-BOC-PCU diamine product was purified with column chromatography and 
stored below 4°C. (4.1 g, 75 % yield) 1H NMR [(CD3)2SO, 400 MHz]: δH 1.02 (AB, JAB = 10.5 Hz, 1H), 
1.44 (AB, JAB = 10.5 Hz, 1H), 1.38 (s, 9H), 2.09 (s, 2H), 2.34 (s, 2H), 2.42-2.45 (m, 4H), 2.86 (AB, JAB = 
6.18 Hz, 1H), 2.90 (AB, JAB = 6.18 Hz, 1H), 2.94 (AB, JAB = 6.18 Hz, 1H), 2.98 (AB, JAB = 6.18 Hz, 1H) 
6.28 (s, 1H), 7.02 (s, 1H). 13C NMR [(CD3)2SO, 100 MHz]: δC 28.2 (CH3), 33.7 (CH2), 39.2 (CH), 40.4 
(CH), 43.0 (CH), 43.0 (CH), 47.9 (CH), 48.1 (CH2), 77.1 (C), 77.7 (C), 156.2 (C) 
The removal of t-BOC from the diamine was achieved by stirring the compound in methanol (30 mL) and 
conc HCl (12M, 5 mL) overnight.  
SYNTHESIS OF THE CAGE AMINE AMIDE 3 
Sodium hypochlorite (45 mL) and 4M NaOH (24 mL) were added to 7 g of the diamide.  The reaction 
was stirred for an hour at 80°C and then left to stir at room temperature for 24 hours.  HCl (1 M) was then 
added to adjust the PH to 7 before the reaction was concentrated in vacou.  The crude product was then 
purified using column chromatography CHCl3:MeOH:25 % NH4OH (88 : 10 : 2) (1.6 g, 28 % yield).  The 
amine amide (2.5 g, 10.6 mmol) was dissolved in 15 mL of water and 1.5 equivalence (eq) of NaHCO3 
was added while stirring.  The resulting solution was cooled to 5°C and t-BOC anhydride (1.2 eq) was 
added slowly as a solution in cooled THF (15 mL).  The mixture was stirred at 0°C for 1 hour and 
allowed to warm to room temperature overnight.  Water was then added and extracted four times with 
DCM, dried over MgSO4 and concentrated under reduced pressure.  The crude t-BOC-PCU amine amide 
product was purified with column chromatography and stored below 4°C.  (1.9 g, 86 % yield) 1H NMR 
[(CD3)2SO, 400 MHz]: δH 1.02 (AB, JAB = 10.5 Hz, 1H), 1.47 (AB, JAB = 10.5 Hz, 1H), 1.37 (s, 9H), 2.09 
(s, 2H), 2.33 (s, 2H), 2.42-2.45 (m, 4H), 2.92 (m, 2H), 3.12 (m, 1H), 3.16 (m, 1H), 6.20 (s, 1H), 8.32 (s, 
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1H). 13C NMR [(CD3)2SO, 100 MHz]: δC 28.0 (CH3), 33.7 (CH2), 36.4 (CH2), 40.4 (CH), 43.1 (CH), 43.5 
(CH), 45.3 (CH2), 48.0 (CH), 48.1 (CH2), 76.7 (C), 76.9 (C), 77.6 (C), 78.4 (C), 153.3 (C), 156.2 (C), 
172.1 (C), 174.1 (C), 
The removal of t-BOC from the amine was achieved by stirring the compound in methanol (30 mL) and 
conc HCl (12M, 5 mL) overnight 
GENERAL PROCEDURE FOR LOADING OF FIRST AMINO ACID TO THE 2-
CHLOROTRITYL CHLORIDE RESIN 
Activated 2-chlorotrityl chloride resin (1 g, 1.33 mmol) was swelled in dry DCM (10 mL) for 10 
minutes in a sintered glass reaction vessel.  Fmoc-amino acid-OH (3.99 mmol) was dissolved in 
DCM (10 mL) and DIPEA (6.65 mmol) and then added to the reaction vessel.  The mixture was 
bubbled for 2 hours using nitrogen.  The solvent was removed by filtration and the resin was 
washed with DCM (3 x 10 mL).  A few resin beads (~5 mg) were removed from the reaction 
vessel and left to dry in the vacuum oven for an hour.  A solution of 20 % piperidine in DMF 
was added to the dried resin beads (1 mg) and left to stand for 20 min.  General washing 
procedure for manual SPPS: after each step, the resin was washed with DCM (3 x 10 mL), DMF 
(3 x 10 mL) and DCM (3 x 10 mL). 
GENERAL PROCEDURE FOR THE SYNTHESIS OF PEPTIDES USING 
MICROWAVE POWER 
Stock solutions of all amino acids (0.2 mM), DIPEA (1 mM) and HBTU (2 mM) were prepared in DMF 
and peptides were synthesized on a 0.5 mmol scale.  The modified coupling method described in Table 1 
above was used for coupling the subsequent amino acids to the 2-chlorotrityl chloride resin (1 g) 
preloaded with the first amino acid. 
Final cleavage:  The resin bound peptide was removed from the peptide synthesizer and transferred to a 
manual peptide synthesis reaction vessel for the final cleavage.  It was washed with DCM (3 x 10 mL) 
and a cleavage mixture of 5:95 % (v/v) TFA:DCM was added to the resin while nitrogen was bubbled 
through the solution for 10 minutes.  The resin was washed three times with the cleavage mixture and the 
cleaved peptide was removed by filtration and collected in a flask containing water (100 mL).  The filtrate 
was extracted several times with DCM so as to remove the peptide from the water layer.  DCM was 
removed under reduced vacuum with at 40°C and the peptide remained as a white powder. 
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GENERAL PROCEDURE FOR COUPLING OF PEPTIDES TO THE PCU-DIOL 
The cleaved peptide (2.6 eq.) was dissolved in DMF (3 mL) followed by addition of PCU-diol  
(1 eq), EDC (2.4 eq), HOBT (2.4 eq), in DMF (7 mL) and NMM (2.6 eq).  The mixture was 
stirred at room temperature for 24 hours and thereafter evaporated to dryness under reduced 
pressure using a Teflon pump at 40°C.  The crude product was diluted with EtOAc (200 mL) and 
the resulting solution was washed with 1M HCl, sat. aq. NaHCO3 and sat. aq. NaCl, dried over 
MgSO4, filtered and concentrated in vacuo. The product was then purified by reverse phase 
semi-preparative HPLC. 
OVER-EXPRESSION, EXTRACTION AND PURIFICATION OF THE C-SA 
PROTEASE 
Plasmid encoding HIV-1 subtype C protease (containing the mutation Q7K designed to reduce the 
hypersensitive autolytic site) is expressed as inclusion bodies (Ido et al., 1991) in Escherichia coli BL21 
(DE3) pLysS cells. Briefly, Escherichia coli cells harboring the plasmid DNA were grown at 37 °C in LB 
medium supplemented with 100 μg/mL of ampicillin and 35 μg/mL of chloramphenicol. The overnight 
culture was diluted 100-fold into fresh 2 × YT medium supplemented with ampicillin (100 μg/mL) and 
chloramphenicol (35 μg/mL) and grown at 37 °C. When the optical density (OD600) of the culture reached 
0.4 to 0.5, over-expression of the HIV-1 C-SA protease was induced by adding IPTG. IPTG was added to 
final concentrations of 0.4 mM. Over-expression of the protease was allowed to continue for four hours.  
The cells were pelleted after growth and resuspended in ice-cold extraction buffer [10 mM Tris, 1 mM 
EDTA, and 1 mM PMSF (added only fresh before use), pH 8]  and disrupted using an ultra-sonicator. 
Following the addition of MgCl2 and DNase I to final concentrations of 10 mM and 10 U/μL, 
respectively, the culture medium was stirred on ice until the viscosity of the mixture decreased. The cells 
were then ruptured by sonication and centrifuged at 15 000 × g for 30 minutes at 4 °C. The pellet was 
resuspended in ice-cold extraction buffer containing 1 % (v/v) of Triton X-100. Cell debris and protease-
containing inclusion bodies were pelleted by centrifugation at 15 000 × g for 30 minutes at 4 °C. The 
pellet was then resuspended in a freshly prepared solubilization buffer containing 10 mM Tris, 2 mM 
DTT, 8 M urea, pH 8.0, at room temperature, and centrifuged at 15 000 × g for 30 minutes at 20 °C.  
The protease, in the supernatant, was purified by passing through an anion exchange (DEAE) column 
previously equilibrated with solubilization buffer. Upon elution from the column, the protease was 
acidified by adding formic acid to a final concentration of 25 mM. Precipitation of significant amount of 
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contaminating proteins occurred upon acidification. Following an overnight incubation, the precipitated 
contaminants were removed by centrifugation at 15 000 × g for 30 minutes at 4 °C.  
HIV-1 protease was refolded by dialysis into 10 mM formic acid at 4 °C. Subsequently, the protease was 
dialyzed into storage buffer containing 10 mM sodium acetate, 1 mM NaCl and 1 mM DTT, pH 5.0. The 
folded protease was concentrated to a final volume of ~5 mL and stored at -20 °C.  
IN VITRO HIV-1 PROTEASE ACTIVITY 
The catalytic activity of the HIV-1 protease was monitored following the hydrolysis of the chromogenic 
peptide substrate Lys-Ala-Arg-Val-Nle-p-nitro-Phe-Glu-Ala-Nle-NH2.  This substrate mimics the 
conserved KARVL/AEAM cleavage site between the capsid protein and nucleocapsid (CA-p2) in the Gag 
polyprotein precursor.  
For this study the chromogenic substrate was synthesized using the Discovery CEM Liberty microwave 
peptide synthesizer on the Rink amide resin.  The substrate was cleaved from the resin and deprotected 
using 95 %:5 % (v/v) TFA:TIS for 3 hours.  It was then precipitated using cold ether and purified via 
reverse phase semi-preparative HPLC on a Shimadzu instrument and characterized using the Bruker 
microTOF-Q II instrument (Table 2).   
To determine the concentration of the inhibitors that resulted in 50 % inhibition (IC50) of HIV-1 protease 
enzyme activity, the protein (100 nM) and chromogenic substrate (50 μM) were added into a 120µL 
microcuvette containing increasing concentrations of inhibitor in a pH 5.0 buffer (50 mM sodium acetate 
and 0.1 M NaCl).  Protease hydrolytic activity was measured by monitoring the relative decrease in 
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Supplementary Table 2. Percentage yields for the coupling of peptides to the cage diols and the size as 
confirmed by High-resolution mass spectroscopy, 




1a -Phe-Ile-Ala-Ala(OMe) 38 1127.6023 
C59H83N8O14 
1127.5986 (M+H+) 
1b -Phe-Val-Ala-Ala(OMe) 59 1099.5710 
C57H79N8O14 
1099.5705 (M+H+) 
1c -Val-Ala-Ala(OMe) 48 805.4342 
C39H61N6O12 
805.4337 (M+H+) 






C59H75N12O10S2        
1175.5160 (M+H+) 


















































Supplementary Table 3: 1H and 13C chemical shift of PCU-VAA as measured by HSQC, COSY, 
HMBC, ROESY and 1H and 13C spectra. The chemical shift was referenced to 2.50 ppm for COSY and 
ROESY the correlation aided in assignment are marked in black (sequential correlations) and the long-
range interactions through space, measured by ROESY, are marked in red. 
Atom δ1Ha,b δ13Ca,d COSY (δ1Ha,b) HMBC ROESY (δ1Ha,c) 
1/7 2.43 42.4    
2/6 2.51 42.4    
3/5 2.40 43.8 4a, 4s, 9/10  4a, 4s, 9/10 
4a 1.04 33.6 3/5, 4s 9/10 4s, 3/5 
4s 1.45 33.6 3/5, 4a  4a, 3/5, 9/10 
8/11x - 76.9 -   
8/11y - 70.0 -   
9/10 2.17 49.9 3/5  3/5, 4s, 6’ 
1’a 2.24 44.4  1/7, 2’, 8/11 3’x, 3’y 
1’s 2.30 43.8   3’x, 3’y 
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2’ - 171.5 -   
3’x(NH) 7.85 - 4’ 2’ 1a’, 1s’, 4’, 5’, 6’ 
3’y(NH) 7.91 - 4’ 2’ 1a’, 1s’, 4’, 5’, 6’ 
4’ 4.24 57.3 3’x, 3’y, 5’ 2’, 5’, 6’, 7’, 
8’ 
3’x, 3’y, 5’, 6’, 7’, 9’ 
5’ 2.00 30.4 4’, 6’,7’ 4’, 6’, 7’ 3’x, 3’y, 4’, 6’, 7’, 9’ 
6’ 0.84 17.8 5’ 4’, 5’, 7’ 3’x, 3’y, 4’, 5’, 9’, 9/10 
7’ 0.89 19.2 5’ 4’, 5’, 6’ 4’, 5’ 
8’ - 170.4 -   
9’(NH) 8.06 - 10’ 8’, 10’, 11’ 4’, 5’, 6’,11’ (1’, 2/6) 
10’ 4.25 47.9 9’, 11’ 11’ 11’ 
11’ 1.20 17.8 10’ 10’, 12’ 9’, 10’ 
12’ - 172.1 -   
13’x(NH) 8.17 - 14’ 12’, 14’, 15’ 14’,15’ 
13’y(NH) 8.41 - 14’ 12’, 14’, 15’ 14’,15’ 
14’ 4.24 47.6 13’x , 13’y, 15’  13’x, 13’y 
15’ 1.27 16.9 14’ 14’, 16’ 13’x, 13’y, 14’ 
16’ - 172.9 -   
17’ 3.61 51.8 - 16’  
a Solvent (CD3)2SO. 
b 400 MHz for 1H. 
c 600 MHz for 1H. 
d 100 MHz for 13C. 
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Supplementary Table 4. 1H and 13C chemical shift of PCU-PVAA as measured by HSQC, COSY, 
HMBC, ROESY and 1H and 13C spectra. The chemical shift was referenced to 2.50 ppm for COSY and 
ROESY the correlation aided in assignment are marked in black (sequential correlations) and the long-
range interactions through space, measured by ROESY, are marked in red. 
Atom δ1Ha,b δ13Ca,d COSY (δ1Ha,b) HMBC ROESY (δ1Ha,c) 
1/7 2.20 42.3 2/6  1’a, 2/6, p4-p8 
2/6 2.37 38.8 1/7, 3/5  1/7, 4a 
3/5 2.20 43.7 2/6, 4a, 4s, 9/10x, 
9/10y 
 4a, 4s, 9/10x, 9/10y 
4a 0.94 33.4 3/5  4s, 9/10x, 9/10y, 3/5, 2/6 
4s 1.25 33.4 3/5  4a, 3/5, (p4-p8) 
8/11x  76.3    
8/11y  77.0    
9/10x 1.53 48.8 3/5, 9/10y  9/10y, 3/5, 4a, p4-p8, 
NHpx 
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9/10y 1.66 48.8 3/5, 9/10x  9/10x, 3/5, 4a, NHpy, p4-
p8 
1’a 1.96 44.7 1’s 1/7, 2’, 
8/11, 9/10 
1/7, 1’s, p4-p8, NHpx 
1’s 2.15 44.7 1’a  1’a, p4-p8, NHpx, NHpy 
2’  170.8    
NHpx 7.97  p1x, p1y p1x, p1y, 2’ 1’s, 1a, p1x, p2’a, 9/10x 
NHpy 8.36  p1x, p1y p1x, p1y, 2’ 1’s, p1x, p2’a, 9/10y 
p1x 4.60 53.9 p2a, p2s, NHpx, 
NHpy 
p2a, p2s, p3, 
p9 
p2a, p2s, 3’x, NHpx, 
NHpy, p4-p8 
p1y 4.76 53.5 p2a, p2s, NHpx, 
NHpy 
p2a, p2s, p3, 
p9 
p2a, p2s, 3’y, p4-p8 
p2a 2.78 37.4 p1x, p1y, p2s p1x, p1y, 
p3, p9 
p1x, p1y, 3’x, 3’y, NHpx, 
NHpy, p4-p8 
P2s 3.05 37.4 p1x, p1y, p2a p1x, p1y, 
p3, p9 
p1x, p1y, 3’x, 3’y, NHpx, 
NHpy, p4-p8 
p3  138.3    
p4-p8 7.06-7.32 126.2-129.2 p4-p8 p2a, p2s 1’a, 1’s, 1/7, p1x, p1y, p2a, 
p2s, 4s, 6’, 7’, 9/10x, 9/10y 
3’x(NH) 7.91  4’ 4’, p9 p1x, p2a, p2s, 4’, 5’, 6’, 7’ 
3’y(NH) 8.04  4’ 4’, p9 p1y, p2a, p2s, 4’, 5’, 6’, 7’ 
4’ 4.18 57.5 3’x, 3’x 5’, 8’ 5’, 6’, 7’, 3’x, 3’y, 9’y 
5’ 1.97 30.6 6’, 7’ 4’, 6’, 7’, 8’ 4’, 6’, 7’, 3’x, 3’y 
6’ 0.81 18.1 5’ 4’, 5’, 7’ 4’, 5’, 10’, 14’, p4-p8, 3’x, 
3’y, 13’x, 13’y, 9’x 
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7’ 0.86 19.1 5’ 4’, 5’, 6’ 4’, 5’, 10’, 14’, p4-p8, 3’x, 
3’y, 13’x, 13’y, 9’x 
8’  170.3    
9’x(NH) 7.98  10’ 10’, 11’, 12’ 4’, 6’, 7’, 10’, 11’ 
9’y(NH) 8.03  10’ 10’, 11’, 12’ 4’, 10’, 11’ 
10’ 4.23 47.8 9’, 11’, 9’x, 9’y 11’, 12’ 6’, 7’, 11’, 9’x, 9’y, 13’x, 
13’y 
11’ 1.23 18.1 10’ 10’, 12’ 9’x, 9’y, 10’ 
12’  172.0    
13’x(NH) 8.20  14’ 14’, 15’ 6’, 7’, 10’, 15’ 
13’y(NH) 8.23  14’ 14’, 15’ 6’, 7’, 10’, 15’ 
14’ 4.25 47.5 13’x, 13’x, 15’ 15’, 16’ 6’, 7’, 15’, 17’ 
15’ 1.26 16.9 14’ 14’, 16’ 13’x, 13’y, 14’ 
16’  172.9    
17’ 3.61 51.8  16’ 14’ 
a Solvent (CD3)2SO. 
b 400 MHz for 1H. 
c 600 MHz for 1H. 
d 100 MHz for 13C. 
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Supplementary Table 5: 1H and 13C chemical shift of PCU-PVAZ as measured by HSQC, COSY, 
HMBC, ROESY and 1H and 13C spectra. The chemical shift was referenced to 2.50 ppm for COSY and 
ROESY the correlation aided in assignment are marked in black (sequential correlations) and the long-
range interactions through space, measured by ROESY, are marked in red. 
Atom δ1Ha,b δ13Ca,d COSY (δ1Ha,b) HMBC ROESY (δ1Ha,c) 
1 2.40 42.3 2, 7   
2 2.46 36.5 1, 3  4a 
3 2.40 39.0 2, 4a, 4s, 10  4a, 4s, 10 
4a 1.05 43.1 3  2, 3, 4s, 5, 6 
4s 1.45 43.8 3  3, 4a, 5, 6, 10 
5 2.33 43.2 4a, 4s, 6, 9  4a, 4s, 5’s, 6, 9 
6 2.45 33.4 5, 7  4a, 4s, 5 
7 2.24 33.4 1, 6   
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8/11x  76.5    
8/11y  77.1    
9 1.92 47.7 5, 10  5, 10 
10 2.13 49.2 3, 9  3, 4s, 9 
A1’a 3.26 45.5   4’, 5’s 
A1’s 3.41 45.5  A2’ 4’, 5’s, 17’ 
A2’  169.2    
1’ 3.36 41.9   15’, 17’, 21’ 
2’ (NH) 8.31 8.31  3’, 4’ 4’, 5’a, 5’s, 14’, 15’, 17’, 
21’ 
3’  170.3    
4’ 4.91 49.8 5’a, 5’s, 12’x 5’, 6’, 13’ 5’a, 5;s, A1’a, A1’s, 2’, 7’-
11’, 12’, 20’ 
5’a 2.83 37.5 4’ 3’, 4’, 6’, 7’-
11’ 
2’, 4’, 7’-11’, 14’ 
5’s 2.93 37.5 4’ 3’, 4’, 6’, 7’-
11’ 
A1’a, A1’s, 2’, 4’, 5, 7’-11’, 
12’, 14’, 20’ 
6’  137.3    
7’-11’ 7.19-7.25 126.4-129.4  6’ 4’, 5’a, 5;s, 16’, 21’ 
12’x(NH) 8.21  4’ 4’, 13’ 4’, 5’s, 15’, 17’, 20’, 21’ 
12’y(NH)      
13’  170.4    
14’ 4.19 57.2 15’, 18’ 13’, 15’, 16’ 2’, 5’a, 5;s, 15’, 16’, 18’x, 
18’y 
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15’ 1.91 30.9 14’, 16’, 17’ 13’, 15’, 16’ 2’, 12’, 14’, 15’, 16’, 17’, 
18’x, 18’y 
16’ 0.77 17.9 15’ 14’, 15’, 17’ 14’, 7’-14’, 15’, 18’x, 18’y 
17’ 0.79 19.2 15’ 14’, 15’, 16’ 1’, 2’, 12’, 15’, 18’x, 18’y, 
20’, 22’ 
18’x(NH) 7.64  14’ 14’, 19’ 14’, 15’, 16’, 17’, 20’, 21’ 
18’y(NH) 7.71    14’, 15’, 16’, 17’, 20’, 21’ 
19’  172.3    
20’ 4.11 50.1 21’, 22’ 19’, 21’, 23’ 5’a, 5’s, 12’, 17’, 18’x, 
18’y, 21’, 22’ 
21’ 1.19 18.1 20’ 19’, 20’  1’, 2’, 7-11’, 12’, 18’x, 
18’y, 20’, 22’ 
22’(NH) 7.94  20’ 20’, 21’, 23’ 17’, 20’, 21’ 
23’  155.6    
24’ 5.16 65.6  25’ 26’-30’ 
25’  137.0    
26’-30’ 7.30-7.36 126.4-19.4  25’ 24’ 
a Solvent (CD3)2SO. 
b 400 MHz for 1H. 
c 600 MHz for 1H. 
d 100 MHz for 13C. 
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HMBC spectrum of PCU-PVAA 
279 
 




































































































































































COSY spectrum of PCU-OPVAZ, 3a 
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MATERIALS AND METHODS 
Analytical analysis was performed on an Agilent 1100 HPLC with a flow rate of 1 mL/min on a Waters 
Xbridge C18 (150 mm x 4.6 mm x 5 microns) coupled to a UV detector (215 nm) and an Agilent VL ion 
trap mass spectrophotometer in the positive mode.  Semi-preparative HPLC was carried out on a 
Shimadzu semi-preparative instrument with a flow rate of 17 mL/min on a Ace C18 (150 mm x 21.2 mm 
x 5 microns) with a UV/VIS detector (215 nm) and an automated fraction collector.  A two-buffer system 
was employed, utilizing formic acid as the ion-pairing agent.  Buffer A consisted of 0.1 % formic 
acid/H2O (v/v) and buffer B consisted of 0.1 % formic acid/acetonitrile (v/v).  High resolution mass 
spectroscopic analysis was performed on a Bruker MicroTOF QII mass spectrometer in positive mode 
with an internal calibration.  Peptides were synthesized on an automated CEM Liberty microwave peptide 
synthesizer (see Table 1 for conditions, not same as supplier).  All 1H, 13C, HSQC, COSY and HMBC 
NMR data were recorded on a Bruker AVANCE III 400 MHz spectrometer.  The ROESY data was 
recorded on a Bruker AVANCE III 600 MHz spectrometer. 
SYNTHESIS OF PCU DIACID 1 
A solution of the diene 5 (31) (15.0 g, 58.0 mmol) in dry methanol (100 mL) was purged with nitrogen 
for 6 h while cooling in a dry ice–isopropanol bath (−78 °C).  Ozone was bubbled into the reaction 
mixture until a blue–purple color persisted indicating the presence of excess ozone in the system and 
hence the completion of the reaction. The excess ozone gas was purge with nitrogen and the solvent 
(MeOH) removed in vacuo.  Formic acid (100 mL) was added to the ozonide and the mixture was cooled 
in an ice bath with stirring.  Hydrogen peroxide (150 mL, 30 %) was then added drop-wise to the stirring 
cooled reaction mixture.  The reaction was left to attain ambient temperature for 1 h and refluxed gently 
for 12 h, the resulting mixture was concentrated in vacuo to yield the diol diacid 1 (15.6 g, 92 % yield) as 
a white solid. mp: 153–157°C, 1H NMR [(CD3)2SO, 400 MHz]: δH 1.03 (AB, JAB = 10.4 Hz, 1H), 1.51 
(AB, JAB = 10.4 Hz, 1H), 2.23 (s, 3H), 2.26 (s, 2H), 2.37 (s, 2H), 2.48–2.50 (m, 3H), 2.57–2.59 (m, 2H). 
13C NMR [(CD3)2SO, 100 MHz]: δC 33.6 (CH2), 38.9 (CH), 42.3 (CH), 43.9 (CH), 44.2 (CH2), 50.0 (CH), 
76.6 (C), 172.5 (C). 
 
SYNTHESIS OF PCU DIAMIDE 6 
The PCU diol diacid 1 (5.0 g, 17.0 mmol),NH4Cl (2.4 g, 44.2 mmol), HOBt (5.7 g, 37.4 mmol), EDC (7.1 
g, 37.4 mmol), and NMM (4.9 mL, 44.2 mmol) was dissolved in dimethylformamide (DMF) (30 mL) and 
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stirred at room temperature for 36 h. The reaction mixture was concentrated in vacuo.  The crude product 
was dissolved in ethylacetate and washed successively with 1 M HCl (50 mL), 10 % NaHCO3 (50 mL), 
and brine (50 mL).  The organic solution was dried over Na2SO4 and concentrated in vacuo.  The crude 
product was purified via column chromatography on silica gel using CHCl3:MeOH:25 % NH4OH (88 : 10 
: 2, Rf = 0.3,72 % yield) to obtain a white solid. mp; 207–209 °C, IR vmax: 3172, 2961, 1656, 1408, 1287, 
728, 634, and 436 cm−1. Mass spectrometry (time of flight) [MS (TOF)] calculated for C15H21N2O4 (M + 
H+) 293.1496, found 293.1484.  1H NMR [(CD3)2SO, 400 MHz]: δH 1.03 (AB, JAB = 10.5 Hz, 1H), 1.48 
(AB, JAB = 10.5 Hz, 1H), 2.09 (AB, JAB = 14.4 Hz, 1H), 2.19 (AB, JAB = 14.4.5 Hz, 1H) 2.19 (s, 2H), 2.40 
(s, 2H), 2.41 (s, 2H), 2.48 (s, 2H). 13C NMR [(CD3)2SO, 100 MHz]: δC 33.5 (CH2), 38.9 (CH), 42.5 (CH), 
43.8 (CH), 43.9 (CH2), 49.3 (CH), 76.6 (C), 173.8 (C). 
SYNTHESIS OF PCU DIAMINE 2 
Sodium hypochlorite (90 mL) and 4 M NaOH (48 mL) were added to 7 g of the diamide.  The reaction 
was stirred for an hour at 80°C and then left to stir at room temperature for 24 hours.  HCl (1M) was then 
added to adjust the pH to 7 before the reaction was concentrated in vacou.  The crude product was then 
purified using column chromatography CHCl3:MeOH:25 % NH4OH (88 : 10 : 2) (2.9 g, 53 % yield).  The 
diamine (2.5 g, 10.6 mmol) was dissolved in 15 mL of water and 3 equivalence (eq) of NaHCO3 was 
added while stirring.  The resulting solution was cooled to 5°C and t-BOC anhydride (2.4 eq) was added 
slowly as a solution in cooled THF (15 mL).  The mixture was stirred at 0°C for 1 hour and allowed to 
warm to room temperature overnight.  Water was then added and extracted twice with DCM.  The organic 
layer was back extracted with saturated NaHCO3.  The aqueous layer was acidified to pH1 and then 
extracted with DCM twice.  All organic layers were combined, dried over MgSO4 and concentrated under 
reduced pressure.  The crude t-BOC-PCU diamine product was purified with column chromatography and 
stored below 4°C. (4.1 g, 75 % yield) 1H NMR [(CD3)2SO, 400 MHz]: δH 1.02 (AB, JAB = 10.5 Hz, 1H), 
1.44 (AB, JAB = 10.5 Hz, 1H), 1.38 (s, 9H), 2.09 (s, 2H), 2.34 (s, 2H), 2.42-2.45 (m, 4H), 2.86 (AB, JAB = 
6.18 Hz, 1H), 2.90 (AB, JAB = 6.18 Hz, 1H), 2.94 (AB, JAB = 6.18 Hz, 1H), 2.98 (AB, JAB = 6.18 Hz, 1H) 
6.28 (s, 1H), 7.02 (s, 1H). 13C NMR [(CD3)2SO, 100 MHz]: δC 28.2 (CH3), 33.7 (CH2), 39.2 (CH), 40.4 
(CH), 43.0 (CH), 43.0 (CH), 47.9 (CH), 48.1 (CH2), 77.1 (C), 77.7 (C), 156.2 (C) 
The removal of t-BOC from the diamine was achieved by stirring the compound in methanol (30 mL) and 
conc HCl (12M, 5 mL) overnight.  
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SYNTHESIS OF THE CAGE AMINE AMIDE 3 
Sodium hypochlorite (45 mL) and 4M NaOH (24 mL) were added to 7 g of the diamide.  The reaction 
was stirred for an hour at 80°C and then left to stir at room temperature for 24 hours.  HCl (1 M) was then 
added to adjust the PH to 7 before the reaction was concentrated in vacou.  The crude product was then 
purified using column chromatography CHCl3:MeOH:25 % NH4OH (88 : 10 : 2) (1.6 g, 28 % yield).  The 
amine amide (2.5 g, 10.6 mmol) was dissolved in 15 mL of water and 1.5 equivalence (eq) of NaHCO3 
was added while stirring.  The resulting solution was cooled to 5°C and t-BOC anhydride (1.2 eq) was 
added slowly as a solution in cooled THF (15 mL).  The mixture was stirred at 0°C for 1 hour and 
allowed to warm to room temperature overnight.  Water was then added and extracted four times with 
DCM, dried over MgSO4 and concentrated under reduced pressure.  The crude t-BOC-PCU amine amide 
product was purified with column chromatography and stored below 4°C.  (1.9 g, 86 % yield) 1H NMR 
[(CD3)2SO, 400 MHz]: δH 1.02 (AB, JAB = 10.5 Hz, 1H), 1.47 (AB, JAB = 10.5 Hz, 1H), 1.37 (s, 9H), 2.09 
(s, 2H), 2.33 (s, 2H), 2.42-2.45 (m, 4H), 2.92 (m, 2H), 3.12 (m, 1H), 3.16 (m, 1H), 6.20 (s, 1H), 8.32 (s, 
1H). 13C NMR [(CD3)2SO, 100 MHz]: δC 28.0 (CH3), 33.7 (CH2), 36.4 (CH2), 40.4 (CH), 43.1 (CH), 43.5 
(CH), 45.3 (CH2), 48.0 (CH), 48.1 (CH2), 76.7 (C), 76.9 (C), 77.6 (C), 78.4 (C), 153.3 (C), 156.2 (C), 
172.1 (C), 174.1 (C), 
The removal of t-BOC from the amine was achieved by stirring the compound in methanol (30 mL) and 
conc HCl (12M, 5 mL) overnight 
GENERAL PROCEDURE FOR THE SYNTHESIS OF PEPTOID  
The peptoid oligomers to fit into the S1/S1’-S4/S4’ subsite of the HIV protease were synthesized 
via solid phase synthesis on activated 2-chlorotrityl chloride resin 7, scheme 2.  Bromoacetic 
acid was coupled to the resin 7 in the presence of DIPEA in dry dichloromethane (DCM) for 2 
hours and this affording compound 8, scheme 2.  Upon filtration, the amine solution in DMF was 
added and mixed under a stream of nitrogen bubbles to give compound 9.  The chain was 
elongated by coupling bromoacetic acid in the presence of N, N'-diisopropylcarbodiimide (DIC).  
Similarly the corresponding amines were coupled to the extended chain followed by bromoacetic 
acid to give compounds 10-14.  The completed peptoids were cleaved from the resin using 5 % 






























































Scheme 2. General Synthesis of peptoids 
GENERAL PROCEDURE FOR COUPLING OF PEPTOID TO THE PCU-DIOL 
The cleaved peptide (2.6 eq.) was dissolved in DMF (3 mL) followed by addition of PCU-diol  
(1 eq.), EDC (2.4 eq), HOBT (2.4 eq.), in DMF (7 mL) and NMM (2.6 eq.).  The mixture was 
stirred at room temperature for 24 hours and thereafter evaporated to dryness under reduced 
pressure using a Teflon pump at 40°C.  The crude product was diluted with EtOAc (200 mL) and 
the resulting solution was washed with 1M HCl, sat. aq. NaHCO3 and sat. aq. NaCl, dried over 
MgSO4, filtered and concentrated in vacuo. The product was then purified by reverse phase 
semi-preparative HPLC carried out on a Shimadzu Instrument (Ace C18 150 mm x 21.2 mm x 5 
microns) with a UV/VIS detector (215 nm).  There were characterized using NMR Bruker 
AVANCE III 400 MHz and 600 MHz spectrometer and High Resolution Mass Spectroscopic 
analysis performed on a Bruker MicroTOF QII 
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OVER-EXPRESSION, EXTRACTION AND PURIFICATION OF THE C-SA 
PROTEASE 
Plasmid encoding HIV-1 subtype C protease (containing the mutation Q7K designed to reduce the 
hypersensitive autolytic site) is expressed as inclusion bodies (Ido et al., 1991) in Escherichia coli BL21 
(DE3) pLysS cells. Briefly, Escherichia coli cells harboring the plasmid DNA were grown at 37 °C in LB 
medium supplemented with 100 μg/mL of ampicillin and 35 μg/mL of chloramphenicol. The overnight 
culture was diluted 100-fold into fresh 2 × YT medium supplemented with ampicillin (100 μg/mL) and 
chloramphenicol (35 μg/mL) and grown at 37 °C. When the optical density (OD600) of the culture reached 
0.4 to 0.5, over-expression of the HIV-1 C-SA protease was induced by adding IPTG. IPTG was added to 
final concentrations of 0.4 mM. Over-expression of the protease was allowed to continue for four hours.  
The cells were pelleted after growth and resuspended in ice-cold extraction buffer [10 mM Tris, 1 mM 
EDTA, and 1 mM PMSF (added only fresh before use), pH 8]  and disrupted using an ultra-sonicator. 
Following the addition of MgCl2 and DNase I to final concentrations of 10 mM and 10 U/μL, 
respectively, the culture medium was stirred on ice until the viscosity of the mixture decreased. The cells 
were then ruptured by sonication and centrifuged at 15 000 × g for 30 minutes at 4 °C. The pellet was 
resuspended in ice-cold extraction buffer containing 1 % (v/v) of Triton X-100. Cell debris and protease-
containing inclusion bodies were pelleted by centrifugation at 15 000 × g for 30 minutes at 4 °C. The 
pellet was then resuspended in a freshly prepared solubilization buffer containing 10 mM Tris, 2 mM 
DTT, 8 M urea, pH 8.0, at room temperature, and centrifuged at 15 000 × g for 30 minutes at 20 °C.  
The protease, in the supernatant, was purified by passing through an anion exchange (DEAE) column 
previously equilibrated with solubilization buffer. Upon elution from the column, the protease was 
acidified by adding formic acid to a final concentration of 25 mM. Precipitation of significant amount of 
contaminating proteins occurred upon acidification. Following an overnight incubation, the precipitated 
contaminants were removed by centrifugation at 15 000 × g for 30 minutes at 4 °C.  
HIV-1 protease was refolded by dialysis into 10 mM formic acid at 4 °C. Subsequently, the protease was 
dialyzed into storage buffer containing 10 mM sodium acetate, 1 mM NaCl and 1 mM DTT, pH 5.0. The 
folded protease was concentrated to a final volume of ~5 mL and stored at -20 °C.  
IN VITRO HIV-1 PROTEASE ACTIVITY 
The catalytic activity of the HIV-1 protease was monitored following the hydrolysis of the chromogenic 
peptide substrate Lys-Ala-Arg-Val-Nle-p-nitro-Phe-Glu-Ala-Nle-NH2.  This substrate mimics the 
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conserved KARVL/AEAM cleavage site between the capsid protein and nucleocapsid (CA-p2) in the Gag 
polyprotein precursor.  
For this study the chromogenic substrate was synthesized using the Discovery CEM Liberty microwave 
peptide synthesizer on the Rink amide resin.  The substrate was cleaved from the resin and deprotected 
using 95 %:5 % (v/v) TFA:TIS for 3 hours.  It was then precipitated using cold ether and purified via 
reverse phase semi-preparative HPLC on a Shimadzu instrument and characterized using the Bruker 
microTOF-Q II instrument (Table 2).   
To determine the concentration of the inhibitors that resulted in 50 % inhibition (IC50) of HIV-1 protease 
enzyme activity, the protein (100 nM) and chromogenic substrate (50 μM) were added into a 120µL 
microcuvette containing increasing concentrations of inhibitor in a pH 5.0 buffer (50 mM sodium acetate 
and 0.1 M NaCl).  Protease hydrolytic activity was measured by monitoring the relative decrease in 
absorbance at 300 nm using Fpecord 210 spectrophotometer. 
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Supplementary Table 1. The inhibition of wild type C-SA HIV protease by the PCU diol peptoid 
derivatives, yields for the coupling of peptoids to the cage diols and the size as confirmed by High-
resolution mass spectroscopy 
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Table 1. 1H chemical shift and EASY-ROESY correlations of inhibitor 2a.  The chemical shift was 
referenced to 2.50 ppm and the long-range interactions through space, measured by ROESY, are marked 
in red. 
Atom δ1Ha,b ROESY (δ1Ha,b) 
1/7   
2/6 2.09-2.63 4a, 4s 
3/5   
9/10   
8/11 -  
4a 1.44 3/5, 4s 
4s 1.78 3/5, 4a 
1’ 3.41 NH, 3’ 
NH 8.29 1’, 3’ 
2’ - - 
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3’ 4.03 1’, 4’, 6’-10’, 12’, 14’, 15’, NH 
4’ 4.46 3’, 6’-10’ 
5’ - - 
6’-10’ 7.23-7.38 3’, 4’ 
11’ - - 
12’ 4.22 3’, 13’,14’, 15’, 18’ 
13’ 4.66 12’, 14’, 15’ 
14’ 0.85 3’, 12’, 13’ 
15’ 0.99 3’, 12’, 13’ 
16’ - - 
17’ 4.66  
18’ 2.83 12’ 
19’ - - 
20’ 5.02, 5.08 22’-26’ 
21’ - - 
22’-26’ 7.23-7.38 20’ 
a Solvent (CD3)2SO. 












































Supplementary Table 2. EASY ROESY correlations observed in the spectra of PCU-EAIS recorded in 
DMSO-d6 and the D2O as the solvent.  The chemical shift was referenced to 2.50 ppm 
Atom 1H PCU-EAIS ROESY(δ1Hc)(PCU-EAIS) 
(DMSO-d6) 
ROESY(δ1Hc)(PCU-EAIS (D2O) 
1x 2.89 2, 3,6, 7, NHc 2, 3, 7,NHa, NHc, NHcc 
1y 2.97 2, 3, 6, 7, 10, NHa, NHg 2, 3, 7, NHa 
2 2.45 1a, 1s, NHa, NHb 1a, 1s 
3 2.41 1a, 1s, 3’, 4a, 4s, 6, 10, 10’, NHa, 
NHb, NHc, NHg 
1a, 1s, 4a, 4s, 10, NHa, NHc, NHcc 
4a 1.35 (d. J = 10.6 
Hz) 
3, 4s, 5, 6 3, 4s, 5, 6 
4s 1.68 3, 4a, 5, 6, 9, 10 3, 4a, 5, 6, 9, 10 
5 2.66 4a, 4s, 6, 9 4a, 4s, 6 
6 2.75 1a, 1s, 2, 3, 4a, 4s, 5, 7, 9 4a, 4s, 5, 7, 9 
7 2.34 1a, 1s, 6 1a, 1s, 6 
8    
9 2.17 4s, 5, 6, 10 4s, 6, 10 
10 2.77 1s, 3, 4s, 9, 10, NHa, NHb, NHc 3, 4s, 9, NHa, NHc 
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11    
12    
g1’    
g2’ 4.22 g3a’, g3s, g4, NHa g3a’, g3s, g4, NHa, NHg 
g3a’ 1.72 g2’, g3s, g4, NHa, NHg g2’, g3s, g4, NHg, NHbb, 
g3s’ 1.89 g2’, g3a, g4, NHa, NHg g2’, g3a, g4, NHg 
g4’ 2.21 3’, g2’, g3a’, g3s’, 10’, NHa g2’, g3a’, g3s’, NHg 
g5’    
1’    
2’ 4.27 3’, NHb, NHc, NHcc 3’, NHbb, NHc, NHcc 
3’ 1.19 2’, 3, g4’, NHb, NHc, NHcc, 
NHg 
2’, NHbb, NHc, NHcc 
4’    
5’ 4.25 9’, 10’, 11a, 11s, NHd 9’, 11a’, 11s’, 12’ 
6’    
7’ 3.93 8a’, 8s’, 10’, 12’, NHd 8a’, 8s’, NHd 
8a’ 3.62 7’, 8s’, NHd 7’, 8s’, NHd 
8s’ 3.72 7’,8a’, NHd 7’,8a’, NHd 
9’ 1.73 5’, 10’, 11a’, 11s’, 12’, NHc, 
NHcc NHd 
5’, 10’, 11a’, 11s’, 12’, NHc, NHcc, 
NHd 
10’ 0.86 3, g4’, 5’, 7, 9’, 11a’, NHc, NHcc 9’, 11a’, NHcc 
11a’ 1.05 5’, 9’, 10, 11s’, 12’, NHd 5’, 9’, 10, 11s’, NHd 
11s’ 1.43 5’, 7, 9’, 11a’, 12’ NHd, NHc 5’, 9’, 11a’, 12’  
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12’ 0.82 5’, 9’, 11a’, 11s’, NHcc, NHd 5’, 9’, 11a’, 11s’ 
NHa 8.08 1a, 1s, 2,  3, 10, g2’, g3a’, g3s, 
g4’ 
1a, 1s, 2,  3, 10, g2’ 
NHaa    
NHg 8.10 1s, 3, 3’, g3a’, g3s g2’, g3a’, g3s, g4’ 
NHb 7.80 2’, 2, 3, 3’, g2’, g3a’, g3s, g4’  
NHbb 7.94 2’, 2, 3, 3’, g2’, g3a’, g3s, g4’ 2’, 3’, g3a’ 
NHc 8.16 1a, 2’, 3’, 3, 6, 9’, 10’, 11s’ 1a, 2’, 3’, 3, 9’, 10’ 
NHcc 8.20 2’, 3’, 9’, 10’, 12’ 1a, 2’, 3, 3’, 3, 9’, 10’ 
NHd 8.40 2’/5’, 7’, 8a’, 8s’, 9’, 11a’, 11s’, 
12’  
7’, 8a’, 8s’, 9’, 11a’ 























































































































































































































































ROESY spectrum of PCU-PVAZ peptoid 
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